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ABSTRACT
Haemophilus influenzae (Hi) is a gram negative bacillus that commonly colonises the 
upper respiratory tract of humans. While the serotype b capsular form (Hib) of this 
organism accounts for less than 5% of carriage episodes, it is responsible for more than 
95% of all invasive Hi infections. The capsular polysaccharide of Hib, 
polyribosylribitol phosphate (PRP), is an important virulence determinant. Serum 
antibodies specific for PRP correlate with bactericidal activity against the organism, 
and their acquisition with age in populations has an inverse relationship with the 
experience of invasive disease.
The first vaccines to be developed against Hib were based on the capsular 
polysaccharide, but were limited in their application due to the T cell independent 
nature of the antigen, which was not immunogenic in children less than two years of 
age. Chemical conjugation of PRP with a carrier protein such as diphtheria or tetanus 
toxoid converted it into a T cell dependent antigen, capable of eliciting antibody 
production in infants only a few months old, and resulting in the formation of 
populations of ‘memory’ B lymphocytes believed to provide long term protection fi"om 
infection. Efficacy of these conjugate vaccines against both acquisition of the 
organism and progression to invasive disease was subsequently demonstrated.
Hib was a significant cause of morbidity and mortality among British children before 
inclusion of Hib conjugate vaccines in the routine UK infant immunisation schedule in 
October 1992. In contrast to other developed countries, it was scheduled as a three 
dose accelerated primary course at 2, 3 and 4 months of age without a booster dose in
XXX
the second year of life. Vaccine introduction was accompanied by a catch-up 
immunisation campaign in which a single dose was given to children under four years 
of age.
Despite an initial rapid and dramatic fall in Hib disease reports, a resurgence of cases 
occurred from 1999 onwards, predominantly in vaccinated children. This rise has since 
been attributed to a number of factors related to vaccine use. Wearing off of the initial 
catch-up campaign’s effect, rapid waning of immunity induced by the accelerated 
infant schedule and the use of less immunogenic acellular pertussis containing Hib 
combination vaccines in 2000/2001 have all resulted in a reduction in protective 
antibody titres in the population at risk. In keeping with the notion that this should 
correspond with greater likelihood of disease, infants bom prematurely, whose 
response to immunisation is less than term-delivered counterparts, have been shown to 
have a four fold increase in risk of invasive Hib infection.
Hib vaccines have further been demonstrated to delay acquisition of carriage, thereby 
reducing transmission in populations. This indirect effect of immunisation, or ‘herd 
immunity’ was hailed as a major contribution to disease reduction. It may also impair 
the maintenance of long term immunity at a population level, however. Following an 
initial decline in Hib reports associated with vaccine introduction among older 
unimmunised cohorts, adult case numbers in the UK have now returned to pre­
vaccination levels. This rise has occurred in association with a reduction in specific 
antibody titres to Hib in adult age groups which was observed within only two years of 
vaccine introduction. In a surprising finding, a national case-control study of invasive 
Hib infections found a reduced risk of invasive disease among children attending day
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nurseries, or exposed to cigarette smoke. Prior to vaccine use, both of these exposures 
were associated with higher rates of disease, presumed to be mediated through higher 
carriage prevalence. It is possible that repeated antigenic challenge through 
colonisation may result in improved persistence of antibodies elicited by immunisation.
The anticipated medium to long term effects of Hib conjugate vaccine as used in the 
UK on transmission and maintenance of population immunity were simulated using a 
mathematical model. The model further provided a framework in which to investigate 
key assumptions regarding the mechanism of vaccine protection. Good correlation of 
outputs with seroepidemiologic data from the UK was achieved. Exploratory analysis 
of the protective efficacy of immunologic memory within this system reinforced 
individual and population level observations of relatively poor protection against 
invasive disease in individuals whose post-immunisation Hib antibody titres had waned 
to undetectable levels. The anticipated effects of a range of potential vaccination 
strategies which may be employed in the UK to raise antibody titres in the age groups 
at greatest risk and thereby reduce disease incidence were investigated.
The possibility that widespread vaccination may have resulted in an increase in the 
intrinsic virulence of Hib was considered. No change in the clinical presentation of 
Hib disease, or its associated mortality, has been observed in immunised or 
unimmunised children or adults in the UK since vaccine introduction. In the absence 
of more robust genotypic markers of invasive potential, no evidence exists to suggest 
that the vaccine has had any significant impact on microbial population structure.
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The UK’s experience of Hib conjugate vaccines in the medium term has challenged 
previously held notions regarding the effectiveness of immunologic memory for 
disease control in populations. Whether this can be ascribed to the limitations of 
memory per se, or is a particular feature of the immune response to conjugate vaccines, 
which stimulate T cells irrelevant to the pathogen of interest, is debatable. The 
importance of long term surveillance for unanticipated effects of immunisation 
programmes is reinforced. Such considerations are further applicable to the more 
recently licensed meningococcal and pneumococcal conjugate vaccines.
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Chapter 1 -  Introduction to the clinical problem of Hib (Literature Review)
1.0 Introduction
Haemophilus influenzae (Hi) is a non-motile gram-negative bacterium found almost 
exclusively in the upper respiratory tract of humans (Roche RJ et al 1995). Exposure to 
this family of organisms is common, with estimates of asymptomatic colonisation 
prevalence ranging from 25-84% in open communities (Moxon ER 1986). Unencapsulated 
forms of the organism are the most commonly carried, and are a frequent cause of mucosal 
infections involving the upper and lower airway. In contrast, over 95% of all invasive Hi 
infections in childhood including meningitis, epiglottitis and bacteraemia, are attributable to 
the serotype b capsulate form (Hib), which is carried by no more than 5% of the population 
at risk at any one time (Turk DC 1963) (Mendelman PM et al 1992). Hib meningitis was 
almost universally fatal before the availability of antibiotic therapy (Ward HK et al 1932). 
Even with a decrease in mortality, Hib was still recognised to cause between 30 and 50% of 
all cases of bacterial meningitis worldwide (Feltola H 2000), with high rates of long-term 
neurological sequelae (Sell HW et al 1972). This ongoing disease burden, together with 
concerns about development of antibiotic resistance, drove the development of vaccines to 
prevent Hib infections (Anderson P et al 1985).
In this chapter, we will review the characteristics of the organism, including possible 
reasons for its particular virulence. In addition, different states of infection leading to the 
development of natural immunity will be discussed. The application of lessons learned 
from the study of these host-pathogen interactions to vaccine development, and the way in 
which they relate to the observed impact of vaccination are explored.
1.1 Initial description o f Hib
In her classic paper describing Hi, also known as the ‘Pfeiffer bacilli’. Pitman described 
morphologically distinct smooth (S) and rough (R) bacterial colonies growing on 
Levinthal’s transport medium (Pitman M 1931). S organisms were surrounded by discrete 
capsules and were lethal in animal models at a uniformly lower inoculum dose, thus 
exhibiting greater virulence than the R colonies. Specific immunoprécipitation reactions 
were observed when the sera of animals inoculated with an S strain were added to the 
filtrate of a culture of the same strain, indicating that the S forms were of more than one 
distinguishable type.
Two serotypes, designated a and b, were differentiated on the basis of these immunological 
reactions (Pitman M 1931). All of the strains of serotype b (Hib) in this initial study were 
isolated from cases of meningitis. In later unpublished work. Pitman further characterised 
four additional S, or capsulate, types c, d, e and f  (Turk DC 1963). Spontaneous loss of 
capsule and reversion of S to R forms was observed in vitro after prolonged culture, 
particularly in the presence of type specific antibody (Pitman M 1931). The R or ‘rough’ 
forms are described as non-capsulate or non-typeable (nt Hi).
1.2 Population structure o f Hib
More subtle methods for devising the relationships between Hib strains of the same or 
distinct capsular types have since been developed. Organisms may be characterised on the 
basis of their biochemical characteristics (biotyping) (Barenkamp SJ et al 1983) (Musser 
JM et al 1985), or by differences between expressed outer membrane proteins (OMPs) 
(Musser JM et al 1985) (Martin D et al 1990) and lipopolysaccharide molecules (van 
Alphen L et al 1983). Examination of the electrophoretic mobility of a range of common
enzymes produced by Haemophilus (multilocus enzyme electrophoresis, MEE) was the 
basis of defining enzyme type (ET) clones, as a means of assessing genetic relatedness 
(Musser JM et al 1988,1990). Direct genetic study by restriction fragment length 
polymorphism (RFLP) analysis of the capsular {cap) gene locus (Musser JM et al 1990) or 
multi-locus sequence typing (MLST) of common housekeeping genes (Meats E et al 2003) 
has been employed more recently.
These studies have produced a number of interesting observations regarding the global 
relatedness of Hib strains. Hib isolates arose firom one of two separate genetic lineages, 
both of which were quite distinct from antecedents of other capsular types (Musser JM et al 
1990) (Meats E et al 2003). 70% of Hib isolates recovered over a 20-year period 
worldwide belonged to one of four ET clones (Meats E et al 2003). While a number of Hib 
clones were widely distributed, only one or two predominated within a given country or 
large geographical region (Musser JM et al 1990). The distribution of clones appeared 
most strongly associated with the historical movements of distinct racial or ethnic groups, 
and showed very little subsequent change or evidence of mixing of strains (Musser JM et al 
1990).
Further evidence of lack of genetic transfer between Hib clones was seen in the strong non- 
random associations that were found when assessing bacterial characteristics by a range of 
means (Martin D et al 1990) (Musser JM et al 1985,1988, 1990) (Meats E et al 2003). For 
example, consistent relationships were found between particular ET clones and OMP types
Figure 1.0 Similarity of phylogenetic relationships between Hi strains, as assessed by 
MEE and MLST (from Meats E et al 2000)
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or subtypes. Further, characterisation of the genetic relatedness of capsulate Hi strains by 
MEE or MLST produced similar results (Figure 1.0). Such features were typical of a 
highly clonal population structure, suggesting that chromosomal recombination in natural 
populations was an infrequent event. In particular, it appeared that special barriers existed 
to the transfer of genes between cap regions (Musser JM et al 1988).
In contrast, far greater diversity of nt Hi strains confirmed that these were not merely 
capsule deficient serotype b strains, but of distinct genetic lineage with greater evidence of 
recombination (Meats E et al 2003) (Musser JM et al 1985). Marked diversity in genes 
encoding lipopolysaccharide was found in nt Hi strains isolated from children with otitis 
media (Cody AJ et al 2003). This may in part be attributed to greater opportunity for 
exposure to other organisms, as carriage of multiple genetically distinct isolates of nt Hi 
within an individual has been well described, while only one clone of a given capsular type 
of Hi is carried at a time (Trottier S et al 1989) (Smith-Vaughan HC et al 1996) (StSauver J 
et al 2000).
1.3 Importance o f the serotype b capsule as a virulence determinant 
Of the H influenzae family of organisms, serotype b was noted to be strikingly more 
common as a cause of invasive disease than the others. Given the distinct genetic lineages 
from which type b strains derived, it was unclear whether this heightened virulence was 
directly attributable to capsular expression or other genetic factors. The invasive potential 
of specific serotypes was examined by inoculating rats with nt Hi strains, genetically 
transformed to express a range of capsular types (Moxon ER et al 1981,1984) (Zwahlen A 
et al 1989). This method ensured that the only phenotypic differences between strains 
arose from the capsulation locus. Only naturally occurring or transformant serotype b
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strains resulted in persistent bacteraemia in these models, confirming the importance of the 
type b capsular polysaccharide poly ribosyl-ribitol phosphate (PRP) as a virulence 
determinant.
Serotype b organisms demonstrated enhanced intravascular survival (Moxon ER et al
1981), which appeared to be explained by successful evasion of splenic clearance (Zwahlen 
A et al 1989). The type b capsule successfully inhibited activation of the alternative 
pathway of complement, which could be triggered by the organism in the presence of 
specific antibodies to PRP (Sutton et al 1982) (Steele NP et al 1984). While PRP reduced 
the rate of opsonophagocytosis of organisms by polymorphonuclear leucocytes in vitro, 
there was no evidence that it did so any more effectively than the capsules of other 
serotypes a, c, e and f  when compared with unencapsulated strains (Crook G et al 1989). 
The heightened virulence of Hib strains in relation to other Hi capsular types therefore 
remained imperfectly understood.
1.4 Other factors potentially associated with virulence ofHib strains 
There have been reports of particular OMP subtypes of Hib having increased association 
with invasive disease in outbreak settings (Barenkamp SJ et al 1981) and with clinical 
presentation with epiglottitis in Finland (Takala AK et al 1987). Such observations have 
not been subsequently bome out in larger scale analyses. Comparison of outer membrane 
protein subtypes of isolates derived from asymptomatic carriers or children with invasive 
infection in population based studies in the United States and Alaska have revealed no 
significant difference in the frequencies of the most common subtypes between the two 
sources of strains (Hampton CM et al 1983) (Lucher LA et al 2002). Thus, organisms that
are commonly carried are indistinguishable from those causing serious infections using 
current molecular techniques.
The ability to modify surface expressed carbohydrates, adhesion molecules and 
lipopolysaccharide may confer advantage on organisms in adapting to a range of host 
environments. Different bacterial characteristics facilitate survival in, and transfer between, 
diverse anatomical sites such as the nasopharynx and bloodstream (Smith AL 1987) (Roche 
RJ et al 1995). The higher prevalence of carriage of nt Hi would imply improved survival 
in the nasopharynx without capsule. Some have postulated, however, that capsulation may 
improve survival outside the host, thereby improving the likelihood of transmission 
(Moxon ER 1992). Further, Hi enter the bloodstream through being endocytosed by and 
translocating across human endothelial cells. While capsulation is associated with 
enhanced survival in the blood, it makes this translocation more difficult (Moxon ER 
1992).
Whole genome sequencing of Hib has revealed the presence of a number of hypermutable 
sites containing simple sequence repeats, known as ‘contingency loci’ (Bayliss CD et al 
2001) that are found within coding or promoter regions. Changes in the number of repeats 
results in shifting of the reading frame or altered promoter activity, thus acting as an ‘on- 
ofF switch within a small number of generations. Phase variable expression of 
lipopolysaccharide, adhesins and iron acquisition proteins has been demonstrated within Hi 
(Bayliss CD et al 2001), but microbial genetic factors governing the rate of variation are 
unknown. In addition, laboratory Hib strains have been observed to vary in the number of 
copies of the cap gene locus, resulting in altered expression of the capsular polysaccharide
PRP and changes in genetic stability (Kroll JS et al 1988). The significance of these 
findings to survival and virulence in vivo requires further study.
1.5 Asymptomatic colonisation with Hib
H  influenzae strains commonly colonise the upper respiratory tract of humans without 
causing apparent injury. While a broad range of estimates of carriage prevalence have been 
reported, all studies were agreed that non-typeable forms were approximately ten times 
more common in asymptomatic individuals than serotype b organisms (Moxon ER 1986). 
Most estimates of the frequency of Hib carriage have been in the order of 5% or less, but 
varied according to the microbiological techniques used. Transport of swabs taken from 
the oropharynx in an enriched broth, followed by plating onto agar containing 
hyperimmune Hib burro serum, appeared the most sensitive method for detection. Low 
levels of colonisation, which would be missed by plating onto chocolate agar in the first 
instance, could be identified by these means (Michaels RH et al 1975).
A population based US study conducted in the 1970s utilising these sensitive 
microbiological methods reported carriage rates of 0.7% in infants under 6 months, rising 
to between 3 and 5% throughout older childhood and adolescence (Michaels RH et al 1976) 
(Figure 1.1a). Fewer carriers were identified in a Welsh cross sectional survey of children 
up to six years of age, with Hib isolated from only 1.1% of 996 subjects (Howard AJ et al 
1988) (Figure 1.1b). In the latter study however, swabs were taken from the nasopharynx 
and inoculated directly onto chocolate agar plates, making comparison of these findings in 
the two populations difficult. The figure of 1% was very similar to that obtained in a
Figure 1.1: Cross sectional population based studies of Hib carriage prevalence (error 
bars represent 95% confidence intervals)
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survey in Leeds in the 1950s using the same direct plating methods, where 6 of 650 
children under 5 years were found to carry serotype b strains (Dawson B et al 1952).
Several other features of asymptomatic Hib infection have been characterised. A time lag 
of several weeks was observed before acquisition of Hib strains in infants cared for in a 
single room in an orphanage in Jamaica. This delay suggested that Hib transmission did 
not occur readily (Turk DC 1963). Similarly, among household contacts of children 
recovered from invasive Hib infection followed over one year, more than half of the 
initially uncolonized siblings remained so for six months or more while constantly exposed 
to family carriers (Michaels RH et al 1977). Close and prolonged contact between 
individuals would therefore appear to be necessary for spread of the organism to occur.
In a longitudinal study of carriage in nursery attendees, a wide range of values for the 
duration of colonisation was observed, with an average estimate of 2.4 months (Murphy TV 
et al 1985). Observation of infants repeatedly cultured in a Jamaican nursery similarly 
suggested that clearance of Hib usually occurred within 2-3 months, although not all 
children could be followed for prolonged periods (Turk DC 1963). In the Michaels and 
Norden family study described above, some individuals carried for up to one year, although 
this figure may represent successive episodes of clearance and reacquisition (Michaels RH 
et al 1977).
One British longitudinal study suggested a seasonal pattern to Hib carriage, with more 
carriers detected in the autumn and winter months than in summertime (Heath PT et al
1997). It was difficult, however, to distinguish between a true impact of climate and 
temporal variation in mixing between new groups of children, as occurs with
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commencement of school or nursery attendance. Among 66 children repeatedly swabbed 
in a nursery over an 18-month period, the highest rates of colonisation were detected in the 
first six months of the survey (Murphy TV et al 1985). This may be postulated to have 
been due to introduction of naïve individuals into the group, who became colonised for the 
first time, rather than environmental factors.
1.6 Risk factors for Hib carriage
As seen in the population surveys described above (Michaels RH et al 1976) (Howard AJ et 
al 1988), carriage of Hib before the age of 2 years was relatively uncommon (Principi N et 
al 1999) (StSauver J et al 2000). In the Welsh carriage study, the only children under 2 
who were carriers were those with older siblings living in the household (Howard AJ et al
1988). The role of an older child with wider social networks as the introducer of Hib to the 
family was confirmed in subsequent case-control studies (Principi N et al 1999). Further, 
the number of people living in the home had a direct relationship with the likelihood of 
carriage, but this association lost its influence once children began attending school on a 
regular basis (Lerman SJ et al 1979). The importance of mixing with children outside a 
normal family setting to acquisition of Hib was also shown by the higher prevalence of 
colonisation demonstrated in children in orphanages (Turk DC 1963) (Mpairwe Y 1970) 
and attending day care centres (Turk DC 1963) (Murphy TV et al 1985) (Stephenson WP et 
al 1985) (Principi N et al 1999).
Close contacts of a child with invasive Hib infection exhibited markedly increased rates of
carriage compared with those expected in the wider population. This association was
observed in household (Johnson RD et al 1943) (Boisvert PL 1948) (Turk DC 1963)
(Michaels RH et al 1975)(Michaels RH et al 1977) (Ward JI et al 1979), nursery (Ginsburg
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CM et al 1977) (Prober CG et al 1982) (Murphy TV et al 1983a) (Li Kl et al 1986) 
(vonRosen lA et al 1990) and institutional (Johnson RD et al 1943) (Straker EA 1945) 
(Glode MP et al 1976) settings. Similarly, secondary household contacts of children 
exposed to a case exhibited higher colonisation prevalence than would otherwise have been 
expected (Murphy TV et al 1983a) (Li KI et al 1986). Causality in this association remains 
unclear; are Hib disease cases more likely to arise in situations where carriage prevalence is 
already high, or are there features of the organisms causing serious infections, or of the 
disease state itself, that contribute to heightened transmissibihty of strains? By definition, 
invasive Hib infections involve transfer of the organism to occult sites such as the 
bloodstream or cerebrospinal fluid (CSF), from where spread to other hosts is unlikely to 
occur. Very high rates of carriage have been repeatedly observed without disease (Turk 
DC et al 1963) (Murphy TV et al 1985). The possibility that characteristics of specific 
strains may make them both more transmissible and more invasive remains intriguing.
Integrity of mucosal surfaces may be important in reducing the likelihood of bacterial 
adherence. Factors associated with damage to the mucosa, including exposure to cigarette 
smoke and a history of atopy have been linked with carriage of multiple strains of nt Hi in 
one study (StSauver J et al 2000).
1.7 Invasive disease due to Hib
Despite a population prevalence of Hib carriage in the order of 1 to 5% among children in 
the developed world, serious infections due to this organism were relatively rare, affecting 
between 30 and 60 per 100,000 children within the first five years of life (Clements DA et 
al 1993) (Peltola H 2000). In addition, the relationship between carriage prevalence and 
invasive disease incidence was not consistent with age. While Hib colonisation in
12
population surveys was uncommon in children less than 2 years old (Michaels RH et al
1976) (Howard AJ et al 1988), the vast majority of paediatric Hib disease cases in 
industrialised countries occurred between 6 and 24 months of age. The incidence then fell 
sharply, becoming rare after the 5* birthday (Fothergill LD et al 1933) (Booy R et al 1993) 
(Anderson EC et al 1995) (Figure 1.2). The proportion of all paediatric disease experienced 
in the first 12 months of life was much greater in the developing world (Peltola H 2000). 
This trend to early infections was also marked among indigenous populations in Alaska 
(Ward JI et al 1981), northern Canada, the United States (US) (Siber GR et al 1990) (Wolff 
MC et al 1999) and central and northern Australia (Guthridge S et al 2000).
Common clinical presentations of invasive Hib disease included meningitis, epiglottitis, 
cellulitis, bone and joint infections, bacteraemia and pneumonia (Booy R et al 1993) 
(Anderson EC et al 1995). Globally, 52% of bacteraemic Hib infections presented with 
meningitis. Hib was further estimated to be the causative organism in between 30% and 
50% of all cases of childhood bacterial meningitis (Peltola H 2000). Hib was almost the 
sole cause of epiglottitis in children (Berenberg W et al 1958) (Gorelick MH et al 1994) 
(Hugosson S et al 1994). The incidence of epiglottitis varied between developed countries 
for reasons that were incompletely understood, with the highest rates observed in 
Switzerland and Australia (Clements DA et al 1993) (Peltola H 2000). The importance of 
Hib as a cause of non-bacteraemic radiologically defined pneumonia in the developing 
world was highlighted by a 20 to 25% reduction in this disease presentation in children 
immunised against Hib in a large phase III vaccine efficacy study conducted in the Gambia 
(Mulholland K et al 1997). This recent finding led to substantial re-estimates of the global 
disease burden of Hib (Peltola H 2000).
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Prior to the availability of effective antimicrobial therapy, Hib meningitis in infancy was 
usually fatal, with an estimated mortality in the US in the 1930s of 92% (Ward HK et al 
1932). Early attempts at intrathecal therapy using hyperimmune horse serum resulted in 
some reduction in bacterial count within the CSF of patients with Hib meningitis, but 
unfortunately relapse and death occurred in all but one of 13 cases (Pitman M 1933). 
Administration of antiserum with complement fared only slightly better (Ward HK et al 
1932). With the advent of antibiotics including penicillin and streptomycin, chances of 
survival improved considerably (Braid F et al 1949). In many parts of the developing 
world, case fatality rates associated with Hib infection remain high, largely due to limited 
access to medical resources (Ferreccio C et al 1990) (Bijlmer HA et al 1992) (Steinhoff MC
1998). In the US and Europe, less than 5% of all Hib infections in the antibiotic era result 
in death (Clements DA et al 1993), with the highest risk of mortality in neonates and the 
elderly (Anderson EC et al 1995).
In spite of the improved survival associated with antibiotic use, long-term neurological 
morbidity after recovery from Hib meningitis was common. Sequelae included hearing 
impairment and global developmental delay, with estimates of severe residual disability 
occurring after 4-30% of cases, and moderate sequelae in 5-14%, depending on the 
methods of assessment and definitions employed (Sell HW et al 1972) (Feigin RD et al
1976) (Clements DA et al 1993). Thus, prevention rather than treatment of Hib infections 
remained a desirable objective.
1.8 Risk factors for invasive Hib disease
Social and environmental risk factors for invasive disease due to Hib were very similar to
those associated with increased carriage rates. As early as the 1950s, it was noted that Hib
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cases were more likely to have an older sibling at home than the rest of the population 
(Ounsted C 1950) (Ounsted C 1951) (Turk DC 1975) (Istre et al 1985) (Zielinski A et al 
2003). Again, a dose dependent relationship with the number of exposures to other family 
members was observed, with increasing household crowding conferring additional risk 
(Cochi SL et al 1986) (Clements DA et al 1992) (Vadheim CM et al 1992).
In a series of case-control studies, enrolment in day care nurseries (Istre et al 1985) (Cochi 
SL et al 1986) (Takala AK et al 1989) (Clements DA et al 1992) (Fogarty J et al 1995) 
(Zielinski A et al 2003) was the most consistent single variable overrepresented among 
cases. The age specific relative risk of invasive Hib infection in day care decreased with 
age from 12.3 for children less than one year, to 7.2 in 1-2 year olds and 3.8 in 2-3 year 
olds in one large epidemiologic study (Redmond SR et al 1984). Not surprisingly, the 
impact of day care attendance was greatest for children without older siblings in the 
household (Takala AK et al 1989) (Clements DA et al 1992).
Low parental education (Broome CV 1987a) and low household income (Vadheim CM et 
al 1992) were identified as risk factors for Hib disease in two studies. The extent to which 
the relationship with these socio-economic indices was mediated through other variables 
was not clear.
Exposures having an impact on mucosal integrity and immunity were associated with 
alterations in risk. The presence of smokers in the household increased the likelihood of 
disease in one study (Vadheim CM et al 1992). Breast-feeding was protective in several 
studies, particularly in the first 12 months of life (Cochi SL et al 1986) (Takala AK et al
1989) (Petersen GM et al 1991) (SilfVerdal SA et al 1997) (Wolff MC et al 1999).
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Close contact with a child with Hib disease was a strong risk factor for carriage, as noted 
above. Similarly, secondary eases of invasive Hib infection were rare but well described in 
household (Filice GA et al 1978) (Ward JI et al 1979) (Trollfors B 1991) and day care 
settings (Fleming DW et al 1985) (Osterholm MT et al 1987) (Murphy TV et al 1987) 
(Makintubee S et al 1987) (Marks MI 1987). Rarely, a child recovered from Hib infection 
experienced a recurrence of disease, arising either from persistent Hib carriage (Edmonson 
MB et al 1982) or reinfection from a close contact (Cates KL et al 1987). On these 
grounds, Rifampicin was recommended for children recovering from Hib disease and their 
household members in order to break the cycle of transmission (Brunell PA et al 1984) 
(Cartwright KAV et al 1991). Chemoprophylaxis was also advocated for infants in a day 
care centre where two or more cases of invasive disease had occurred within 60 days in the 
US (Brunell PA et al 1984) or within 120 days in Britain (Cartwright KAV et al 1991). 
When given at a dose of 20 mg/kg/day for at least 2 days it was shown to be safe and 
efficacious in eliminating Hib carriage (Murphy TV et al 1983b) (Glode MP et al 1985) 
(Campos J et al 1987). Prevention of secondary disease cases was demonstrated when 
Rifampicin therapy was compared with placebo in randomised controlled trials (Band JD et 
al 1984).
A number of underlying medical conditions were identified as conferring increased risk of 
Hib disease in several studies. Particular host factors predisposing to infections with 
encapsulated organisms included sickle cell disease (Goldblatt D et al 1996), 
immunodeficiency syndromes (Farrand RJ 1970), a history of recurrent infections (Takala 
AK et al 1989) (SilfVerdal SA et al 1997) and some malignancies (Broome CV 1987a). A
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preceding history of non-specific chronic illness (Vadheim CM et al 1992) (Fogarty J et al 
1995) was also over-represented amongst cases.
In the US, African-Americans experienced a higher rate of Hib infections than the 
Caucasian population, although the extent to which this resulted from confounding due to 
social factors was not clear (Broome CV 1987a) (Vadheim CM et al 1992). Among 
indigenous populations in North America and Australia the annual incidence of Hib 
meningitis alone exceeded 150 per 100,000 in children under 4 years of age (Peltola H 
2000). High transmission pressure was believed to contribute to increased rates and early 
onset of disease in these communities (Ward JI et al 1981). Immunoglobulin subclass 
deficiency was noted in Apache children and suggested as a further aetiologic factor (Siber 
GR et al 1990). Genetic differences in immune responsiveness to Hib capsular 
polysaccharide have also been implicated in the marked excess of disease observed in these 
ethnic groups (Siber GR et al 1990) (Lucas AH et al 1999) (Guthridge S et al 2000).
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1.9 Development o f natural immunity against Hib
In 1932, Ward and Wright observed that the bactericidal power of blood against ‘influenza 
bacilli’ depended primarily on humoral antibody (Ward HK et al 1932). Fothergill and 
Wright extended these studies in order to seek an explanation for the striking age specific 
incidence of invasive Hib infections (Fothergill LD 1933). The bactericidal activity of 
human sera collected across a wide age range was tested against a fatal ‘smooth’ strain of 
Hi isolated from a case of meningitis. A reciprocal relationship between bactericidal 
activity and invasive disease incidence was demonstrated, with maternally derived antibody 
providing initial protection, waning to leave infants susceptible over the first few years of 
life. From the age of 3 onwards, levels of immunity were observed to rise, becoming 
permanent in adulthood (Fothergill LD 1933) (Figure 1.3 a). These findings were later 
repeated in similar studies (Norden CW 1974).
Alexander and co-workers provided conclusive proof that the bactericidal antibodies in 
hyperimmune serum were specific for Hib capsular carbohydrates, by demonstrating loss of 
functional activity of serum after absorption with a purified capsular polysaccharide 
preparation (Alexander HE et al 1944). Strong correlation between antibody directed 
towards PRP and the ability to kill Hib strains in vitro (Anderson P et al 1972) (Johnston 
RB et al 1973) and in vivo in animal models (Shaw S et al 1976) (Schneerson R et al 1971) 
was subsequently demonstrated.
More recent population studies of the age distribution of prevalence of anti-PRP antibodies 
consistently found the same inverse relationship with disease incidence as that observed by 
Fothergill and Wright, whether measuring their concentration by haemagglutination
18
Figure 1.3: Relationship between humoral immunity against Hib and invasive disease 
incidence, by age. Figures from:
a) Fothergill LD and Wright J 1933
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(Schneerson R et al 1971), radioantigen binding assay (RABA) (Anderson P et al 1977a) 
(Kayhty H et al 1983a) (Sansoni A et al 1992) (Hazlewood M et al 1993) or enzyme linked 
immunosorbent assay (ELISA) (Ballereau F et al 1999) (Trotter CL et al 2003) (Figure 
1.3b). A naturally occurring antibody concentration of 0.15 ng/ml showed the best 
reciprocal correlation with meningitis incidence in one study in Finland (Kayhty H et al 
1983a) (Figure 1.3c). On this basis, an antibody threshold of 0.15 pg/ml was defined as 
‘protective’ in the short term against invasive Hib infections (Kayhty et al 1983a).
Rising anticapsular antibody titres within individuals have been temporally associated with 
known exposure to Hib following documented episodes of carriage (Michaels RH et al
1977) (Hall DB et al 1987) and recovery from invasive Hib infection (Schneerson R etal 
1971) (Kayhty H et al 1981) (Trollfors B et al 1992). Circumstantial evidence of 
asymptomatic infection in close contacts was inferred from evidence of boosting of specific 
immunity to Hib in children and adults exposed to a disease case in their household 
(Norden CW 1974) or nursery (Greenfield S et al 1972). The magnitude of the antibody 
response increased with age, and was greater in children recovering from epiglottitis than 
meningitis (Johnson FDR et al 1996). Of note, hyporesponsiveness to the Hib capsular 
polysaccharide was observed in children aged less than 18-24 months, who exhibited 
minimal or no serum antibody response to either exposure to the organism or immunisation 
with purified PRP (Norden CW et al 1972) (Anderson P et al 1977a) (Michaels RH et al
1977) (Kayhty H et al 1981). In contrast, the production of specific anticapsular mucosal 
IgA during convalescence from invasive Hib disease appeared to be independent of both 
age and serum IgG levels, and was observed in even the youngest infants (Pichichero ME et 
al 1981).
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Poor serum responses to polysaccharides in human infants are in keeping with a 
progressive sequence of immune responsiveness to different forms of antigen seen in 
humans and other higher vertebrates. Proteins are consistently recognised earlier in 
ontogeny than carbohydrates (South MA 1972) (Howard JG et al 1976) (Goldblatt D 
1998a). Capsular polysaccharides are able to directly stimulate mature B lymphocytes to 
produce antibody without the assistance of T cells, and are thus described as ‘T cell 
independent’ (TI). Immature B cells are unable to respond to TI antigens without the extra 
stimulation afforded by T cell help (Goldblatt D 1998b) (Rijkers GT et al 1998) (Valiante 
NM et al 1999). This observation has been attributed to general immaturity of the B cell 
compartment in infants (Nossal GJV 1997), which may be due to diminished expression of 
CD21 on the surface of neonatal B cells. CD21 is a co-stimulatory receptor that binds 
activated complement components (Rijkers GT et al 1998). An alternative view suggests 
that hyporesponsiveness may simply reflect lack of previous priming exposure to 
polysaccharides in the context of a whole organism, and so is more a marker of 
inexperience than incapacity (Hougs L et al 1999). Whatever the cause, this inability to 
generate a specific immune response against Hib in the first two years of life can be seen to 
correlate with the highest incidence of invasive disease (Figure 1.3a-c).
Antibodies to a range of surface exposed OMPs and lipopolysaccharide were also 
demonstrated in the serum of children convalescing from Hib infection (Gulig PA et al
1982) (Claesson BA et al 1987) (Johnson PDR et al 1993). This observation stimulated 
enthusiasm regarding the potential role of such antigens as vaccine candidates (Gulig PA et 
al 1982). Early reports of passive protection induced by OMP antibodies in an infant rat 
model (Shenep JL et al 1983) were not confirmed in subsequent studies, however
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(Srikumar R et al 1992). This line of enquiry into vaccine development was therefore 
terminated.
A range of other organisms including E coli KlOO and an Actinobacillus species express 
cell wall antigens that cross-react with the Hib capsular polysaccharide (Robbins JB et al 
1973) (Myerowitz RL et al 1978) (Insel RA et al 1982). Of particular note, infants may be 
able to mount an immune response to such antigens at an age when hyporesponsiveness to 
PRP persists (Robbins JB et al 1973). As such, they may have an important role in priming 
for natural immunity. These ‘cross reactive’ antibodies were demonstrated to exhibit 
immunochemical and bactericidal activity against Hib (Myerowitz et al 1978). While cross 
reactive antibodies consistently bound Hib capsular polysaccharide, however, the binding 
of antibodies induced by Hib infection or PRP immunisation to radiolabelled PRP was not 
inhibited by addition of free E coli KlOO capsular polysaccharide (Insel RA 1982). Further, 
vaccination with PRP reduced the proportion of antibodies that were cross reactive in post­
immunisation sera compared with pre-immunisation sera (Insel RA et al 1982). Thus, 
focussing of the immune response towards PRP may be expected to occur over time as 
antibody specificity is skewed in favour of the Hib capsular polysaccharide.
1.10 Function o f anticapsular antibodies
Antibodies to PRP activate both the classical and alternative complement pathways (Steele 
NP et al 1984), and opsonise the organism for phagocytosis (Musher D et al 1986).
Variable correlation between serum IgG levels and bactericidal fimction has been observed 
within individuals (Musher D et al 1986). Such diversity can be explained by differences in 
the avidity of antibody produced in response to PRP exposure (Amir J et al 1990) (Nahm 
MH et al 1995). Avidity refers to the strength of binding of antibodies to long
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polysaccharide chains (Nahm MH et al 1995). Antibodies with weaker binding exhibit less 
function in in vitro assays. TI antigens elicit short-lived antibody responses that do not 
demonstrate classical maturation of avidity, but clonal selection of B cells may result in a 
slight drift towards increasing avidity over time within an individual (Goldblatt D 1998a).
Very high serum levels of specific IgG antibody prevented adherence of Hib to the nasal 
mucosa of infant rats (Kauppi M et al 1993) (vanAlphen L et al 1996). At lower titres, 
bacterial replication at the mucosal surface was diminished, thereby reducing colonisation 
density without eradication (Kauppi M et al 1993) (van Alphen L et al 1996). These 
actions of anti-PRP antibodies to prevent or impair colonisation were not mediated through 
the Fc component of the antibody molecule, and were therefore not dependent on 
complement activation or phagocytosis (Kauppi-Korkeila M et al 1996). The exact 
mechanism of interference with carriage remains unclear, as does the relative contribution 
of antibody derived from serum and mucosal sources.
1.11 Restricted gene region usage in anticapsular antibodies 
Two experimental approaches can be used to characterise the genetic makeup of the 
immune response to Hib: direct sequence analysis of monoclonal antibodies, and 
serological analysis using antibodies directed against the antigen combining site. Genetic 
studies of antibodies reactive against PRP in adults showed marked uniformity of heavy 
( V h )  and light ( V l )  chain variable region gene usage between individuals. Four V h  regions 
and 12 Vl regions were commonly expressed. This consistency of genetic composition led 
to the description of ‘canonical’ combinations of Vh and Vl segments (Adderson EE et al 
1992) (Adderson EE et al 1993) (Lucas AH et al 1999). Vr genes used are of the Vnllla 
and Vnlllb families, in equal distribution. Of these, the Vyllla regions most commonly
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combine with k  light chains, while the VnlHb family pair with either k  or ^ Vl regions 
(Lucas AH et al 1999).
The use of serological probes directed against the antigen combining site has allowed 
extension of these studies to the immune response of infants and children to Hib (Lucas AH 
et al 1999). Two common cross-reactive idiotypes have been identified. HibId-1 is 
expressed by anti-PRP antibodies utilising the kII-A2/A18 variable region. HibId-2 is a 
marker for antibodies containing the A,VII variable region (Granoff DM et al 1993) (Lucas 
AH et al 1999). Idiotypic analysis of the immune response to PRP of both adults and 
children as young as 18 months using HibId-1 demonstrated a consistent pattern of 
expression of this most dominant idiotype across all ages studied. Thus, canonical gene 
usage was seen to be present early in the ontogeny of the immune response to 
polysaccharides (Lucas AH et al 1990) (Lucas AH et al 1999).
1.12 Development ofHih polysaccharide vaccines
As described in section 1.9 above, antibodies with binding specificity for the serotype b 
capsule were demonstrated to have bactericidal fimction against Hib, and provided passive 
protection in animal models. Bacterial polysaccharide immune globulin (BPIG), which 
contains high levels of anti-PRP antibody, was subsequently demonstrated to protect 
humans in high-risk groups against Hib infections (Robbins JB et al 1973) (Santosham M 
et al 1987). On the basis of these observations, the first Hib vaccines to be developed 
comprised purified capsular polysaccharide, PRP. These vaccines were found to be safe 
and immunogenic in adults and children over the age of two years. The peak antibody 
response achieved following immunisation was greater with increasing age (Robbins JB et
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al 1973) (Smith DH et al 1973) (Parke JC et al 1977) (Makela PH et al 1977) (Makela O et 
al 1987). The previously described hyporesponsiveness of immature B cells in children 
less than two years of age to carbohydrate antigens limited PRP immunogenicity in those at 
greatest risk (Makela PH et al 1977) (Kayhty H et al 1984).
As mentioned earlier, PRP is a TI antigen. It further belongs to a subset of polysaccharides 
known as TI-2 antigens, in which T lymphocytes may play a regulatory but not essential 
role. Additional features of the immune response to TI-2 antigens include the inability to 
induce immunologic memory, and an antibody repertoire restricted in both isotype and 
idiotype. As such, each new exposure to a given TI-2 antigen elicits essentially the same 
short-lived antibody response, dominated by IgG2 and IgM (Rijkers GT et al 1998). In 
contrast, ‘memory’ humoral immune responses are characterised by the formation of 
populations of long-lived T and B lymphocytes. Ongoing clonal selection favours the 
survival of B lymphocytes producing antibody of higher binding avidity than is seen 
immediately following primary immunisation (Rajewsky K 1996). These memory B cells 
have the capacity to rapidly produce high titres of antibodies with superior function on re­
exposure to antigen (Ahmed R et al 1996). The isotype distribution of ‘memory’ or 
‘anamnestic’ responses is composed of relatively more IgG and IgA than IgM (Ahmed R et 
al 1996).
In safety and immunogenicity studies, serum anticapsular antibodies declined rapidly 
following immunisation with PRP, particularly in the youngest children (Kayhty H et al 
1984). Following repeat vaccination, antibody titres did not differ significantly from those 
observed in children receiving a first dose of vaccine at the same age, thus confirming the 
anticipated absence of priming for memory responses (Kayhty H et al 1984). In infants
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aged less than 2 years, immune responses were poor, and IgM antibodies to the 
polysaccharide tended to predominate. A shift in dominance to IgG and IgA after this age 
(Kayhty H et al 1983b) possibly reflected natural priming by exposure to Hib or cross­
reactive antigens in the older group (Peltola H et al 1977). The post-primary immunisation 
IgG subclasses observed in children aged 24-83 months were a mixture of IgG 1 and IgG2, 
with a predominance of IgG 1 (Granoff DM et al 1988). Idiotypic analysis of antibodies 
induced by immunisation with PRP revealed no apparent difference from ‘natural’ 
antibodies in expression of the HibId-1 and HibId-2 idiotypes (Lucas AH et al 1999).
1.13 Efficacy o f Hib polysaccharide vaccines
Phase III efficacy trials of Hib polysaccharide vaccines confirmed the clinical relevance of 
these attributes of the immune response to a TI-2 antigen. Estimates of efficacy over the 
first 5 years of life in the US were low, in the order of 40% (Parke JC et al 1977). Large- 
scale Finnish trials involving approximately 98,000 children aged 3 months to 5 years 
clarified estimates of age specific efficacy. No protection against invasive Hib infection 
was observed in children under 15 months. In contrast, of 13 Hib disease cases detected 
over the first year following immunisation in children older than 15 months, none occurred 
in the cohort who had received Hib vaccine (Makela PH et al 1977). During the second 
year of follow-up, some waning of vaccine protection was observed, with 2 Hib cases 
reported in children immunised at 18 months of age or older compared with 5 in the control 
group, although one apparent vaccine failure had a predisposing risk factor for meningitis 
(Peltola H et al 1977). After four years, vaccine efficacy in these older children was 
calculated to be 90% (Peltola H et al 1984). Given the distribution of Hib incidence over 
the first 5 years of life, it was estimated that immunisation at 18 months of age could result 
in a 60% reduction in all Hib disease in Finland (Peltola H et al 1984).
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Based on the results of these clinical trials, an antibody concentration of 1.0 pg/ml or 
greater was suggested to be the best correlate of immunisation induced protection against 
Hib meningitis (Kayhty et al 1983a) (Peltola H et al 1984). This figure was considerably 
higher than the protective level of 0.15 pg/ml associated with naturally acquired antibody. 
It was suggested that the difference may be explained by the presence of antibodies to 
bacterial components other than the polysaccharide following Hib exposure, or inferior 
binding avidity of antibody induced by PRP immunisation (Kayhty et al 1983a) (Peltola H 
et al 1984).
Nasopharyngeal carriage of Hib was not affected by immunisation in the Finnish trials. 
Pre-vaccination prevalence of colonisation was 4.6% in the children who took part, rising 
two years later to 7.4% in the Hib vaccinated group, and 7.7% in the unimmunised (Peltola 
H etall977).
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1.14 Development of Hib conjugate vaccines
The limitations of polysaccharide vaccines as described above - absence of protection in the 
most vulnerable group of infants, and short-lived immunity, necessitated further vaccine 
development. These problems can be seen to have arisen from the nature of the Hib 
capsular polysaccharide itself, which is a TI-2 antigen.
As early as 1929, Avery and Goebel observed that physical coupling of monosaccharides to 
protein antigens produced immunogenic complexes that elicited antibody production 
specific to the carbohydrate moiety in rabbits (Avery OT et al 1929). Further studies of 
antibody production induced by carbohydrates conjugated to a series of protein carriers 
suggested that distinct receptors (Mitchison NA 1967), perhaps present on different cell 
populations (Rajewsky K et al 1969) were responsible for recognising the two separate 
classes of antigenic determinants thus represented. Both T and B lymphocytes were 
subsequently shown to co-operate in the response to hapten-carrier complexes. Interaction 
between lymphocyte populations was possible as long as the two antigens were chemically 
coupled, even when separated by a spacing molecule (Fong et al 1978).
This engagement of T cell help was characteristic of the immune response to protein 
antigens, which is thus termed T cell dependent (TD). Epitopes of proteins ingested and 
degraded by antigen presenting cells are expressed on the cell surface in association with 
major histocompatibility complex (MHC) class II molecules. T cells recognising these 
antigeniMHC complexes become activated and assist B cells expressing the same protein 
epitopes to produce antibody through secretion of cytokines and binding of co-stimulatory 
molecules (Figure 1.4). TD responses are age independent, and induce populations of long-
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Figure 1.4: Cellular interactions involved in the immune response to conjugates, 
figure from Ada G 2001
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lived memory B cells that produce antibodies demonstrating maturation of binding avidity 
over time (Insel RA 1995) (Rajewsl^ K 1996) (Nossal GJV 1997) (Goldblatt D 1998a) 
(Ada G 2001).
This means of converting a TI to a TD antigen was recognised to have potential for 
application to the production of vaccines against encapsulated organisms (Anderson P et al 
1985). Several groups of researchers, working in parallel, developed the first vaccines 
against Hib based upon the hapten-carrier principle. Smith and Anderson produced a 
vaccine in which PRP oligosaccharides were directly coupled with CRM197, a mutant 
diphtheria toxin. The conjugate was more immunogenic than PRP alone in weanling 
rabbits and primed for memory responses (Anderson P et al 1977b). Schneerson and 
Robbins established that, when chemically coupled with a range of proteins including 
diphtheria and tetanus toxoids via a spacer molecule, the immunogenicity of intact PRP 
polymers in mice, rabbits and monkeys was enhanced (Schneerson R et al 1980, 1984).
Following further studies in animal models and adults, Hib conjugate vaccines 
incorporating a range of carrier proteins including diphtheria toxoid (PRP-D) (Eskola J et al 
1985), C R M 1 9 7  (HbOC) (Anderson P et al 1985,1987), tetanus toxoid (PRP-T) (Claesson 
BA et al 1989) and Neisseria meningitidis outer membrane proteins (PRP-OMP) (Einhom 
MS et al 1986) were shown to be safe and immunogenic in human infants. In addition, 
antibody responses deemed protective could be elicited in groups of children previously 
identified to be at increased risk of invasive Hib infection, including those with sickle cell 
disease or immunoglobulin subclass deficiency (Weinberg GA et al 1990). Conjugate 
vaccines were also immunogenic in individuals recovered from invasive Hib infection
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(Kaplan SL et al 1988), including those who had developed disease despite immunisation 
with PRP (Weinberg GA et al 1990).
The primary response to conjugate vaccines was dominated by IgG (Granoff DM et al 
1988) (Granoff DM et al 1993), with the vast majority of antibodies in infants following 
primary immunisation belonging to the IgGl subclass (Kayhty H et al 1988) (Weinberg GA 
et al 1988) (Granoff DM et al 1988). Boost responses were a mixture of IgGl and IgG2 
(Kayhty H et al 1988) (Weinberg GA et al 1988). Transudation of IgG to mucosal surfaces 
was observed at high serum antibody levels following vaccination, as measured in saliva 
(Kauppi M et al 1995). IgA antibodies were also found in saliva. Following primary 
immunisation these were mainly of the IgA2 subclass, which is usually produced locally in 
the mucosa. Following boosting in the second year of life, a shift to IgAl predominance 
was seen, reflecting increased serum levels of IgA (Kauppi-Korkeila M et al 1998).
Priming for immunologic memory was evidenced by mature for age responses to booster 
doses of plain PRP at 9-12 months following Hib conjugate immunisation in infancy 
(Anderson P et al 1985, 1987) (Goldblatt D et al 1998c). These recall responses were later 
characterised as rapid, detectable within 7-10 days of booster immunisation (Dagan Ret al 
2001). Further evidence of induction of immunologic memory was inferred in subsequent 
studies from the demonstration of avidity maturation of antibody over the year following 
primary vaccination (Goldblatt D 1998d) (Pichichero M et al 1999).
The four Hib conjugate vaccines that have been licensed for use, PRP-D, HbOC, PRP-
OMP and PRP-T, varied in their carrier proteins, size and structure of polysaccharide
molecules and chemical means of combining the two (Decker MD et al 1998) (Figure 1.5).
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Figure 1.5: Structure of different Hib conjugate vaccine formulations, figure from 
Decker MD et al 1998
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These differences were reflected in their immunogenicity and ability to prime for memory 
responses (Lucas AH et al 1999). PRP-D was the least immunogenic preparation in infants 
and is no longer in routine use in most countries (Decker MD et al 1998) (Weinberg GA et 
al 1988). Unlike PRP-T and HbOC, PRP-OMP elicited high antibody concentrations 
following the first dose in infants as young as 2 months of age (Granoff DM et al 1993) 
(Decker MD et al 1998). It was suggested that its superior immunogenicity was due to 
OMP acting as both carrier and adjuvant (Perez-Melgosa M et al 2001). While this would 
appear advantageous, priming with PRP-OMP resulted in only modest memory immune 
responses on subsequent boosting, far smaller than either of the other two conjugate 
formulations (Lucas AH et al 1999).
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Additional evidence of superior printing for memory by PRP-T and HbOC was 
demonstrated by a greater focussing of the range of antibody producing cells produced by 
vaccination. A preponderance of antibodies expressing HibId-1 was seen after primary 
immunisation with either the tetanus or CRM197 conjugate, compared with the production 
of a wide range of idiotypes in response to PRP-OMP. Following boosting with plain 
polysaccharide, this difference became more marked (Granoff DM et al 1993) (Chung GH 
et al 1995) (Lucas AH et al 1999). Minor sequence polymorphisms leading to structural 
variations in canonical antibodies have been demonstrated to impact on avidity and 
functional activity (Lucas AH et al 2003). Regardless of the idiotypes produced, evidence 
of superior avidity maturation leading to improved function was observed following HbOC 
or PRP-T compared with PRP-OMP (Schlesinger Y et al 1992) (Chung GH et al 1995) 
(Lucas AH et al 1995). It should further be noted that variation in immunogenicity and 
functional activity of PRP-T and HbOC between vaccine lots was also demonstrated in 
these studies (Granoff DM et al 1993) (Chung GH et al 1995).
1.15 Efficacy trials o f Hib conjugate vaccines
Phase III trials of PRP-D (Eskola J et al 1987,1990), HbOC (Black SB et al 1991) 
(Vadheim CL et al 1994) and PRP-T (Vadheim CL et al 1993) (Booy R et al 1994) showed 
83-100% protection against invasive Hib infections in Western children following three 
doses of conjugate vaccine in infancy. Higher estimates of efficacy were obtained after a 
booster dose in the second year of life in the studies where initial protection was less than 
100%. Consistent with the enhanced immunogenicity profile of conjugate vaccines in 
infants, vaccine effect was independent of age (Heath PT 1998). A large-scale field trial of 
PRP-T in the Gambia demonstrated not only 95% protection against classical invasive Hib 
disease, but also a 2 1 % reduction in all cases of radiologically confirmed pneumonia
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(Mulholland K et al 1997). This study demonstrated that Hib was a more common cause of 
bacterial pneumonia in children than had earlier been thought, suggesting that the impact of 
Hib vaccines in the developing world could be greater than previously estimated.
Post licensure surveillance of Hib conjugate vaccines has shown near eradication of disease 
in the short term in almost all Western countries which have implemented them including 
the US (Shinefield HR et al 1995) (Bisgard KM et al 1998), Canada (Wenger JD 1998), the 
United Kingdom (UK) (Slack MPE et al 1998) the Netherlands (vanAlphen L et al 1997) 
and Scandinavia (Jonsdottir KE et al 1992) (Peltola H et al 1999) (Garpenholt O et al 
2000). Unfortunately, high cost of the vaccine has limited its global distribution. 
Consequently, it is estimated that as little as 8 % of Hib disease is prevented worldwide by 
immunisation, a figure which falls to 2 % if radiologically confirmed pneumonia believed to 
be attributable to Hib is included (Peltola H 2000).
At a population level, a marked and unanticipated indirect effect of immunisation was 
observed due to the ability of Hib conjugate vaccines to delay acquisition of oropharyngeal 
carriage of the organism in infancy (Murphy TV et al 1993) (Barbour ML et al 1995) 
(Adegbola RA et al 1998) (Forleo-Neto E et al 1999) (Fernandez J et al 2000). This effect 
on acquisition was relatively short-lived in the face of ongoing community transmission of 
the organism. Children vaccinated as babies in early phase II studies of Hib conjugate 
vaccines were demonstrated to carry at the same prevalence as unvaccinated children by 
pre-school age. Interestingly, the density of colonisation in the immunised group, assessed 
by quantitative methods, appeared to be reduced (Barbour ML et al 1993).
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With widespread vaccine uptake, however, a sustained reduction in Hib colonisation 
prevalence was seen in a wide range of countries including Finland (Takala AK et al 1991), 
the US (Mohle-Betani JC et al 1993) and the UK (Heath PT et al 1997). Subsequent 
interruption of transmission resulted in a decrease in the incidence of invasive Hib 
infections in all age groups, even those too young or old to be immunised. This ‘herd 
immune’ effect was most marked initially in the UK, where the introduction of routine 
infant vaccination was augmented by a catch-up campaign involving all children less than 
four years of age. Hib disease incidence was subsequently observed to fall rapidly in all 
age groups within twelve months (Rushdy A et al 1999). This was in contrast to the 
situation in the Netherlands where catch-up immunisation was not employed, and disease 
rates in the unvaccinated cohorts declined slowly over several years (vanAlphen L et al 
1997).
Serological correlates of protection against Hib had been defined for immunity acquired 
naturally and following polysaccharide vaccination (Kayhty H et al 1983a). As Hib 
conjugate vaccines do not only produce short-lived antibody responses, but prime for 
immunologic memory, reliable markers correlating with efficacy were more difficult to 
define (Plotkin SA 2001). Figures published from the UK in 2000 showed that Hib 
antibody concentrations waned rapidly following primary immunisation, without apparent 
loss of vaccine impact. Ongoing clinical protection was attributed to a combination of 
immunologic memory and herd immunity (Heath PT et al 2000). Persistence of boost 
responses to PRP was observed at 4-5 years (Scheifele DW et al 1999) and 9-10 years 
(Makela PH et al 2003) of age in children primed in infancy with conjugate vaccines. Such 
demonstration of memory immune responses, with maturation of avidity, was considered 
by some to be sufficient to expect efficacy (Kayhty H 1994) (Granoff DM 2001).
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Functional measures of the immune response were thought to be more predictive of disease 
prevention within an individual than the serum antibody concentration per se, but these 
were time consuming and more difficult to employ on a large scale (Granoff DM et al 
1995).
Definition of protective correlates was also complicated by the strong indirect protective 
effects associated with widespread immunisation. Interruption of Hib transmission through 
a reduction in carriage meant that the protection afforded to an individual by vaccination 
was greater than could be estimated by serum antibody concentrations alone (Kayhty H 
1994). It was further difficult to determine the critical antibody concentrations required to 
maintain herd immunity. One study attempted to define serum IgG anticapsular antibody 
concentrations associated with reduced Hib carriage (Fernandez J et al 2000). Based on the 
correlation between post immunisation antibody concentrations with documented 
colonisation several months later, a protective titre of 5 pg/ml or greater was suggested. 
Given the low levels of antibody observed in countries like the UK in association with 
persistent herd immunity (Heath PT et al 2000), it is likely that this threshold was an 
overestimate.
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1.16 A cautionary tale: Hib conjugate vaccines in Alaska
The fallibility of conjugate vaccines has been evidenced in specific high-risk populations. 
PRP-D vaccine was estimated to be 83% effective in preventing invasive Hib infections 
after 3 doses in Finnish infants (Eskola J et al 1987). In contrast, the observed efficacy in 
Alaskan native infants in a similarly conducted study was only 35% (Ward JI et al 1990). 
Prior to vaccination, this ethnic population experienced extremely high rates of disease with 
an observed incidence of 332 cases per 100,000 in children under 5 years of age (Singleton 
R et al 2000). The incidence of early-onset disease was as high as 2960 per 100,000 in the 
first year of life among infants in the Yukon Kuskokwim Delta (Singleton RJ et al 1994). 
The more immunogenic conjugate vaccine PRP-OMP proved to be more effective than 
PRP-D in this population, reducing invasive Hib incidence to just 17 per 100,000 under 5 
years of age after its introduction in January 1991 (Singleton R et al 2000).
Following this initial success, however, an alarming resurgence of disease was observed 
among Alaskan native children in 1996-1997, predominantly in age-appropriately 
immunised children. Associated factors were a recent switch to primary immunisation 
using HbOC (Lucher LA et al 1999) and evidence of high prevalence of ongoing 
nasopharyngeal carriage among children living in rural areas (Singleton R et al 2000). No 
evidence of clonal shift among Hib strains isolated from carriers or cases, which would be 
suggestive of changing virulence of the organism, could be found (Lucher LA et al 2002). 
The conclusion was made that the poorer immunogenicity of HbOC after one or two doses 
had left infants vulnerable to acquiring Hib infection in the face of high transmission 
pressure. It was once again recommended that PRP-OMP be used for initial immunisation 
of all infants (Bulkow LR et al 1999) (Singleton R et al 2000). It remained unclear which
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age groups were the primary reservoir for ongoing Hib colonisation in these communities 
(Dargan JM et al 2000).
This experience highlighted the importance of tailoring vaccine delivery to suit the 
observed pre-vaccine epidemiology of invasive Hib infections within a given population. It 
also warned against assuming equal efficacy of immunisation in all settings when 
predicting possible vaccine impact.
1.17 Conclusion
Hib is an organism that commonly colonises the upper respiratory tract of humans. More 
rarely, it invades into the bloodstream, producing localised infections including meningitis 
and epiglottitis, making it a significant cause of morbidity and mortality worldwide. The 
ability of the serotype b capsule to prevent activation of the alternative complement 
pathway is postulated to be a major virulence determinant. This assertion is strengthened 
by the observation that antibodies directed against the capsular polysaccharide PRP 
correlate with bactericidal activity in serum.
Infants and children under the age of two years exhibit immune hyporesponsiveness to 
carbohydrates including PRP, which are TI antigens. This places them at greater risk of 
developing serious infection due to Hib. In consequence, the first Hib vaccines to be 
developed based on the capsular polysaccharide were ineffective in preventing disease in 
this group of children at greatest risk. Conjugate vaccine technology was able to overcome 
this limitation. Chemical coupling of PRP with a range of protein carriers converted it to a 
TD antigen, to which infants could mount a specific immune response. TD antigens prime 
for immunologic memory, characterised by maintenance of populations of long lived B
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lymphocytes which rapidly produce highly functional antibody on re-exposure to the 
priming antigen. Antibodies induced in infants by conjugate immunisation appear identical 
to those resulting from natural exposure to Hib.
In keeping with their enhanced immunogenicity, Hib conjugate vaccines have proven 
highly efficacious in the prevention of invasive disease both in large-scale vaccine trials 
and following widespread implementation in whole populations. An additional indirect 
benefit of immunisation was conferred by the ability of conjugates to delay acquisition of 
Hib carriage, thus reducing ongoing transmission. A note of caution was introduced by 
reports of a resurgence of Hib disease in Alaskan native infants. The initiating event was a 
switch to the use of a less immunogenic conjugate vaccine formulation 5 years after Hib 
immunisation was introduced. This experience highlighted the fallibility of vaccines and 
the importance of tailoring the scheduling and type of conjugate vaccine used to underlying 
epidemiology.
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Chapter 2 -  Implementation of the Hib vaccine schedule in the UK -  epidemiologic 
consequences
2.0 Introduction
Conjugate vaccines against Hib were introduced into the UK’s routine infant immunisation 
schedule in October 1992. In contrast to many other developed countries, the vaccine was 
administered as an accelerated primary infant course at 2, 3 and 4 months of age, without a 
booster dose. Between 1992 and 1993, a ‘catch-up’ immunisation scheme for children 
under four years of age supplemented the vaccine’s implementation (O’Brien H 1994). 
Despite an initial dramatic reduction in invasive Hib disease in all age groups, a resurgence 
of infections was noted from 1999 onwards. The number of reports of serious Hib disease 
almost doubled each year from that time until 2002, with the majority of cases occurring in 
fully immunised children (Trotter CL et al 2003a).
2.1 Hib vaccine introduction and scheduling in the UK
The UK has changed the timing of its primary infant immunisation schedule several times 
over the last forty years. In the early 1960s, an accelerated three dose primary course of 
diphtheria, tetanus and pertussis was given followed by a booster in the second year of life. 
In response to low uptake of the fourth dose, the fourth dose was dropped and the schedule 
lengthened to 3 ,4 V2 - 5  and 8 V2 - 1 1 months of age to maximise immunogenicity. This 
decision was made despite concerns that attendance for immunisation was poorest after 6 
months of age (Ramsay ME et al 1991) and therefore in May 1990 to further improve 
immunisation coverage the switch was made back to the accelerated schedule at 2, 3 and 4 
months without a subsequent booster (Ramsay ME et al 1991). Comparable 
immunogenicity and safety of both regimens was confirmed in controlled studies (Ramsay
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ME et al 1992, 1993). In addition, antibody titres deemed protective against diphtheria, 
tetanus and pertussis were demonstrated to persist for 4 years after an accelerated course 
completed by the age of 6  months (Ramsay ME et al 1991).
Conjugate Hib vaccines were introduced into this infant schedule in October 1992, to be 
given concomitantly with the triple vaccine. In a relatively unique decision for a 
developed country, no booster dose was included
(http://www.hpa.org.uk/infections/topics_az/vaccination/vac_sced.htm). In North 
America, Hib was scheduled for use at 2 ,4  and 6  months of age, with a fourth dose at 12- 
18 months (http://www.cdc.gov/nip/recs/child-schedule.PDF). In Scandinavian countries, 
the primary course was most commonly 2 doses, at 3 and 5 or 4 and 6  months, with a 
booster late in the first or early in the second year of life (Peltola H et al 1999). While no 
formal policy statement regarding the absence of a fourth dose accompanied vaccine 
introduction in the UK, subsequent authors attributed the lack of need for a booster to the 
conjugate vaccine’s ability to prime for immunologic memory (Booy R et al 1997).
Over the first 12 months of Hib vaccine implementation, ‘catch-up’ immunisation was 
recommended for all children under 48 months of age. Those less than 13 months old 
were given 3 doses of vaccine and older cohorts received a single dose (O’Brien H 1994). 
Coverage data from a single child health record’s system in the North East Thames region 
provided the best available estimate of national catch-up immunisation uptake (O’Brien H 
1994). Quarterly rates of coverage achieved in relation to vaccination targets are shown in 
Figure 2.0. By the end of 1993, uptake by birth cohort over the first year of the campaign 
was as follows: 1989 (3-4 year olds) -  34%, 1990 (2-3 year olds) -  77%, 1991 (1-2 year 
olds) -  87% and 1992 ( 6  month-1 year olds) -  89% (O’Brien H 1994).
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Figure 2.0: Cumulative coverage of Hib catch-up immunisation in North East 
Thames by birth cohort and quarter (from O’Brien H, 1994).
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Figure 2.1: Uptake of 3 doses of Hib vaccine by 12 months of age, compared with a 
single dose of MMR vaccine by 24 months of age (source: COVER data, 
http://www.hpa.org.uk/cdr/archive04/immunisation04.htm)
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2.2 Hib vaccine coverage in the UK 1993-2003
High rates of Hib vaccine coverage for the infant primary course have consistently been 
achieved over the past 10 years as recorded in the Coverage of Vaccination Evaluated 
Rapidly (COVER) statistics collated quarterly throughout the UK by the Health Protection 
Agency (HPA) (http://www.hpa.org.uk/cdr/archive04/immunisation04.htm). Figure 2.1 
shows uptake of 3 doses of Hib by the first birthday in the UK, by quarterly birth cohorts. 
Adverse publicity surrounding the measles, mumps and rubella (MMR) vaccine (Taylor B 
et al 1999) has resulted in declining coverage for a single dose of this vaccine by 2  years, 
now below 80% (Figure 2.1). No such impact has been observed on the other vaccines in 
the primary infant immunisation schedule.
2.3 Hib conjugate vaccine formulations used in the UK
A  number of conjugate vaccine formulations have been licensed for use in the UK over the 
past 10 years (Dr M Ramsay, Immunisation Department, HPA, personal communication) 
(Table 2.0). Different manufacturers’ vaccines were used for catch-up and routine 
immunisation in 1992. Hib was administered in a separate syringe as a single antigen until 
1996, after which time it became available for use as one injection with diphtheria, tetanus 
and whole cell pertussis vaccines (DTwP-Hib). A global shortage of DTwP-Hib 
necessitated the use of a corresponding preparation containing an acellular pertussis 
vaccine (DTaP-Hib), which was distributed in the UK after December 1999 (Figure 2.2). 
Glaxo SmithKline withdrew Trivax-Hib from sale in the UK in 2000.
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Table 2.0: Hib conjugate vaccines licensed for use in the UK, 1992-2003.
Year
Licensed
Type of 
Conjugate
Vaccines in 
combination
Trade
Name
Manufacturer
1992
(infant)
PRP-T Nil Act-Hib Aventis
Pasteur
1992
(catch-up)
HbOC Nil Hibtiter Wyeth
1996 HbOC mixed with 
DTwP
Hibtiter Wyeth
1996 PRP-T DTwP Act-Hib
DTwP
Aventis
Pasteur
1997 PRP-T DTwP Trivax-Hib Glaxo
SmithKline
1999 PRP-T DTaP Infanrix-Hib Glaxo
SmithKline
Figure 2.2: Hib vaccine formulations distributed in the UK by month, December 1999 
to October 2001. Source: Dr Mary Ramsay, Immunisation Department, HPA
□  Infanrix-Hib O Act-Hib DTP DHib alone ■  Trivax-Hib
100% 
90% - 
80% - 
70% - 
60% - 
50% - 
40% - 
30% - 
20% - 
10%  - 
0%
O) O O CD O CD o
CD CD CD CD o CD o CD O CD CD
Ü JD iL C 6 ) ■è (!) jO iL C O)(D Q) 9- 3 D 0) 0) 3 3
Q LL. < “ 3 < o O U_ < —i <
o
t3O
44
2.4 Impact o f Hib immunisation on invasive disease in the UK 
Literature Review
Prior to the introduction of Hib vaccination, the Publie Health Laboratory Serviee (PHLS) 
established a Regional Survey of invasive Hi disease (Anderson EC et al 1995). The 
purpose for this network of microbiology laboratories was to provide an accurate 
assessment of the baseline Hib disease burden in the UK, from which to monitor the 
impact of introducing routine immunisation. The Survey was initiated in Oxford in 1985, 
extended to Wales in 1988 and was expanded to include four additional healthcare regions 
(East Anglia, Northern, North-Western and South-Western) in 1990. The population 
denominator thus represented was approximately 35% of all England and Wales (Anderson 
EC et al 1995).
The case definition of invasive Hi infection required isolation of the organism from a 
normally sterile site, or detection of Hib antigen in conjunction with Gram-negative 
organisms on Gram stain. Strains were typed in local laboratories, and sent to one of two 
centralised referenee laboratories (Oxford in England, Bangor in Wales) for confirmatory 
identification by immunotyping and polymerase chain reaction (PCR). Reports were 
compared with two additional sources of data in order to maximise ascertainment. These 
were notifications of meningitis obtained by the Office for National Statistics (ONS), and 
all invasive Hi disease reported directly to the PHLS Communicable Disease Surveillance 
Centre (CDSC) (Anderson EC et al 1995).
Of almost 1,000 reports of invasive Hi infeetions made over a 2-year period, 82% were due 
to Hib. The age specific incidence of Hib disease calculated in this survey is shown in 
Figure 1.2 of Chapter 1. As in other developed countries, children between 6  months and 2
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years of age were at highest risk, with a decline in incidence thereafter. In all, 8 8 % of 
notified cases occurred by the age of 5 years. The distribution of clinical presentations by 
age group is shown in Table 2.1. Hib most commonly caused meningitis in ehildren and 
pneumonia in adults. Epiglottitis was relatively rare in children less than 2 years of age. 
The case fatality rate for all Hib infections was 3.9% (95% Cl 2.6-5.5), with most deaths in 
neonates and the elderly (Anderson EC et al 1995). These patterns were similar to those 
previously reported from the Oxford region alone (Booy R et al 1993).
Table 2.1: Clinical presentation with invasive Hib infection, by age group, PHLS 
Regional Survey (from Anderson EC et al 1995)
Clinical
Diagnosis
Total
Cases
% o f
all
cases
No
cases
< 2
yrs
% of 
cases 
< 2  
yrs
No
cases
2-15
yrs
% o f
cases
2-15
yrs
No
cases
>15
yrs
% o f
cases
>15
yrs
Meningitis 437 56 314 65 1 1 1 52 8 1 2
Epiglottitis 1 1 1 14 34 7 6 6 31 1 0 15
Pneumonia 41 5.5 13 3 7 3 2 1 31
Cellulitis 54 7 50 1 0 3 1.5 1 1.5
Septie arthritis 37 5 24 5 1 1 5 2 3
Osteomyelitis 6 < 1 6 1 0 0 0 0
Bacteraemia 63 8 27 6 15 7 18 27
Other 2 0 2.5 13 3 0 0 7 1 0
Unknown 3 < 1 2 < 1 1 < 1 0 0
Total 772 1 0 0 483 1 0 0 214 1 0 0 67 1 0 0
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2.4.1 Overall trends in disease presentation after vaccine introduction 
Methods
Following Hib vaccine introduction, surveillance for invasive Hi infections was extended 
beyond the regional survey to include all of the UK and Republic of Ireland. As before, 
local laboratories were asked to refer strains to central laboratories in England and Wales 
to confirm identification by serotyping and PCR. From 1995 onwards, all isolates were 
sent to a single Haemophilus Reference Unit (HRU), based at the John Radcliffe Hospital 
in Oxford (Trotter CL et al 2003a). For isolates not referred to the HRU, the source 
laboratory typing results were used. In order to meet the case definition for the purposes of 
this analysis, Hib had to be cultured either from a normally sterile site or from an upper 
airway swab in a patient presenting with clinical epiglottitis.
Additional clinical reports were made through the orange card reporting system of the 
British Paediatric Surveillance Unit (BPSU) between 1992 and 2000. Every paediatrician 
in the UK received a monthly reporting card asking whether one or more of a number of 
notifiable diagnoses had been seen in the preceding month. From 1992 to 1995, clinicians 
were asked to report invasive Hi infections in vaccinated children, and in all children 
regardless of vaccination status from 1995 onwards. Cases identified in this way were 
followed up by the HRU in order to obtain an isolate, if possible.
The BPSU study was conducted in collaboration with the Oxford Vaccine Group (OVG) of 
the University of Oxford Department of Paediatrics, who had a particular interest in 
clinical and immunological risk factors associated with Hib vaccine failure (Booy R et al 
1997). Ethical approval for the study was obtained from the Central Oxford Research
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Ethics Committee in 1991, and again from the South-East Multi-Centre Research Ethics 
Committee in 2001 (McVemon J et al 2003b).
Data represented in the figures below were derived from a single reconciled 
dataset maintained by the HPA’s HRU and CDSC. Reports of cases presenting to the end 
of June 2003 were included, as downloaded in September 2003. Due to less consistent 
ascertainment from areas of the UK outside England and Wales, figures were reported 
from these two countries only.
Results
The distribution of all invasive Hi reports, by typing status and serotype, is shown in 
Figure 2.3. The proportion of isolates typed over the period improved from 70% in 1990 
to 80% in 2002. This increase reflected greater referral of strains to the HRU with time. 
Hib’s relative contribution to the total burden of Hi infeetions fell sharply after 1992, 
remaining low to 1998, but rose again subsequently.
A dramatic reduction in all invasive Hib infections was observed following introduction of 
widespread vaccination late in 1992. This effect was not restricted to children of an age 
eligible for immunisation (Figure 2.4). Excellent disease control was maintained until 
1999, when the number of eases began to rise, most markedly in ehildren aged 1-4 years, 
and adults 15 years or older. Despite a steep increase in paediatric reports between 1999 
and 2 0 0 2 , numbers remained well below those observed prior to vaccine use.
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Figure 2.3: Serotype distribution of all invasive Hi reports, 1990-2002
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Figure 2.4: Invasive Hib infections by age group, England and Wales 1990-2002. 
Combined CDSC/HRU dataset.
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The most marked impact of vaccine on disease reduction was seen in children less than 
two years of age. Figure 2.5 shows the median paediatric (<15 years) age at presentation 
with Hib, by year, with interquartile ranges. An increase in the most common age at 
disease from the second to the third year of life reflected high vaccine efficacy in the 
youngest infants. There was no corresponding shift of the burden of Hib to older age 
groups (5 years and older) who had not previously experienced high rates of invasive 
infection.
Figure 2.5: Median age at presentation with invasive Hib infection, 1990-2002. 
Broken lines represent interquartile ranges.
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Clinical presentations of invasive Hib infection by age group over the period 1993 to 2002 
are given in Table 2.2. Data are presented according to the same age divisions used in 
Table 2.1, describing the condition pre-vaccination. Apart from an increase in the 
proportion of cases presenting with bacteraemia in the paediatric age groups, no change in 
the distribution of age specific presentations was observed. It is likely that the increased 
diagnosis of bacteraemia may reflect an increasing clinical trend to take blood cultures
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from febrile children in the UK in recent years, rather than representing any real 
epidemiological change.
Table 2.2: Clinical presentation with invasive Hib infection by age group, England & 
Wales, 1993-2002
Clinical Total % o f No % o f No % o f No % o f
Diagnosis Cases all cases cases cases cases cases cases
cases < 2 < 2 2-15 2-15 >15 >15
yrs yrs yrs yrs yrs yrs
Meningitis 348 33 203 59 1 2 1 33 24 7
Epiglottitis 178 17 19 5 93 26 6 6 18
Pneumonia 119 1 1 1 0 3 13 4 96 27
Cellulitis 32 3 19 5 7 2 6 2
Septic arthritis 32 3 17 5 8 2 7 2
Osteomyelitis 1 < 1 1 < 1 0 0 0 0
Bacteraemia 182 17 40 1 2 59 16 83 23
Other 174 16 37 1 1 61 17 76 2 1
Unknown 1 < 1 1 < 1 0 0 0 0
Total 1067 1 0 0 347 1 0 0 362 1 0 0 358 1 0 0
The overall Hib case fatality rate rose from 3.9% to 7.5% (95% Cl 5.9, 9.5) with 
widespread vaccine use. It had previously been observed that mortality from Hib is 
highest in infants under 6  months of age and the elderly (Anderson EC et al 1995). In this 
dataset, the death rate in children aged 6  months to 15 years was 4.4% (2.9, 6.5), rising to
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13.3% (9.5, 18.0) in adults 15 years and older. With a fall in paediatric cases, the relative 
contribution of adult data to mortality statistics was greater, thereby increasing the overall 
proportion of cases in which death was the outcome. Of particular importance, there was 
no statistically significant difference in death rates between vaccinated [3.6% (2.2, 5.6)] 
and unvaccinated [4.6% (1.5,10.4)] children with invasive Hib infection.
2.4.2 Incidence of invasive disease in children under 5 vears of age, vaccination status and
duration of protection bv vaccination
Methods
Numbers of disease reports by age for children under 5 years in England and Wales were 
converted to incidence rates using annual population denominators reported by the ONS 
rhttp://www.statistics.gov.ukV Because of the change in case ascertainment through the 
BPSU study in 1995, when unvaccinated as well as vaccinated cases were included, only 
figures from 1996 onwards were included to ensure comparability.
Vaccination status of Hib cases was confirmed by contacting the child’s usual general 
practitioner, or from computerised records held in local child health departments. 
Immunisation dates and batch numbers were collected and stored on the CDSC/HRU 
database. From this information, the proportion of children presenting with Hib infection 
could be calculated who had received three doses of vaccine in the first year of life, prior to 
onset of disease.
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Figure 2.6: Annual incidence of invasive Hib infections in children less than 5 years of 
age, England and Wales reports to June 2003, combined CDSC/HRU dataset. 
(Percentage in brackets refers to proportion of cases occurring after three doses of 
vaccine in infancy)
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Figure 2.7: Cumulative number of vaccinated children presenting with invasive Hib 
infection in each birth cohort year by age in days: England and Wales reports to June 
2003, combined CDSC/HRU dataset.
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Age at onset of disease was calculated for vaccinated children with confirmed invasive Hib 
infection. Results were grouped by year of birth cohort, in order to compare the duration 
of protection conferred by the vaccine over time.
Results
The incidence of invasive Hib infection in children less than 5 years of age in England and 
Wales is shown in Figure 2.6. Following a nadir of 0.68 per 100,000 in 1998, disease 
incidence rose steadily to 4.6 per 100,000 in 2002. As can be seen from the proportion of 
children presenting each year who had been fully immunised, the majority of the increase 
in disease occurred in the vaccinated proportion of the population, rising from 6 8 % in 1998 
to 91% in 2002.
Figure 2.7 plots the cumulative number of Hib reports arising from children bom in 
sequential years. Changes in the duration of protection conferred by immunisation can be 
seen in birth cohorts as early as 1998. An increase in the number of cases was observed in 
children bom each year from 1998 to 2000. In addition, the onset of disease was earlier in 
each successive group, with a marked reduction in the 2000 birth cohort. While very few 
children bom in 2002 had presented with invasive Hib infection by the end of June 2003, 
the data shown suggest some improvement in vaccine protection compared with those bom 
in 2 0 0 0 /2 0 0 1 .
2.4.3 Incidence of invasive disease in adults 15 years of age and over 
Methods
Case ascertainment for invasive Hi in adults was as detailed above, with the exception of 
clinical reporting through the BPSU study. Presumably due to a lower clinical profile of
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Hib disease in imvaccinated age groups, referral of adult isolates to the HRU over time was 
initially poor at just under half in 1991, improving to 73% in 2002. As greater consistency 
of reporting was observed from the five enhanced surveillance regions (East Anglia, 
Northern, North West, South West and Oxford) involved in the Regional Survey, these 
data are represented separately. In a further attempt to correct for changes in typing of 
adult Hi isolates, the following formula was used when examining the entire dataset for 
England:
Known Hib Strains
Adjusted Hib Reports = Known Hib Reports + (  All Typed Strains x  Untyped Strains) 
Results
A  total of 3,408 adult invasive Hi infections were reported over the period 1991-2002, of 
which 561 (16%) were due to Hib, 1353 (40%) nt Hi and 1291 (38%) untyped (Table 2.3). 
Nine cases of Hib infection were included where the isolate was from a non-sterile site 
with a clinical diagnosis of epiglottitis. The three most common clinical presentations of 
invasive Hib infection in adults were pneumonia (n=127,28%), bacteraemia (n=99, 22%) 
and epiglottitis (n=90,20%), together constituting approximately two thirds of all reports. 
The outcome of Hib disease was known for 77% of cases reported between 1991 and 2002; 
the case fatality rate in adults during each year ranged from 0 to 27%, and was 8.1% in 
2002.
A decrease in adult infections due to serotype b was observed following introduction of 
Hib vaccine in October 1992, falling to 1998 and then rising to 2002 (Table 2.3 and Figure 
2.8). This trend was also seen in cases from the five regions with enhanced surveillance
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Figure 2.8: Number of adult (over 15 years) Hib reports and median Hib antibody 
titres with 95% CIs (30-39 year olds) by year, England.
5 regions
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Figure 2.9: Frequency distribution of age at presentation with invasive disease: 
a) Non-typeable H  influenzae b) H  influenzae type b
Age at Presentation (years) Age a t P resentation (years)
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throughout the period, and in the national dataset after adjusting for untyped isolates, using 
the method described above (Figure 2.8).
Table 2.3: Numbers (and percentages) of laboratory reported invasive isolates in adults 
(over 15 years) by typing status and serotype, combined HRU/CDSC dataset, 1991-2002.
Year of 
Report
Hib ntH i Other Caps Untyped Total
1991 78 (32%) 32(13%) 4(2%) 130 (53%) 244
1992 73(33%) 39(18%) 10(4.5%) 98(44.5%) 220
1993 64 (23%) 71 (25%) 12 (4%) 135 (48%) 282
1994 36 (17%) 71 (32%) 6(3%) 106 (48%) 219
1995 35 (13%) 120 (46%) 18 (7%) 90 (34%) 263
1996 17 (7%) 105 (45%) 27 (12%) 83 (36%) 232
1997 29 (10%) 121 (44%) 22 (8%) 105 (38%) 277
1998 13 (5%) 150 (54%) 17 (6%) 97 (35%) 277
1999 33 (11%) 142 (49%) 14 (5%) 102 (35%) 291
2000 33 (10%) 155 (47%) 21 (7%) 119(36%) 328
2001 46 (13%) 171 (49%) 24 (7%) 110(31%) 351
2002 104 (25%) 176 (41%) 28 (7%) 116(27%) 424
Total 561 1353 203 1291 3408
Amongst adult cases with a serotype, the age distribution differed between Hib and nt Hi 
infections (Figure 2.9). While nt Hi was predominantly a cause of serious infections in the 
elderly, a bimodal distribution in Hib cases could be seen, peaking at 30 and 65 years, ages 
at which household exposure to children is common (www.statistics.gov.uk/StatBase). In 
keeping with these observations, the trend in adult infections followed closely the changing 
incidence of childhood disease (Figure 2.10).
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2.4.4 Comparison of laboratory derived invasive disease reports with hospital admissions
data for epiglottitis
Methods
Cases of epiglottitis due to Hib in England were identified fi"om the same CDSC/HRU 
dataset of invasive Haemophilus infections described above. In order to meet the case 
definition for the purposes of this analysis, Hib had to be cultured either fi*om a normally 
sterile site or from an upper airway swab in a patient presenting with clinical epiglottitis.
In order to gain an idea of completeness of reporting of Hib epiglottitis, figures derived 
from the microbiology reports were compared with a national dataset describing hospital 
admissions. English hospital providers submit data annually to the Department of Health 
regarding inpatient episodes, to comprise the Hospital Episode Statistics (HES) database. 
Between 1989 and 1994, discharge diagnoses were classified according to International 
Statistical Classification of Diseases Version 9 (ICD-9) criteria. From 1995 onwards, 
the corresponding ICD-10 codes have been used. Inpatient admissions for epiglottitis 
between March 1989 and March 2002 were identified by searching for the following codes 
from ICD-9: acute epiglottitis 464.3, acute laryngitis and tracheitis 464 and ICD-10: J05.1 
Acute epiglottitis, J05 Acute obstructive laryngitis (croup) and epiglottitis.
Two other organisms implicated in the aetiology of epiglottitis in adults are Group A 
Streptococcus and Streptococcus pneumoniae (Trollfors B et al 1998). Laboratory reports 
of blood isolates of these pathogens in adults 15 years of age and over are routinely 
compiled by CDSC. Additional surveillance for pneumococcal infections was conducted 
by the Respiratory and Systemic Infection Laboratory (RSIL) of the Specialist and 
Reference Microbiology Laboratory from 1996 onwards. These data were compared with
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reports of all bacteraemias attributable to Haemophilus influenzae, for the years 1990 to 
2002.
Results
524 laboratory reports of Hib epiglottitis were received between 1990 and 2002. The 
proportion of all invasive Hib disease presenting as epiglottitis remained constant at 
between 10 and 20% of cases, in both children and adults (data not shown). Similarly, 
there was no obvious increase in case fatality over time, with 13 deaths in children and 7  in 
adults over the period. These represented rates of 6 % and 11%, respectively, for cases in 
which the survival outcome was known (75% of paediatric and 78% of adult cases). 4374 
hospital admissions for infections with a focus in the upper airway were recorded from the 
beginning of 1990 to the end of March 2002.
Figures 2.11a and 2.11b show the numbers of epiglottitis cases per year in England for 
children less than 15 years and adults 15 years and over, respectively. Data on the number 
of laboratory reports of Hib epiglottitis are contrasted with the HES figures. Due to the 
necessarily broad range of case definitions included in the searches of the hospital datasets, 
a range of other presentations referable to the upper airway are included in these figures 
which may not fit a classic case definition of epiglottitis. An initial decrease in the number 
of paediatric cases is clear Ifom both sources. A reduction in the number of adult reported 
Hib cases occurred in the mid to late 1990s, rising again in 2002. Less certain is the 
overall impact of vaccination on all hospital admissions for upper airway infections in 
adults, which appear to have increased in number in recent years. This is in keeping with 
the more diverse aetiology of epiglottitis in this age group.
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Figure 2.11a: Laboratory reported cases and hospital admissions for epiglottitis in 
English children <15 years of age, 1990-2002
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Figure 2.11b: Laboratory reported cases and hospital admissions for epiglottitis in 
English adults >15 years of age, 1990-2002
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Table 2.4 documents the number of blood isolates of Group A Streptococcus, 
Streptococcus pneumoniae and Hi reported to CDSC and RSIL between 1990 and 2002 in 
adults 15 years of age and over. An increase in all reports is seen over time. While some 
of the rise in pneumococcal infections may be attributed to increased ascertainment 
through RSIL, active follow-up of cases through this laboratory focussed primarily on 
disease in children under five years of age, and thus would be expected to have a lesser 
impact on the number of adult isolates identified.
Table 2.4: Blood isolates of Group A Streptococcus, Streptococcus pneumoniae and 
Haemophilus influenzae in adults 15 years and over (England and Wales)
Year H influenzae Group A Strep Str Pneumo Total
1990 163 406 2645 3214
1991 205 408 2948 3561
1992 174 413 2665 3252
1993 2 2 2 455 2951 3628
1994 183 416 2849 3448
1995 193 389 3322 3904
1996 177 554 3907 4638
1997 218 558 4302 5078
1998 2 2 1 602 3868 4691
1999 2 2 1 624 3816 4661
2 0 0 0 2 2 2 763 3800 4785
2 0 0 1 258 778 3201 4237
2 0 0 2 321 829 3530 4680
61
Conclusions — invasive disease
The introduction of routine immunisation against Hib in the UK in October 1992 was 
initially responsible for a decrease in invasive Hib disease incidence in all age groups 
(Slack MPE et al 1998). The fall in adult cases mirrored that observed in immunised 
children and was indicative of a ‘herd immunity’ effect (Sarangi J et al 2000). While the 
relative contribution of nt Hi to the overall disease burden of Hi increased in consequence, 
no evidence of replacement with other capsular serotypes was seen (Heath FT et al 2001).
The greatest impact on invasive Hib infections was noted in the very young, who were at 
highest risk of disease. An 87% reduction in Hib meningitis in children less than 5 years 
of age within a year of vaccine introduction has previously been reported (Urwin G et al 
1994). Consequently, the median age at Hib disease in childhood increased in the years 
following vaccine introduction, then plateaued. Of significance, there was no subsequent 
shift of the burden of infection into older paediatric age groups who had not previously 
experienced high rates of disease. In addition, no evidence of any change in disease 
severity was observed in immunised or unimmunised children, as indicated either by the 
range of clinical presentations or case fatality attributable to Hib.
A worrying increase in serious Hib infections was seen between 1999 and 2002, 
predominantly among vaccinated children. The incidence of disease in children less than 5 
years old rose almost 7 fold to 4.6 per 100,000 over this period, but remained well below 
the pre-vaccination incidence of 30 per 100,000. Similar trends in hospital statistics 
describing episodes of admission for epiglottitis in childhood confirmed the validity of the 
microbiological data, and placed in context earlier case reports of a resurgence in 
epiglottitis (McEwan J et al 2003). The increase in paediatric cases was associated with
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evidence of a reduction in the duration of protection afforded by Hib vaccine from 1998 
onwards, with decreasing age at clinical presentation with infection most marked in 
children bom in 2 0 0 0  and 2 0 0 1 .
After correcting for variability of reporting over time, a corresponding increase in adult 
Hib disease cases has been noted. Adults of the ages most likely to mix with children, both 
as parents and grandparents, seem most liable to Hib infections. This observation is not 
surprising, given the high documented rates of parental carriage in families with a child 
known to be colonised or recovering from invasive disease due to Hib (Boisvert PL 1948, 
Michaels RH et al 1977, Barbour ML et al 1995). In 1975, Turk predicted that widespread 
Hib immunisation may delay Hib carriage, or force circulation into older age groups, so 
that ‘a young mother might pass on to her newborn baby the organism itself rather than 
[the] passive immunity’ (Turk DC 1975). While we believe that transmission is most often 
from child to parent, the reverse may also occur (Glode MP et al 1984) and may have 
contributed towards some of the increase in invasive disease observed in children in recent 
years.
The importance of surveillance across the entire age spectrum is emphasised by the 
detection of this increase in adult disease - an unexpected consequence of the widespread 
use of Hib vaccine. Of the eleven countries participating in the European Union Invasive 
Bacterial Infections Surveillance Network (EU-IBIS), only the Netherlands has noted a 
similar recent rise in adult Hib cases, from 8  reports in 2001 to 15 in 2002, the same 
number observed before vaccine introduction in 1993 (Source: National Reference 
Laboratory for Bacterial Meningitis, the Netherlands). Given the relative size of the two 
populations, this incidence is approximately half that observed in adults in the UK last
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year, but similarly mirrors an increase in paediatric reports in the Netherlands (Rijkers GT 
et al 2003).
2.5 Impact o f Hib immunisation on carriage in the UK 
Literature Review
In order to understand trends in invasive Hib infection in immunised and unimmunised 
cohorts, a greater understanding of the vaccine’s effect on Hib transmission in the UK was 
required. A cross sectional population based study of Hib carriage prevalence was 
conducted in Wales in the late 1990s, as described in Chapter 1, Section 1.5 (Figure 1.1b) 
(Howard AJ et al 1988). The only other study of this type undertaken in the UK took place 
in the 1950s and showed similar results (Dawson B et al 1952). In order to be able to 
monitor the effect of Hib vaccine on colonisation, the PHLS conducted a series of carriage 
studies in pre-school aged children in England and Wales following the introduction of Hib 
vaccine into the routine infant immunisation schedule in 1992. In addition, a single survey 
of Hib carriage in children of primary school age was conducted in Oxfordshire by the 
OVG in late 2001.
Outbreaks of Hib infection within nurseries were rare but well described prior to 
widespread vaccine use (Fleming DW et al 1985) (Osterholm MT et al 1987)(Murphy TV 
et al 1987)(Makintubee S et al 1987)(Marks MI 1987). The HRU was notified of an 
outbreak of Hib among fully immunised children in a nursery in Northamptonshire in 
2002. An investigation was conducted in order to study the likelihood of Hib transmission 
and the role of chemoprophylaxis in this setting.
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2.5.1 Carriage Studies 
Methods
Personnel in six public health laboratories (Bangor, Manchester, Ipswich, Newcastle, Gloucester, 
Swansea) recruited children in local playgroups, nursery schools and child welfare clinics on two 
occasions, in June/July 1992 and 1994. A third survey was performed in Bangor and 
Manchester in June/July 1997, and a fourth in Oxfordshire and Gloucestershire in 2002. In a 
separate study of pneumococcal carriage, 103 children of the same age had swabs sent for 
Hib isolation in June 2002 (R George, personal communication). Children recruited in 
1992 were not eligible for vaccination; children swabbed in 1994 would have been offered a 
single dose of Hib conjugate vaccine between 1 and 4 years of age as part of an initial ‘catch­
up’ immunisation programme and those studied in 1997 and 2002 would have been offered 
routine Hib vaccine at 2,3 and 4 months of age.
Children between 5 and 10 years old were recruited for a separate swabbing study in 
Oxfordshire schools in late 2001, conducted by the OVG. Seven schools took part in a 
variety of locations including suburban Oxford, nearby market towns and villages. The 
study was approved by the Oxfordshire Research Ethics Committee, the Oxfordshire 
Health Authority and the Local Education Authority.
Microbiological methods were essentially the same in both sets of surveys. After obtaining 
parental consent, throat swabs were collected and inserted into Haemophilus transport medium. 
They were then plated onto enriched Columbia Hib antiserum agar plates which were incubated 
at 37°C and in 5% CO2 . Due to a shortage of antiserum for the nursery studies in 1997 and 
2002, some swabs were initially plated onto chocolate agar. Presumptive Hib colonies were 
subcultured and referred to the HRU in Oxford for serotyping, and conftrmatoiy genotyping.
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Results
The results of the nursery studies demonstrated the expected decline in Hib carriage 
prevalence (Table 2.5), Ninety-five percent confidence intervals for the 1992 estimate did 
not overlap with those from any other year. In 2002, a year of increased invasive disease 
incidence, combined data from separate studies in pre-school children still revealed no 
carriers among 384 individuals swabbed.
Four hundred and seventy-six oropharyngeal swabs were collected from primary school- 
aged children in Oxfordshire. Eight children [1.7% (0.07,3.3)] were found to be carrying 
Hib, two carried serotype e (0.4%), and another two were colonised with serotype f  (0.4%). 
Prevalence appeared to increase with age, although numbers were small (Table 2.6). Five 
of the Hib carriers attended one school, and three of these were in the same year level 
(Year 5), but none were related.
66
i g o
g g
VOOv
g
m
g
•noo
g 8o
*oo
*s
g g
g
o
g
R
g
as
r -
m
G\r-
«NT
g
Ov(N<N
o
00oooo
g
VOOv
oo
o
m
g
00
W)
o
o
r -
o
3
«0
Ov
0 \
*
Ov
*
r ~
VO
<N
■§
&I
C«
£
oT
I
I
w
•H
( S
I
g
g
0 \
I
1
!
* 0
I
00
V )
c4
ov
cn
Ov
gen
S
oCO
CO
oo
oo
o v
CO
COvn
VO
I
g;
k
Ov
OV
3
k
Ov
OV
H
■I
• S
I
J
' o
o
I
I
1
I
I
W
3^ov
rt
CO
o
csasCN
ooo inCO
<N 8
<N
?ni
2
ni
CO
in
c5
VO
VO04
m
oooo
CO
8
804
2
ov
0Ô
g
o
Ov§
o
g
VO
s
aCO
o v
§
VO ooin
0 4
s
CO 2
0 4
u
I IÜ Ia I1 I I
f
i
2
I
VO
OS
o
o
VO
Ooo
o
VO
0 4
in
CO
o
ing
CÎV
CO
VO
e
5  S?
g E
Table 2.6: Prevalence of Hib carriage by age, Oxfordshire school study
Age Number of Children 
Swabbed
Number of Hib 
Carriers
Carriage Prevalence
5-6 years 58 0 0
6-7 years 79 2 2.5%
7-8 years 8 6 0 0
8-9 years 1 1 2 1 0.9%
9-10 years 76 1 1.3%
1 0 - 1 1  years 65 4 6 .2 %
All ages 476 8 1.7%
2.5.2 Investigation of nursery Hib outbreak 
Methods
The HRU was notified of an outbreak of Hib in a nursery in Wellingborough, an urban 
market town in the East Midlands of England (population: 70,000). 94 children, including 
4 pairs of siblings, were enrolled in this centre, cared for by 21 staff. Two children of a 
part time staff member attended for several hours each week. Care was in four rooms 
divided by age, with 10 children less than 18 months, 29 aged 18-30 months, 22 aged 30- 
36 months and 33 older than 36 months. The younger two and the older two groups ate 
meals together.
Paediatricians from Kettering General Hospital alerted Northampton Health Protection 
Unit to two cases of invasive Hib infection in children who attended this nursery occurring 
within one week. The first child, aged 15 months, presented with meningitis, and the 
second, a 13 month old, with septic arthritis. The nursery manager assisted in notifying 
staff and parents of enrolled children to attend for rifampicin prophylaxis ( 2 0  mg/kg/day as 
a single dose for 4 days). Hib vaccination dates and batch numbers for all children were
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confirmed from regional Child Health Computer records, or General Practitioners. Parents 
and staff gave consent to swabbing and questionnaire studies relating to Hib carriage.
Oropharyngeal cultures were obtained using described microbiological methods (Barbour 
ML et al 1993). Both tonsillar fossae were sampled using a cotton tipped wooden swab, 
which was immediately placed into tryptone soy broth enriched with X and V factors. 
Swabs were plated onto enriched Columbia antiserum agar plates 2-6 hours later using a 
standardised method with radial streaking of a central 5 pi inoculum, and a heavier 
peripheral inoculum. They were then incubated at 37°C and in 5% CO2 for 48 hours. 
Colonies exhibiting iridescent haloes were subcultured and identified as type b by 
serotyping and PCR, through the PHLS HRU. Antibiotic sensitivities were demonstrated 
by standard disc diffusion methods, and minimal inhibitory concentrations (MICs) 
determined using the Etest® strip system (AB Biodisk, Sweden). In order to further 
characterise the relatedness of strains, comparative restriction endonuclease digests of 
chromosomal DNA were performed using the enzymes Mfel and Pstl.
The rooms in which children were cared for and the number of hours per week in nursery 
were derived from attendance records. Parents were asked to complete a questionnaire 
detailing exposure to factors known to influence the likelihood of Hib carriage, including 
crowding and smokers in the household (increased risk) and breast feeding (decreased risk) 
(Cochi SL etal 1986).
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Results
Ninety-three children in the nursery were fully immunised against Hib. One was only old 
enough to have received two doses. Eighty-nine of 92 children without Hib disease, both 
index cases, and all staff members received Rifampicin prophylaxis (uptake 97.4%). One 
parent refijsed the medication for her child and a further two did not attend. Twins with 
intercurrent illness received the medication at home.
Swabs were collected from 87 of the 8 8  available healthy children (one refused), all 21 
staff and 2 children of a staff member. Two Hib carriers were identified, one child and one 
staff member, from the same room as the index cases. One child in another room carried a 
serotype f  strain. The four Hib isolates were resistant to Trimethoprim, with the same MIC 
(1.5 pg/ml), and showed a similar migration pattern on gel electrophoresis (Figure 2.12). 
One month later, 7 of the 10 children in this room were re-swabbed, with their 3 carers. 
Two (one an index case) had left the nursery, and one was on hohday. No Hib strains were 
isolated on this occasion.
Of the three children in the under 18 months’ room with evidence of Hib exposure, two 
attended nursery for more than 40 hours per week, compared with one of 7 non-caniers. 
One colonised child had been breastfed (33%), compared with 6  of 7 not colonised (8 6 %). 
Only the child with asymptomatic carriage shared a bedroom at home, and the only child 
with a smoker in the household was not a carrier. All of those who were colonised, and 5 
of the 7 who were not, reported recent upper respiratory infection, but none had received 
antibiotics.
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Figure 2.12: Electrophoretic gel migration patterns of isolates from Hib nursery 
outbreak, following digestion with the restriction endonucleases MFel and Pstl. 
Isolates 1 and 2 are the invasive disease strains, 3 and 4 the carriage strains, and 5 is 
the reference strain RM7004.
Sample 1 2 3 4 5 1 2 3 4  5
Enzyme WFel MFe1 MFel MFel MFel Pstl Pstl Pstl Pst1 Pstl 
Lane 1 2 3 4 5 6 7 8 9  10
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Conclusions — carriage
In the PHLS studies, the prevalence o f asymptomatic Hib colonisation decreased in pre­
school children within a few years of introduction of the Hib vaccine programme. No 
resurgence of carriage was seen in later time periods when invasive disease rates were 
rising, with no carriers detected in the last two surveys (McVemon J et al 2004b).
Ongoing Hib colonisation among older children was evidenced by the study in Oxfordshire 
schools. While the overall carriage prevalence was 1.7%, clustering of isolates was 
observed, with multiple carriers detected in a single school. This study provided clear 
evidence of ongoing community transmission of Hib in an age group previously postulated 
to introduce the organism into family settings, thereby exposing infants to risk (Ounsted C 
1951).
Within a single room in the nursery studied where an outbreak of Hib disease had 
occurred, 3 of 10 (30%) children and 1 of 3 (33%) carers acquired Hib. Such figures are 
comparable to the observed carriage prevalence in unvaccinated nursery contacts of 
children with invasive disease (Prober CG et al 1982) (Li KI et al 1986). Infants 
immunised with conjugate Hib vaccine show delayed acquisition of carriage (Barbour ML 
et al 1995), but carry at the population rate by pre school age (Barbour ML et al 1993). 
Transmission pressure is thus capable of overwhelming the vaccine’s effect and must be 
appreciable in a nursery setting where children spend long hours together.
In an exploratory analysis of other risk factors for carriage, 6  of 7 children who did not 
carry Hib had been breastfed, compared with only 1 of 3 who did acquire the organism. A
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history of breastfeeding has previously been found to protect infants under one year against 
carnage, with an odds ratio o f 0.3 (0.1,0.8) (Cochi SL ct al 1986).
Rifampicin prophylaxis is recommended for children recovering from Hib disease and 
their household contacts based on studies from the pre-vaccine era (Cartwright KA et al 
1991). Reacquisition of the same or novel strains within 10-30 days of the course of 
antibiotic is possible even when compliance is high (Glode MP et al 1985). None of the 
children and staff swabbed for a second time in our study, three of whom had previously 
been exposed to Hib, showed evidence of reacquisition.
An outbreak of invasive Hib infection within fully vaccinated children in a day care 
nursery is a rare but concerning event. Rifampicin was used effectively in this instance to 
block transmission of the organism. The risk of occurrence of a secondary case cannot be 
estimated from this single report (McVemon J et al 2004a).
2.6 Impact o f Hib immunisation on population immunity to Hib in the UK 
Literature Review
The acquisition of natural immunity to Hib in unvaccinated populations was thoroughly 
described in Section 1.9 of Chuter 1. Briefly, passive immunity was provided by 
maternal antibody in the first few months of life. This waned, to leave infants without 
measurable semm activity against Hib over the next 2-3 years (Fothergill LD et al 1933). 
Anti-PRP titres began to rise after the third birthday, becoming stable in adult life (Kayhty 
Heta l  1983).
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Changing population immunity to Hib in the UK following vaccine introduction was 
studied using two data sources. In an initial exploratory analysis, reports of Hib antibody 
concentrations measured at the routine immunology laboratory of the Churchill Hospital, 
Oxford, were compared over the years 1995 to 2001. This hypothesis generating data led 
to a formal study conducted by the PHLS using reference serum stored in their 
seroepidemiology unit (Trotter CL et al 2003b).
2.6.1 Hib antibodv measurements, Churchill Hospital Oxford. 1995-2001 
Methods
Anonymised laboratory reports were obtained from 14,000 Hib antibody requests referred 
to the Churchill Hospital routine Immunology Laboratory, Oxford between 1995 and 2001. 
No information was available regarding the indications for performing the measurement. 
Samples were taken from individuals ranging in age from birth to 80 years. Assays were 
conducted using the standardised HbO-HA ELISA developed by the Centres for Disease 
Control, Atlanta (Phipps DC et al 1990). Antibody titres were log transformed in order to 
approximate a normal distribution, and geometric mean concentrations calculated with 
95% confidence intervals to allow between group comparisons.
Results
Distribution of ages at serum collection by year of measurement is shown in Table 2.7. 
Geometric mean antibody concentrations by age group and year of serum collection are 
detailed in Table 2.8. Results are represented graphically for the years 1995, 1997 and 
2001 in Figure 2.13. The intervening years’ results are omitted from the figure for the sake 
of clarity. A decline in Hib antibody titres was observed when 1995 was compared with 
subsequent years. Age groups most affected included children aged 3 to 5 years.
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teenagers, and the elderly (over 50 years). There was also a suggestion of waning maternal 
immunity, with a reduction in antibody concentrations in infants aged 0 - 6  months.
Because of the nature of the data represented, it was uncertain whether this apparent 
reduction in immunity could have resulted from changes in the laboratory assay used over 
time.
Table 2.7: Age of donor and year of serum collection, Hib antibody reports, Churchill 
Hospital Oxford, 1995-2001
Age 1995 1996 1997 1998 1999 2 0 0 0 2 0 0 1 Total
0 - 6  months 103 1 2 1 109 1 2 1 134 137 137 862
6 - 1 2  months 152 144 137 161 129 169 189 1081
1 - 2  years 262 249 184 204 223 213 246 1581
2-3 years 141 156 1 2 1 159 185 180 180 1 1 2 2
3-4 years 85 123 123 132 1 1 1 144 143 861
4-5 years 80 118 134 119 1 0 2 130 1 0 0 783
5-8 years 142 176 141 218 226 194 265 1362
8 - 1 2  years 1 0 1 130 125 133 140 167 168 964
12-16 years 84 116 85 99 93 109 136 722
16-25 years 73 97 90 79 78 94 118 629
25-30 years 65 97 38 35 57 54 62 408
30-40 years 143 197 106 1 2 0 1 1 2 143 203 1024
40-50 years 1 2 1 149 76 36 71 99 150 702
50-60 years 107 129 78 65 67 114 213 773
60-70 years 151 1 2 2 63 50 71 99 173 729
70-80 years 72 109 46 48 29 62 130 496
Total 1882 2233 1656 1779 1828 2108 2613 14099
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Table 2.8: Geometric mean concentrations of anti-PRP antibody by age and year of serum
collection, Churchill Hospital Oxford, 1995-2001 (95% confidence intervals)
Age
Year of Serum Collection
1995 1996 1997 1998 1999 2000 2001
0-6 months 0.78 
(0.57,1.07)
0.70 
(0.52, 0.95)
0.34 
(0.25,0.46)
0.33 
(0.24,0.45)
0.24 
(0.19, 0.31)
0.36 
(0.28,0.47)
0.23 
(0.18, 0.29)
6-12
months
1.54 
(1.17,2.04)
1.27 
(0.96,1.68)
0.80 
(0.61,1.06)
0.79 
(0.60,1.04)
0.72 
(0.54,0.96)
0.72 
(0.57,0.92)
0.81 
(0.64,1.02)
1-2 years 1.32 
(1.05, 1.67)
1.14 
(0.93,1.40)
0.74 
(0.58,0.96)
0.54 
(0.42, 0.68)
0.68 
(0.55,0.85)
0.67 
(0.54, 0.84)
0.57 
(0.46, 0.71)
2-3 years 1.60 
(1.12,2.28)
1.68
(1.28,2.22)
0.76 
(0.53,1.10)
0.74 
(0.54,1.00)
0.65 
(0.50,0.85)
0.58 
(0.44,0.76)
1.22 
(0.89,1.67)
3-4 years 2.18
(1.38,3.44)
1.44 
(1.05,1.97)
0.63 
(0.44, 0.89)
0.87 
(0.63,1.21)
0.84 
(0.60,1.18)
1.14 
(0.79, 1.66)
0.69 
(0.50,0.94)
4-5 years 2.20
(1.45,3.36)
1.64 
(1.23,2.20)
0.60 
(0.44, 0.81)
0.72 
(0.52,1.00)
0.72 
(0.49,1.06)
0.66 
(0.47, 0.92)
0.52 
(0.35,0.78)
5-8 years 1.10 
(0.79,1.54)
1.17 
(0.92,1.50)
1.17 
(0.89,1.54)
0.70 
(0.55,0.88)
0.73 
(0.58,0.91)
0.68 
(0.53,0.88)
0.77
(0.61,0.97)
8-12 years 1.11 
(0.75,1.64)
1.22 
(0.92,1.63)
0.65 
(0.47,0.90)
0.70 
(0.52,0.95)
0.81 
(0.61,1.08)
1.01 
(0.78,1.30)
0.78 
(0.60,1.02)
12-16 years 2.03 
(1.14,2.92)
1.44 
(1.06,1.96)
1.02 
(0.72,1.45)
0.64 
(0.46,0.90)
0.83 
(0.58,1.19)
0.53 
(0.38,0.73)
0.66 
(0.49,0.90)
16-25 years 1.64
(1.05,2.56)
1.20 
(0.87,1.65)
0.95 
(0.67,1.35)
0.87 
(0.57,1.31)
0.96 
(0.65,1.42)
1.03 
(0.76,1.41)
1.11 
(0.83,1.48)
25-30 years 1.63 
(1.12,2.36)
1.13 
(0.80,1.60)
1.08 
(0.62,1.88)
0.38 
(0.23,0.64)
0.55 
(0.36,0.84)
0.60 
(0.39,0.95)
0.92 
(0.58,1.45)
30-40 years 1.87
(1.41,2.46)
1.18 
(0.95,1.47)
0.77 
(0.57,1.06)
0.84 
(0.62,1.14)
0.71
(0.51,0.98)
0.73 
(0.56,0.95)
0.85 
(0.67, 1.08)
40-50 years 2.86 
(2.08,3.93)
1.20 
(0.91,1.60)
1.03 
(0.70,1.51)
0.63 
(0.37,1.09)
0.86 
(0.57,1.31)
1.27 
(0.92,1.76)
1.07 
(0.81,1.42)
50-60 years 2.18
(1.55,3.06)
1.19 
(0.91,1.56)
0.75 
(0.50, 1.12)
1.14 
(0.71,1.83)
0.91 
(0.59,1.40)
0.70 
(0.52, 0.94)
0.87 
(0.68, 1.10)
60-70 years 2.23 
(1.69,2.94)
1.24 
(0.91,1.68)
0.83 
(0.56,1.25)
0.47 
(0.29, 0.76)
0.51 
(0.35,0.75)
0.52 
(0.37, 0.71)
0.99 
(0.74,1.32)
70-80 years 1.52 
(1.06,2.17)
1.14 
(0.82,1.58)
0.71 
(0.44,1.16)
0.40 
(0.26,0.63)
0.71 
(0.36,1.42)
0.44 
(0.29,0.67)
0.76 
(0.55,1.06)
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Figure 2.13: Geometric mean concentrations (GMCs) of Hib antibody by age group
and year, Churchill Hospital Oxford 1995-2001
1 9 9 5
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Age at serum collection
2.6.2 HP A Seroepidemiology study 
Methods
The impact of Hib vaccine introduction on population immunity was formally studied 
using sera stored by the HP A Seroepidemiology Unit. Serum left over from diagnostic 
specimens is collected anonymously each year from a range of laboratories across England 
for this purpose (Osborne K et al 2000). Testing for antibodies to PRP was conducted at 
the HP A, Porton Down, using the same HbO-HA ELISA described above (Phipps DC et al 
1990). Sera from children under the age of 16 in 1990/1991, 1994, 1997 and 2000 were 
selected to represent pre- and post-vaccine periods. In addition, samples collected from adults 
aged 30-39 years were also tested from the same time points.
Antibody concentrations by age and year of collection were reported as medians, due to the 
highly skewed nature of the data. The significance of differences between groups was 
assessed using the Kruskal-Wallis test, in ST AT A 7.0. Titres were also represented in
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relation to the previously described thresholds of 0.15 and 1 . 0  pg/ml, thought to correlate with 
protection against Hib infection (Kayhty H et al 1983).
Results
These data were collated by Dr Caroline Trotter of the Statistics, Modelling and Economics 
Department, HPA, Colindale, who authored the paper describing the paediatric component of 
this study (Trotter CL et al 2003b). Figures and tables below are taken from the manuscript.
Striking changes in levels of immunity to Hib were observed over the period of the study 
(Figure 2.14). With the introduction of immunisation, a significant increase in Hib antibody 
concentrations was observed in one-year old infants, which persisted in aU subsequent time 
points (p<0.0001 for all comparisons with 1990/1991). Most evident was the impact of catch­
up immunisation on Hib antibody concentrations in children aged between 3 and 4 years in 
1994. Children of the same age in later years had much lower litres, consistent with rapid 
waning of immunity following primary infant immunisation. A corresponding increase in the 
proportion of toddlers without detectable serum antibody against PRP was observed (Figure 
2.15).
Antibody levels to Hib in 30-39 year old English adults, collected at four time points over 
the period, showed a trend in keeping with the numbers of reports of invasive disease 
(Figure 2.8). A significant fall in median Hib antibody titres was noted from 1.29 pg/ml 
(0.90, 1.64) in 1991 to 0.70 pg/ml (0.57, 0.89) in 1994 (p=0.006) with a further non­
significant decrease to 0.53 pg/ml (0.35, 0.73) in 1997. A small non-significant increase to 
0.69 pg/ml (0.52, 0.95) was seen in 2000 (p=0.197).
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Figure 2.14: Median Hib antibody concentrations, by age and year (from Trotter CL 
et al 2003b)
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Figure 1: Median Hib antibody titres
(R=routinely vaccinated group, C=catch-up group, U=unvaccinated cohort).
Figure 2.15: Hib antibody concentrations in relation to the thresholds 0.15,1.0 and 10 
Mg/ml, by age and year of collection (from Trotter CL et al 2003b)
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Conclusions -population immunity
Infant immunisation has resulted in the induction of antibody titres deemed protective in 
the age group at greatest risk of serious Hib infections, namely infants less than 24 months 
of age. These antibodies wane rapidly, within 2 to 3 years, in the absence of a booster 
dose. The catch-up immunisation campaign that accompanied vaccine introduction in 
1992 and 1993 resulted in very high levels of immunity throughout the first five years of 
life, seen in both the Oxfordshire and HPA datasets, which have not been subsequently 
observed in cohorts immunised in infancy.
Adults and older children who had never been immunised experienced a decline in overall 
levels of Hib antibody within two years of vaccine introduction. This reduction in 
immunity was initially temporally associated with falling disease incidence, and may have 
contributed to a recent resurgence in invasive Hib infections in adults.
2.7 Conclusion
Immunisation against Hib was introduced in the UK in October 1992 as an accelerated 
primary schedule at 2, 3 and 4 months of age without a booster dose. Vaccine introduction 
was supplemented over the first year of use by a national catch-up immunisation campaign 
involving children under the age of four years. Coverage of the three dose primary course 
by the age of one year remained greater than 90% over the next ten years. Hib vaccines 
used in the UK have changed over time, from single antigen vaccines to combinations with 
diphtheria, tetanus and whole cell pertussis (DTwP-Hib). Due to problems with vaccine 
supply, a similar preparation containing acellular pertussis (DTaP-Hib) was used in 
2000/2001.
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The UK’s immunisation strategy was very effective in inducing a rapid reduction in the 
incidence of disease among vaccinated children. An associated decrease in oropharyngeal 
Hib carriage was responsible for a ‘herd immune’ effect. As a result, the incidence of Hib 
disease in cohorts too young or old to be immunised also declined. A slight increase in the 
average age at Hib presentation, from the second to the third year of life, reflected high 
protective efficacy in the youngest infants. No other significant changes in the clinical 
presentation of Hib disease occurred, in vaccinated or unvaccinated individuals. In 
addition, no evidence of a shift in disease to other capsular serotypes was observed.
Despite this initial success, a steady increase in the incidence of invasive Hib infections 
ascertained primarily through laboratory reporting was observed in children and adults in 
England and Wales from 1999 onwards. Most of these children had been fully immunised. 
Similar trends in hospital admissions for epiglottitis in childhood were seen, confirming 
the microbiology data.
The rise in disease incidence was not accompanied by an evident increase in Hib 
colonisation in children of pre-school age. Ongoing Hib transmission in the community 
was demonstrated by detection of carriage in children attending primary schools, and 
through experience of an outbreak of disease among vaccinated infants and toddlers in a 
day care centre. Adults in age groups most commonly exposed to children in household 
settings experienced higher rates of invasive infection than the veiy elderly.
Study of changes in population immunity to Hib resulting from vaccine introduction added 
to our understanding of invasive disease trends. Levels of specific anti-PRP antibody in 
children under two years of age rose following introduction of infant immunisation. This
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observation correlated with the greatest reduction in invasive disease within any age group. 
The initial Hib catch-up immunisation campaign was associated with induction of very 
high antibody titres in toddlers, which persisted throughout the first five years of life. 
Subsequent cohorts of children, immunised only in infancy, had much lower levels of 
antibody to Hib from three years of age onwards as antibody concentrations waned rapidly 
following the primary course. Children bom after the catch-up period showed a 
progressive reduction over time in the duration of antibody protection associated with 
immunisation, most marked in 2000. The beneficial effects of the catch-up campaign on 
immunity may have enhanced the apparent impact of the infant primary schedule. The 
other change temporally associated with reduced vaccine protection in 2 0 0 0  was use of 
DTaP-Hib vaccines.
A significant fall in the median anti-PRP antibody concentration in English adults occurred 
only two years after Hib vaccine’s implementation. The interruption of Hib transmission 
observed in children may be expected to have reduced opportunities for natural boosting of 
immunity in all age groups. This would suggest that recurrent colonisation could be 
required to maintain high levels of serum immunity. The subsequent creation of a 
susceptible pool of adults might have contributed to a resurgence of disease.
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Chapter 3 -  Factors associated with increasing Hib incidence in epidemiological 
analyses
3.0 Introduction
In examining the possible reasons for the increase in Hib incidence in the UK, it 
must be borne in mind that the application of vaccines in whole populations is much 
more complex than the controlled environment of a Phase III efficacy trial. Vaccine 
schedules evolve as new public health priorities and products emerge on the scene. 
With respect to the Hib vaccines themselves, the formulation and availability of 
manufacturers’ products has changed over time, with consequences for 
immunogenicity.
A number of host and environmental variables were associated with increased risk of 
invasive Hib infection before immunisation was available (Section 1.8 of Chapter 1). 
If vaccine efficacy was reduced in susceptible individuals, niches for ongoing 
transmission and disease might occur. Sociological changes leading to an expansion 
of ‘at-risk’ groups in the population may be expected to be associated with changes 
in epidemiology over time. Further, identification of clinical and immunological 
risk factors contributing to vaccine failure would be desirable in order to offer such 
children additional protection through extra doses of vaccine or other measures. The 
assessment of clinical, social and environmental factors correlating with disease risk 
is essential in order to appreciate the contribution of non-vaccine related variables to 
disease trends.
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Unanticipated effects of vaccine introduction on transmission, while beneficial in the 
short term, may have far reaching effects on boosting of natural immunity within a 
population. Such an impact may not be apparent in an efficacy trial, where 
vaccinated individuals move within a wider unimmunised community. The resulting 
creation of new pools of susceptible individuals may open up opportunities for 
transfer of infection and increased rates of progression to invasive disease.
These issues have been addressed in part in the course of a number of studies 
conducted by the HPA, OVG and BPSU over the past ten years. Findings to date 
will be outlined in the following chapter.
3.1 Vaccine factors associated with changing Hib epidemiology in the UK, 1993- 
2002
Literature Review
Catch-up immunisation of children up to 4 years of age with the HbOC conjugate 
vaccine was an integral part of the UK’s Hib immunisation strategy over the first 
year of introduction. As described in Section 2.3 of Chapter 2, a range of Hib 
conjugate vaccine formulations have subsequently been licensed for use in the UK’s 
infant schedule over the past 10 years. PRP-T was initially administered as a single 
antigen for routine infant immunisation. Combination DTwP-Hib vaccines were 
widely used from 1996 onwards, with a switch to a single manufacturer’s DTaP-Hib 
vaccine fi'om late 2 0 0 0  to mid 2 0 0 1 .
Antibody titres following a single dose of Hib conjugate vaccine increased with age 
at administration (Madore D et al 1990a, 1990b) (Rothstein EP et al 1991). In
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infancy, the nature and schedule of vaccine also impacted on peak anti-PRP 
concentrations achieved (Vidor E et al 2001). While there was no consistent 
evidence that combination with DTwP had any effect on immunogenicity of the Hib 
component (Vidor E et al 2001), DTaP caused a significant reduction in immunity to 
Hib when administered in the same syringe as PRP-T (Bell F et al 1998) (Schmitt HJ 
et al 1998). The reduction in Hib antibody titres was most striking in an accelerated 
schedule such as that used in the UK (Vidor E et al 2001), and was more noticeable 
with each additional dose of DTaP-Hib given as part of the primary course (Daum 
RS et al 2001). Based on demonstration of priming for immunologic memory 
following DTaP-Hib in infancy (Zepp F et al 1997) (Goldblatt D et al 1999) 
(Poolman J et al 2001), the clinical relevance of these lower antibody concentrations 
to protection against disease was questioned (Eskola J et al 1999) (Poolman J et al 
2001).
Early estimates of vaccine impact reported firom the UK compared rates of Hib 
disease before and after 1992, thereby measuring both direct and indirect (herd 
immunity) effects of immunisation. Reported vaccine efficacy over the first five 
years of life as assessed by these means was 97.6% (Heath PT et al 2000a). Given 
the changing epidemiology of Hib in the years following conjugate vaccine 
introduction, a further analysis of vaccine efficacy was conducted by the HPA in 
order to see whether different vaccines or schedules were temporally associated with 
altered protection. As both vaccinated and unvaccinated children were subject to the 
same degree of indirect protection conferred by herd immunity, contemporaneous 
incidence rates were compared between the two groups to allow measurement of 
direct vaccine efficacy.
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In a further study, the possible contribution of DTaP-Hib to a resurgence in disease 
was examined by comparing vaccines received by Hib vaccine failures (cases) with 
those received by folly immunised children without disease (controls).
3.1.1 Analvsis of vaccine efficacv 
Methods
The HPA study of direct vaccine efficacy has been published (Ramsay ME et al 
2003). Methods of case ascertainment for invasive Hib infection and confirmation 
of vaccination status were as described earlier in Section 2.4. Full protection was 
assumed from 7 days after the completion of 3 doses of vaccine before 13 months, or 
a single dose after this age. Partially vaccinated children were excluded from the 
analysis. Coverage data for routine and catch-up immunisation were derived from 
sources used previously (httD://www.hpa.org.uk/cdr/archive04/immunisation04.htm) 
(O’Brien H 1994).
Effectiveness was calculated by the screening method, which is described in the 
following equation:
Vaccine effectiveness = 1-[PCV(1-PPV)]/[[(1-PCV)PPV]
where PCV is the proportion of the cases who are vaccinated and PPV is the 
proportion of the population vaccinated, or vaccine coverage. Direct vaccine 
protection was assessed by period of birth and time since scheduled vaccination 
using univariate and multivariate logistic regression models. The statistical analysis
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for this study was conducted by Nick Andrews of the HPA’s Statistics, Modelling 
and Economics Department. Full details of the statistical methods employed are 
outlined in the published paper (Ramsay ME et al 2003).
Results
Table 3.0 is derived from Table 3 of Ramsay ME et al 2003.
Table 3.0: Summary of vaccine effectiveness estimates (%) with 95% 
confidence intervals by year of birth and time since vaccination.
Vaccination 
schedule, 
period of birth
Efficacy overall 
(95% Cl)
Efficacy <2 yrs 
(95% Cl)
Efficacy >2 yrs 
(95% Cl)
Catch-up
Jan 1989-Jul 1992
^7.7 97.1
(7J.4,
77.7 
(3.2, P7.;;;
Infant
Aug 1992-Dec 2001
4P.4 
(37.^, 64.7;
60.P 
(42.0, 73.d;
27.3 
(:2 &g, JP.f^
Infant
Aug 1992-Dec 1993
48.6 
(-31.6, 9.9)
74.5
(25.5,91.9)
-55.9
(-1046, 78.8)
Infant
Jan 1994-Dec 1995
75.1 
(50.3, 87.5)
67.4 
(4.8, 8 8 .8 )
79.8
(51.7,91.5)
Infant
Jan 1996-Dec 1997
65.4 
(26.5, 83.7)
8 8 . 0  
(64.2, 96.0)
29.9 
(-125, 78.1)
Infant
Jan 1998-Dec 1999
42.0
(-16.6,71.2)
72.8 
(32.6, 89.0)
-17.0 
(-272, 63.2)
Infant
Jan 2000-Dec 2002
25.8
(-36.3, 59.6)
35.6 
(-17.8, 64.8)
- 0 0  
(oo, 72.0)
Total
Either schedule 
Jan 1989-Dec 2001
56.7 
(42.5,67.4)
6 6 . 1  
(51.2,76.4)
37.3 
(-3.1,61.9)
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In brief, the overall estimate of vaccine efficacy in the UK was 56.7% (42.5, 67.4), 
which was surprisingly low. Even allowing for 2% underestimation of vaccine 
coverage, efficacy only rose to 71.8%. Children vaccinated over 1 year of age during 
the catch-up campaign [87.1% (65.5, 95.2)] were much better protected than those 
immunised in infancy [49.4% (31.8, 64.1)] (Table 3.0 and Figure 3.0). Vaccine 
protection waned rapidly, falling sharply beyond two years of immunisation (Table 
3.0 and Figure 3.0). A decline in short term protection conferred by infant 
immunisation was observed in cohorts of children bom in 2 0 0 0  and 2 0 0 1  when 
compared with those bom in other years (Table 3.0 and Figure 3.1).
3.1.2 Analvsis of vaccines administered to cases and controls 
Methods
DTaP-Hib was distributed in the UK between January 2000 and October 2001 
(Section 2.3). Hib cases bom between 01/10/1999 and 31/06/2001 were thus 
selected for analysis. Hib immunisation dates and batch numbers were confirmed 
with general practitioners or child health computer records. Date of birth-matched 
controls were chosen firom anonymised immunisation data downloaded from a single 
child health system covering children resident in the South-East of England.
Vaccines were identified fi'om batch numbers, using information supplied by the 
manufacturers. In the few instances where there was any uncertainty regarding the 
formulation of one manufacturer’s product, batches were categorised as DTwP-Hib 
for cases and DTaP-Hib for controls. Conditional logistic regression was used to 
compare the number of doses of the full primary immunisation series given as DTaP- 
Hib between each case and their matched controls. The statistical analysis was 
conducted by Nick Andrews of the HPA’s Statistics, Modelling and Economics 
Department (McVemon J et al 2003a).
Figure 3.0: Vaccine efficacy by schedule and time since vaccinafion (95% 
CIs)
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Figure 3.1: Short term vaccine efficacy by birth cohort (95% CIs)
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Results
One hundred and thirty cases who had received three doses of vaccine before disease 
were identified. Complete batch number information was unavailable for 19 (15%), 
leaving 111 for study. 3,834 (64%) of an initial control dataset of 5,952 fully 
vaccinated children had a full set of valid batch numbers recorded. Each case was 
matched by date of birth (DOB) with a median of 39 controls (range 4 to 60).
Age at the third dose of vaccine differed between groups, with 18% (701/3,834) of 
controls and 9% (10/111) of cases completing the course over 160 days of age. As 
this difference may have influenced access to the DTaP-Hib combination, a further 
analysis was performed in which controls were restricted to include only those who 
completed vaccination in the same time frame as their DOB matched index case.
Age at completion was stratified as follows: <120 days, 120-159 days and >160 days.
Results of the conditional logistic regression analyses are shown in Table 3.1. 
Significantly more cases than controls had received three doses of DTaP-Hib during 
their primary vaccination schedule compared with one or no doses. A significant 
trend for increasing risk of vaccine failure with each additional dose of the aP 
combination was also observed. No effect of age at third dose was observed 
(McVemon J et al 2003a).
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Discussion — vaccine factors
Changes over time in the levels of specific immunity to Hib observed in British children 
were noted in Section 2.6 of Chapter 2. A marked positive impact of catch-up 
immunisation on peak antibody titres achieved and persistence throughout the period of 
risk was observed (Trotter CL et al 2003). The analysis of vaccine efficacy has 
demonstrated that such an immunogenicity profile was associated with more effective 
protection against invasive Hib disease than primary infant immunisation. Further, in 
keeping with the observed rapid waning of antibody titres following the primary course, 
efficacy declined sharply in the two years following vaccination in infancy (Ramsay ME 
et al 2003).
An additional reduction in vaccine effect was noted in 2000/2001, when compared with 
infants bom in other years (Ramsay ME et al 2003). It had previously been observed that 
the age of presentation with invasive disease declined in vaccinated children bom in those 
years (Section 2.4.2, Figure 2.7), implying a shorter duration of vaccine protection. As 
had also been noted in Section 2.3 of Chapter 2, these were years during which a single 
manufacturer’s DTaP-Hib combination vaccine was distributed in the UK, due to a 
shortage of DTwP-Hib. The hypothesis that the reduced immunogenicity of DTaP-Hib 
vaccines may have resulted in reduced protection against infection was tested in a matched 
case-control study design. An increased risk of Hib vaccine failure was noted in fully 
immunised children who had received 2 or 3 doses of their primary course as DTaP-Hib, 
compared with 3 doses of another Hib vaccine (McVemon J et al 2003a). Thus, the 
clinical importance of the lower antibody concentrations was confirmed when this vaccine 
was used in an accelerated primary schedule without a booster dose.
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3.2 Host and environmental factors associated with ongoing Hib disease in the UK, 1993- 
2002
Literature review
A range of host and environmental factors associated with increased individual risk of 
invasive Hib infection before introduction of widespread immunisation were outlined in 
Section 1.8 of Chapter 1. The most consistent findings in all analyses were a history of 
known immunodeficiency in the host, and a range of variables associated with increased 
exposure to other children in close settings.
As part of a prospective surveillance study of Hi disease, the OVG initiated a 
questionnaire-based study asking clinicians to identify pre-existing conditions that may be 
associated with heightened susceptibility to infection in children experiencing Hib vaccine 
failure. In addition, acute and convalescent serum specimens were collected, where 
possible, for measurement of immunoglobulins and specific antibody to PRP. Interim 
results were reported in 1997 (Booy R et al 1997) and 2000 (Heath PT et al 2000b).
Of children immunised in the first year of life who presented with vaccine failure, 20% 
were stated to have an underlying clinical risk factor (prematurity, malignancy, 
dysmorphic syndrome, Down’s syndrome, neutropaenia) (Heath PT et al 2000b). A 
subsequent analysis of the contribution of prematurity to vaccine failure found no 
significant increase in risk in premature infants compared with those bom at term [OR 1.5 
(95% Cl 0.9,2.6)] (Heath PT et al 2003). An earlier age at onset of disease was observed 
in those with a history of preterm delivery, in keeping with the reduced immunogenicity of 
conjugate vaccines in such infants (Heath PT et al 2003).
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Immunologie testing revealed that 30% of UK Hib vaccine failures showed some 
abnormality of immunoglobulin classes or IgG subclasses compared with age-specific 
reference values (Heath PT et al 2000b). These findings were consistent with other 
studies of conjugate vaccine failures in the United States and the Netherlands (Holmes 
SJ et al 1991, 1992) (Breukels MA et al 2001). While a previous association had been 
reported between immunoglobulin subclass deficiency and poor specific antibody 
responses to polysaccharide antigens, these findings were of uncertain diagnostic or 
prognostic significance (Shackelford PG et al 1990).
Despite the ‘immunodeficiency’ thus represented, most children who developed invasive 
Hib infection following conjugate vaccine mounted an antibody response to infection that 
was greater than expected for age (Holmes SJ et al 1991,1992) (Breukels MA et al 2001). 
In those who did not, a booster dose almost always elicited antibody concentrations 
deemed ‘protective’ (Holmes SJ et al 1991) (Heath PT et al 2000b) (Breukels MA et al 
2001). The HibId-1 idiotype was equally predominant in both vaccinated and 
unvaccinated children developing Hib disease (Holmes SJ et al 1991). One study reported 
reduced convalescent antibody concentrations and low avidity in children experiencing 
Hib conjugate vaccine failure, but these conclusions were questionable due to small 
numbers of cases and the use of inappropriate controls (Breukels MA et al 2002).
Only one study, conducted in the United States, has addressed social and environmental 
risk factors for invasive Hib infection after vaccine introduction (Jafari HS et al 1999).
The vast majority of cases in this series were not age appropriately immunised. Social 
deprivation was a major risk factor for undervaccination, highlighting difficulty of 
access to routine medical care for the economically disadvantaged in the US (Jafari HS
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et al 1999). In the UK, immunisation is provided as a free publicly funded service to 
all, resulting in consistently high immunisation coverage (Figure 2.1). One may thus 
expect different variables to be associated with ongoing Hib infections in the two 
populations.
Results from the last BPSU report on invasive Hi infection before it was withdrawn 
from the orange card reporting scheme at the end of 2 0 0 0  are shown, thus updating 
findings of the OVG study of clinical risk factors. An analysis of antibody responses in 
Hib vaccine failures using serum collected from this study, compared with historical 
unvaccinated controls, is also described.
In response to the increase in cases from 1999 onwards, the HPA conducted a national 
case-control study of children presenting with invasive Hib infection between January 
1998 and January 2003. Associations with a range of clinical variables addressed by the 
cohort study were reassessed within this new design. In addition, information was 
sought on social and environmental factors known to be correlated with altered risk of 
disease in the pre-vaccine era.
3.2.1 Studv of clinical and immunological risk factors associated with Hib vaccine
failure
Methods
Case ascertainment for invasive Hi infection has already been described. Clinicians 
caring for children experiencing Hib vaccine failure were sent a postal questionnaire 
enquiring after the child’s vaccination status and asking them whether the child had a 
known underlying illness or immunodeficiency which may have predisposed them to
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their infection. In addition, they were asked to tick any of a relevant series of boxes if 
the child had a history of prematurity, malignancy, dysmorphic syndrome, Down’s 
syndrome, chromosomal anomaly or neutropaenia. Written parental consent to release 
of this information was required after the study’s reapproval by the South East Multi- 
Centre Research Ethics Committee in 2001, resulting in a marked reduction in the 
number of complete reports obtained (Dr M Slack, personal communication).
Results
By the BPSU study’s completion at the end of October 2000,719 reports that met the case 
criteria had been made including 517 in vaccinated and 202 in unvaccinated children. 
Ongoing surveillance through the HRU, CDSC, Scottish Centre for Infection and 
Environmental Health (SCIEH) and OVG to the end of March 2001 identified 67 
additional cases (52 vaccinated, 15 unvaccinated). Of this total, 225 cases represented true 
vaccine failures (TVFs). Two hundred and sixteen of the 225 TVF were vaccinated in the 
first year of life: 202 received three doses and 14 received two doses. Nine were 
vaccinated when older than 12 months of age. Medical and immunological conditions 
amongst the cases of TVF are detailed in Table 3.2. Of the 24 children with clinical risk 
factors, 8  had underlying malignancy, 5 a dysmorphic syndrome, 3 Down’s syndrome, 2 a 
chromosomal anomaly and 1 Neutropaenia. Five children had other specific conditions 
identified as increasing their risk of infection.
Table 3.2: Associated conditions of TVF Sept 1992-March 2001
Associated condition
Number of cases where 
information known
Number with risk 
factor (% of known)
Prematurity 206 22 (10.7%)
Immunoglobulin D ef cy 137 36 (26.3%)
Clinical Risk Factor (all) 203 24 (11.8%)
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Convalescent sera were available in 163 cases of TVF. Forty-three (26%) demonstrated 
a convalescent antibody response less than 1 . 0  pg/ml, the level of antibody thought to 
correlate with long-term clinical protection. Of these, information on responses to a 
booster dose of vaccine was available in 24 cases, of whom all but one achieved an 
antibody level above this ‘protective’ threshold (McVemon J et al 2001).
3.2.2 Immunologic memorv and Hib vaccine failure 
Methods
This study aimed to compare the geometric mean concentration of convalescent PRP- 
specific semm antibodies produced following invasive Hib infection between Hib 
conjugate vaccine immunised and unimmunised children. In making this comparison, 
significant confounding factors influencing the immune response to disease were taken 
into account.
Subiect Populations
A. UK Hib vaccine failures
Subjects were identified through enhanced surveillance for invasive Hi infections using 
methods and case definitions described earlier. All children included in this analysis 
had confirmed invasive Hib infection following receipt of three doses of Hib vaccine in 
infancy, at 2,3 and 4 months of age, without a booster dose. Additional clinical 
information was prospectively collected on the cases as part of the BPSU study. Semm 
was collected for measurement of acute and convalescent concentrations of Hib 
antibody and the timing of collection in relation to disease onset was noted. 
Measurement of immunoglobulin classes and subclasses was also performed on 
convalescent specimens and classified as normal or deficient in relation to age 
appropriate reference ranges. This study was approved by the Central Oxford Research
97
Ethics Committee in 1991 and again by the South East Multi-Centre Research Ethics 
Committee in 2001.
B. Unimmunised Australian children with Hib
A cohort of children, previously described (Johnson PDR et al 1996), was selected as an 
unvaccinated historical control group from among patients admitted to the Royal 
Children’s Hospital, Melbourne, Australia between February 1988 and August 1990 
with Hib epiglottitis or meningitis. Of 47 children with meningitis, 46 had positive Hib 
cultures from blood or CSF or both. Forty-five cases of epiglottitis were described -  32 
had a positive blood culture, 8  a positive throat swab and a fiirther 3 were diagnosed on 
latex antigen testing. Two were diagnosed on clinical grounds alone according to the 
judgement of two experienced clinicians. The CMC of convalescent Hib antibodies 
following epiglottitis in the previous study was no different when children without a 
positive blood culture were included in the case definition, compared with the GMC for 
the 32 from whom Hib was grown in the blood. No children had received Hib vaccine. 
Acute and convalescent serum samples were taken and age at presentation, clinical 
diagnosis and timing of serum collection were also noted. The study was approved by 
the Ethics in Human Research Committee of the Royal Children’s Hospital, Melbourne. 
Antibodv Measurement
In the UK, PRP antibody measurements were performed initially using the Farr type 
radioimmunoassay (Booy R et al 1992) with a change to the Centres for Disease Control 
(CDC) standard protocol HbO-HA ELISA (Phipps DC et al 1990) in 1999.
Equivalency studies performed at the time were favourable, with some discordance 
noted in the lowest ranges only (H Griffiths, personal communication). All assays in 
Australia were conducted using the HbO-HA ELISA. Both assays were standardised
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using reference sera supplied by the Food and Drug Administration, US (Phipps DC et 
al 1990) (Booy R et al 1992).
Statistical Analysis
For descriptive statistics, the Wilcoxon ranksum test was used to compare group 
medians. In the comparison of Hib antibodies, a minimum concentration of 0.08 pg/ml 
was assigned for values <0.15 pg/ml. Convalescent antibody measurements were log 
transformed in order to achieve a normal distribution and described as GMCs. For the 
pooled data on vaccinated and unvaccinated children, simple regression analysis was 
performed to assess the relationships between convalescent antibody and both age at 
presentation and timing of serum collection. These were then incorporated into a 
multiple linear regression model, which was used to predict adjusted convalescent 
antibody responses. Student’s t test was used to assess the significance of any 
difference in raw and adjusted GMCs between vaccinated and unvaccinated children. 
The same comparisons were made with children presenting with either meningitis or 
epiglottitis considered separately.
Further exploration of potential confounders was performed using the UK vaccinated 
dataset. The effects of the various clinical and immunologic variables measured on 
logged convalescent antibody concentrations were first assessed using simple linear or 
logistic regression analysis depending on the nature of variables assessed. Their relative 
contributions were then further measured in a multivariate regression model in which all 
potential confounders were included. All statistical analyses were performed using 
STATA 7.0 (STATA 2001).
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Results
From October 1992 to 1®^ January 2001,185 reports of Hib vaccine failure following 
three doses in infancy were notified through surveillance in the UK and Republic of 
Ireland (171 in the UK). Forty-nine of these presented with illnesses other than 
epiglottitis or meningitis, such as pneumonia, bacteraemia, cellulitis or bone and joint 
infections, and were excluded. Children bom prematurely or on whom gestational 
information was unavailable were considered separately (3 of 38 with epiglottitis, and 
13 of 98 with meningitis). Children with incomplete antibody data, for either 
concentration or day of collection (a further 27), were also excluded. This left 25 
vaccinated children presenting with epiglottitis and 6 8  with meningitis. One hundred 
and twelve cases were described in the study of unvaccinated children. Clinical 
presentation was unknown for one, and no convalescent serum was available for 19, 
leaving 45 children with epiglottitis and 47 with meningitis.
Demographic characteristics of the two groups are shown in Table 3.3. Vaccinated 
children presenting with meningitis were 8.5 months older than their unimmunised 
counterparts (p=0.005) and had earlier blood sampling at 28 days, compared with 52 
days (p<0.001). It should be noted, however, that a wide range of ages and sampling 
times was observed in both groups. Raw antibody data for all the children, plotted 
against age at presentation with disease, are shown in Figure 3.2. There was a 
statistically significantly higher concentration of antibodies in the vaccinated group 
(p<0.001) (Table 3.4). This was most marked in infants under 18 months of age. Only 
13% of unvaccinated children in this age group made any antibody response to 
infection, compared with 92% of those who had been immunised. However, age at 
presentation and timing of semm collection were both significantly related to antibody
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concentrations in the multiple regression model (p<0.0001 for both) (Table 3.5). 
Increasing age was associated with an exponential increase in antibody levels, and 
antibodies were seen to decay exponentially with time from illness. When antibody 
levels were adjusted for these confounding factors, a significant difference between the 
convalescent antibody responses of immunised and unimmunised children was only 
observed in those presenting with meningitis (p=0.0003) (Table 3.4).
Relationships between the immune response to Hib meningitis or epiglottitis and the 
additional clinical risk factors of chronic illness, known immunodeficiency, premature 
delivery and deficient immunoglobulins or subclasses described in UK vaccine failures 
were explored (data not shown). The 93 vaccinated children studied above, as well as 
11 prematurely bom children with complete data were included. The only additional 
factor found to influence the magnitude of the convalescent response was a history of 
premature delivery (coefficient -2.57, coefficient standard error 0.74, p=0.0008), which 
remained significantly associated with lower antibody levels in the multiple regression 
model (p=0.047). Comparison of raw Hib GMCs confirmed this finding. Children bom 
prematurely had a GMC of 0.82 pg/ml (95% Cl 0.27,2.54), while in those bom at term 
it was 10.81 pg/ml, (6.62,17.66); (p=0.008). This difference persisted after adjusting 
for age and timing of semm collection: preterm GMC 4.17 pg/ml (2.39, 7.28); term 
GMC 8.93 pg/ml (7.00,11.38); p=0.04, although overlapping confidence intervals are 
noted. For this reason, children delivered prematurely were considered a population of 
outliers and excluded from the earlier comparisons with the unvaccinated cohort. Their 
inclusion in the analysis resulted in lower GMC Hib antibody responses in the 
vaccinated group than those described in Table 3.4. It did not, however, change any of 
the significant differences observed between groups or conclusions drawn.
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3.2.3 National case-control studv of social and environmental factors associated with all
invasive Hib infections of childhood. 1998-2002
Methods
A national postal questionnaire study was conducted in order to look for risk factors 
associated with ongoing invasive Hib infections in the UK over the period 1998-2002, 
using a matched case-control design. This study was conducted within the 
Immunisation Department of the HPA’s Communicable Disease Surveillance Centre 
(CDSC).
Case definition
A sample of cases from the combined CDSC/HRU dataset of confirmed invasive Hib 
infection was defined for this study. Children presenting in England between 
January 1998 and January 2003 who had survived their disease were selected, 
regardless of vaccination status. In order to ensure equivalent access to immunisation, 
only those bom after I®^ January 1993 were eligible for inclusion.
Control identification
Child health system managers and District Immunisation Co-ordinators were advised of 
the study by email in December 2002. Letters were subsequently sent to child health 
contacts in regions where a case had been identified, asking them to nominate 5 children 
on their computer system who were bom on the same day as the index case. 
Immunisation dates and batch numbers were requested, along with the name of the 
child’s registered General Practitioner. The Health Protection Agency has approval 
under Section 60 of the Health and Social Care Act to process such confidential patient 
information for the purpose of monitoring the efficacy and safety of vaccination 
programmes.
106
Approach to Subjects
A two-stage consent process was requested by the ethics committee. In the first 
instance, a letter was sent to the usual General Practitioner of all potential study 
subjects, asking consent to release of the name and address of the child’s parents, and 
enquiring after the appropriateness of an approach to the family at the present time. 
Practices were also asked to check vaccine dates and batch numbers, as supplied by 
child health contacts. Following receipt of written informed consent from the GP, an 
invitation letter and questionnaire were sent directly to the parents of each child.
Study Procedure
A questionnaire inquiring after a range of clinical and environmental risk factors was 
sent to the parents of each study subject. Information requested included:
• Perinatal data: date of birth, birthweight, sex, gestation, breast feeding history
• Medical history: history and nature of chronic illness, antibiotic use over the first 
years of life (never, once/twiee yearly, every few months, almost every month), 
vaccination dates and batch numbers
• Child exposure: type of day care (home only, childminder or nursery, other) and 
number of other children in that care from ages 0-2 years, 2-5 years (<5, 5-10, 
>10)
• Household: parents at home, siblings, bedroom sharing, smokers, presence or 
absence of central heating, home ownership (own outright, own with mortgage, 
rents, lives rentfree)
• Parental information: country of birth, ethnicity, occupational status 
Parents were asked to return the completed questionnaire along with their written 
informed eonsent using a reply paid slip. They were encouraged to seek further
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information from the study investigators by telephone, or to speak with their own 
general practitioner or health visitor if they had any questions regarding the study.
Parental occupations were coded according to the Standard Occupation Classification 
2000 (SOC2000) published by the Office for National Statistics (ONS) 
(http://www.statistics.gov.uk/nsbase/methods qualitv/ns sec/soc2000.asp). Each 
parent was then assigned a National Statistics Social and Economic Classification (NS- 
SEC) from the reduced derivation tables provided by the ONS, on the basis of the 
SOC2000 and their employment status. Operational categories of the NS-SEC were 
linked to Social Class, according to tables available on the ONS website 
(http://www.statistics.gov.uk/methods qualitv/ns sec/contents.aspk In keeping with 
recent changes in the allocation of household level SEC, the parent with higher earning 
potential regardless of gender was assigned to be the household reference person, by 
whose status the family’s social class was determined.
Vaccines were identified from batch numbers, using information supplied by the 
manufacturers as described earlier in Section 3.1.2. If the manufacturer’s product could 
not be identified with certainty from the batch number provided, no code was assigned. 
As in the earlier analysis of batch numbers, the primary question of interest was whether 
DTaP-Hib was over-represented among cases compared with controls. The point of 
repeating the study within this design was to allow matching by area as well as date of 
birth in order to account for possible regional variation in vaccine distribution. In 
keeping with the period of use of DTaP-Hib in the UK, only cases bom after 1®‘ October 
1999 who had received three identifiable doses of a Hib vaecine before disease onset 
were included in the analysis.
108
Statistical methods and sample size
Questionnaire data were entered into a relational Dataease database maintained at 
CDSC on a secure network. The month and year of birth were used as the basis for 
matching cases with controls. Univariable conditional logistic regression models were 
used to examine the relative contribution of the exposures of interest to the risk of 
disease. These relationships were described as odds ratios (ORs) with 95% confidence 
intervals (CIs). Variables significant in the first analysis at the level of p=0.05 or less 
were then included in multivariable models. Each additional exposure was later 
incorporated singly to see whether any achieved significance within this context.
Where two exposures were strongly correlated, only the most significant was used in the 
analysis. Relationships with factors described in terms of a number of levels, such as 
antibiotic use, were explored using all tiers, and as tests for trend.
For the study of vaccine batches, conditional logistic regression was used to compare 
the number of doses of the fiill primary immunisation series given as DTaP-Hib 
between each case and their birth-date and regionally matched controls. All statistical 
analyses were conducted using STATA 7.0 (STATA 2001).
An unmatched study with a sample size of 332 cases and 664 controls would allow 
identification of an OR of 1.5 for an exposure with a control prevalence of 30% with 
80% power and 95% confidence. Such an OR has been previously quoted for the 
additional risk of invasive disease conferred by a smoking household member (Cochi 
SL et al 1986), the prevalence of which is 30% in Oxfordshire (Dr M Barbour, personal 
communication). Odds ratios for other risk factors identified have been much higher, for 
instance, 4.0 for day care attendance, 2.5 for household crowding and 0.3 reflecting
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reduction of risk attributable to breast feeding (Cochi SL et al 1986). Given the 
reported prevalence of each of these exposures in a British population, only 40-60 cases 
(and twice as many controls) would be needed to find similar risks with 90% power and 
95% confidence. The use of a matched design further increased the study’s power.
Results
Three hundred and thirty-two cases were identified which met the selection criteria. 
Names of potential controls were released by child health contacts as requested in 
relation to 301. Of the remaining 31, controls for 18 cases were approaehed directly by 
the PCT in line with individual trust guidelines. No controls could be identified for the 
remaining 13. In all, names of 1,350 potential controls were obtained.
Twenty-three of the cases were not currently registered with a GP in England according 
to child health records. Of the 309 remaining, up to four letters were sent to GPs 
requesting consent to parental approach. By the end of December 2003, responses were 
received in relation to 264 children (85%), with only 14 refusing consent to approach 
parents. Letters were addressed to the doctors of 1,350 potential controls. 1,060 (79%) 
replied, with 8 8  refusals and 972 consents. Parents could be sent a maximum of two 
letters in line with ethical guidelines on approach of subjects. One hundred and thirty of 
250 cases (52%) replied to the invitation, with 127 (51%) agreeing to participate. Nine 
hundred and seventy-two controls were approached -  276 (28%) replied and 259 (27%) 
took part.
The distribution of variables in the population and ORs derived from the univariable 
analyses, matched by month of birth, are shown in Table 3.6. Exposures initially 
included in the multivariable model were: prematurity, antibiotic use, number attending
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nursery between 2-5 years, bedroom sharing, number of parents at home, central heating 
and vaccination status. Number of children in nurseiy from 0-2 years was not included, 
as a significant correlation was found between nursery attendance at different ages. 
Bedroom sharing and central heating were dropped from the model as they did not make 
a significant contribution to risk. The number of smokers in the household was added 
as it was found to be significantly associated with outcome. Results of the final 
multiple regression model are shown in Table 3.7.
A history of prematurity and living in a single parent household were the strongest risk 
factors for invasive Hib infection. Frequent antibiotic use was also associated with 
increased likelihood of disease. Attendance at a day care nursery between the ages of 2 
and 5 years appeared to reduce the risk of infection, decreasing by 20% with eaeh 
additional increment in the number of children cared for in the same environment. 
Surprisingly, having smokers in the household was also associated with a reduced risk 
of invasive infection. Vaccination provided the best protection in this analysis.
Findings of the study of vaccine batches received by cases and controls, matched by 
exact date of birth and region, are shown in Table 3.8. Due to the stringency of 
matching and restriction of dates of birth for the purpose of this analysis, only 49 
observations were included, resulting in substantial loss of power. In spite of this loss 
of data, a clear trend to increasing risk of vaccine failure with each additional dose of 
DTaP-Hib vaccine received in the infant primary course was observed. A doubling of 
risk occurred for each increment, with only a 6 % probability that this finding was due to 
chance.
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Table 3.6: Distribution of variables, results of univariable analyses
Variable Case Control Odds Ratio (95% 
Cl)
p value
Perinatal Data
Birthweight (g) mean (95% 3413 (3296,3530) 3435 (3356,3514) Student’s t test p=0.75
Cl)
Sex F=56, M=75 F=119,M=147 0.97 (0.61, 1.54) p=0.90
Prematurity No=120, Y es= ll No=253, Yes=13 3.37(1.12,10.1) p=0.03
Breastfeeding (BF) No=45, Yes-86 No=88, Yes=178 0.93 (0.56,1.54) p=0.78
Median months BF (range) 6 (1 ,3 0 ) 4.5 (1, 36) Ranksum test p=0.23
Medical History
History o f illness No=99, Yes=32 No=217, Yes=48 1.26(0.71,2.21) p=0,43
Antibiotic Use (stratified) Never=27 Never=73 1.0 p=0.06
l-2/year=71 l-2/yeai=160 1.32 (0.73, 2.38)
Fewmos=19 Few mos=24 2.35 (1.0, 5.51)
Monthly=10 Monthly=7 3.65 (1.18,11.3)
Antibiotic use (trend) 1.54(1.12,2.12) p=0.008
Vaccinationt No=10; Yes=121 No=l; Yes=265 0.03 (0.005,0.27) p=0.001
Child Exposure
Number o f children in care 0=95 0=170 1.0 p=0.25
0-2 yrs (stratified) <5=13 <5=24 1.05 (0.46,2.4)
5-10=2 5-10=7 0.27 (0.03,2.43)
>10=21 >10=64 0.62 (0.34,1.14)
Number o f children in care 0.84 (0.69,1.03) p=0.09
0-2 years (trend)
Number o f children in care 0=52 0=67 1.0 p=0,02
2-5 yrs (stratified) <5=6 <5=10 0.57 (0.16,2.02)
5-10=5 5-10=14 0.38 (0,12,1.22)
>10=56 >10=153 0.41 (0.23, 0.74)
Number o f children in care 0.75 (0.62,0.90) p=0.002
2-5 yrs (trend)
Household
Parents home Both=106 Both=242 2,11 (1.03,4.33) p=0.04
Sole parent=25 Sole parent=24
Number o f siblings 0=22 0=69 1.0 p=0.26
(stratified) 1=68 1=133 1.74 (0.93, 3.3)
2=31 2=46 1.79 (0.87,3.68)
3=7 3=16 1.06 (0.35,3.2)
4 or more=3 4 or more=2 5.23 (0.48, 56.8)
Number o f  siblings (trend) 1.17(0.90,1.52) p=0.24
Bedroom sharing (stratified) 0=77 0=195 1.0 p=0.14
1=43 1=60 1.49 (0.88,2.53)
2=6 2=9 1.60 (0.53,4.82)
3 or more=5 3 or more=2 4.75 (0.83,27.2)
Bedroom sharing (trend) 1.47 (1.05,2,05) p=0.03
Smokers (stratified) 0=96 0=190 1.0 p=0.38
1=22 1=51 0.66 (0.36, 1.2)
2=11 2=20 0.87(0.36, 2.1)
Smokers (trend) 0.83 (0.57,1.2) p=0.32
Heating N o = ll, Yes=120 No=14, Yes=252 0.54(0.21,1.4) p=0.19
Own or Rent (stratified) Own outright=l 1 Own outright=19 1.0 p=0.16
Mortgage=86 Mortgage=207 0.60 (0.25,1,44)
Rents=30 Rents=38 1.06(0.39,2.9)
Rentfree=3 Rentfree=2 1,8 (0,24,13,6)
Own or Rent (trend) 1,3(0.85,2.01) p=0.23
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Variable Case Control Odds Ratio (95% 
Cl)
p value
Parental Variables
Maternal Ethnicity Mother White: 125 Mother White: 248 0.76 (0.28,2.04) p=0.58
(White British/Irish vs Mother Other: 6 Mother Other: 18
Other)
Paternal Ethnicity Father White: 122 Father White: 250 1.04 (0.33,3.22) p=0.95
(White British/Irish vs Father Other: 6 Father Other: 14
Other)
Household Social Class 1=13 1=23 1.0 p = 0 .12
(stratified) n=50 n=137 0.45 (0.19, 1.06)
m=48 m =82 0.70 (0.29,1.7)
IV=10 IV=12 1.23 (0.34,4.4)
V=2 V=2 1.21 (0.12,12.5)
Household Social Class 1.20 (0.88, 1.65) p=0.25
(trend)
Table 3.7: Results of multivariable analysis
Variable Odds Ratio (95% Cl) p value
Prematurity 4.45 (1.3, 15.6) p=0 . 0 2
Single parent household 2.61 (1.1, 6.3) p=0.03
Antibiotic use (trend) 1.59(1.1,2.4) p=0 . 0 2
Number of children in 
nursery age 2-5 yrs 
(trend)
0.78 (0.64, 0.96) p=0 . 0 2
Number of smokers in the 
Household (trend)
0.55 (0.33, 0.91) p=0 . 0 2
Vaccinated 0.02 (0.002, 0.29) p=0.003
Table 3.8: Analysis of vaccines received, controls matched by DOB and region
Variable Case Control Odds Ratio (95% 
CD
p value
Number of Doses of aP 
Combination Vaccine 
(stratified)
0=14
1=3
2=5
3=22
0=19
1=9
2 = 1 2
3=36
1 . 0
0.96 (0.05, 20.3) 
5.3 (0.18,153) 
6 . 6  (0.3,133)
p=0.25
Number of Doses of aP 
Combination Vaccine 
(trend)
2.1 (0.9, 5.0) p=0.06
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Discussion -  host and environmental factors
Studies of risk factors associated with invasive Hib infection have sought to define 
populations of susceptible children who may be a source of ongoing transmission of the 
organism, or be at heightened individual risk of developing invasive disease if exposed. 
Identification of such groups may direct targeted interventions in order to enhance the 
impact of the routine Hib immunisation schedule.
Examination of clinical factors associated with ongoing Hib disease in the vaccine era 
in the BPSU/OVG study revealed that the majority of children presenting with Hib 
vaccine failure appeared perfectly healthy before they developed their infection. Only 1 
in 1 0  had a pre-existing medical diagnosis clearly associated with reduced immune 
function that would have prompted their usual clinicians to consider them at heightened 
risk. As such, an intervention strategy aimed at boosting the immunity of children with 
these diagnoses may have been individually beneficial, but would not have prevented 
the bulk of vaccine failure cases.
A further finding of the BPSU/OVG study was the observation that approximately 1 in 
4 recovered Hib vaccine failures showed some minor deficiency of immunoglobulin 
classes and subclasses. This replicated similar reports fi"om studies conducted 
elsewhere (Holmes SJ et al 1991) (Breukels MA et al 2001). Immunoglobulin subclass 
deficiency was interpreted as potentially significant in light of an earlier established but 
inconsistent link with hyporesponsiveness to polysaccharide antigens and recurrent 
smopulmonary infection (Shackelford PG et al 1990). The most obvious limitation of a 
finding established only by serum testing in convalescence was the inability to intervene 
prospectively to prevent such cases. The other difficulty of interpretation was
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establishing whether children with subclass deficiencies, or indeed any of those 
presenting with conjugate vaccine failure, showed any quantitative or qualitative 
abnormality in their response to immunisation.
Post primary immunisation (5 months) antibody titres were not available for children 
later presenting with invasive Hib infection, as these were not routinely taken or stored. 
Antibody titres collected during the acute phase of disease were not an accurate 
reflection of immunity prior to exposure to the organism, and were very difficult to 
interpret. Reasons for this difficulty included an uncertain duration of Hib colonisation 
prior to invasive disease, which may have produced some natural immunity. Many 
unimmunised children over the age of 2 years presenting with Hib meningitis in the 
1970s had substantial specific antibody elevations within only a few days of disease 
onset (Anderson P et al 2000). Coexistence of bactericidal activity in serum and 
bacteraemia (Schneerson R et al 1971) was postulated to be due to constant seeding of 
the organism from extravascular tissues, in excess of capacity for clearance (Shaw S et 
al 1976). Conversely, binding of antibody by persisting free PRP antigen would be 
expected to reduce measurable titres. Circulating free PRP has been regularly observed 
for between 1 and 30 days of convalescence, and may be found for many months in 
some individuals (O’Reilly RJ et al 1975).
Some measure of priming by infant immunisation was sought by comparing the 
convalescent antibody response to Hib disease as a ‘booster’ in previously vaccinated 
British children with an unvaccinated Australian historical cohort. After correction for 
the confounding effects of age and timing of serum collection (Johnson PDR et al 
1996), a significant difference in the magnitude of the immune response between
115
vaccinated and unvaccinated children was only seen in those presenting with Hib 
meningitis (McVemon J et al 2003b). We attributed this difference to priming for 
immunologic memory by infant immunisation, without clinical protection from disease.
Prior to the use of conjugate vaccines, it was noted that children with epiglottitis tended 
to be older and have higher convalescent anticapsular antibody titres than those with 
meningitis (Whisnant JK et al 1976). It has been suggested that the presence of pre­
existing immunity in these cases was enough to contain invasive disease at the 
epiglottis, perhaps as a result of immunologic priming through prior oropharyngeal Hib 
carriage (Johnson PDR et al 1996). The absence of a difference in convalescent GMCs 
between vaccinated and unvaccinated children with epiglottitis may support the notion 
that both groups were primed. In the Australians, this priming was most likely the 
result of carriage of Hib or cross reactive organisms, and in the UK cohort, may have 
been attributable to vaccination with or without carriage. Alternatively, the greater 
immune response to infection in this group may simply reflect immunologic maturation 
of the response to capsular polysaccharides with age.
Ten of 25 children in a previous study of Hib vaccine failures had low levels of lgG2 
subclass and IgM (Holmes SJ et al 1992), and also showed a reduced convalescent 
antibody response to disease. In the present series, no such difference in Hib antibody 
concentrations was noted in children with abnormalities of immunoglobulins or 
subclasses, using multiple regression analysis. However, the possibility that other 
defects in immune regulation may be over-represented among vaccine failures deserves 
further exploration. A range of polymorphisms in genes responsible for regulating 
antibody responses, initiating or modulating pathogen recognition or clearance have
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been implicated in conferring such susceptibility to a range of diseases (Kwiatkowski D 
2000).
A history of premature delivery had a marked effect on antibody response in this study. 
Some of the reduction in titres may be explained by the lower age of this subset with a 
median age of 2 0  months (range 10-51) compared with those delivered at term [28 
months, (range 7-91)]. However, persistently lower antibody levels were observed, 
even following adjustment for age and timing of serum collection. These results would 
strongly suggest defective induction of memory in our population of premature infants. 
Lower primary antibody responses (Slack MH et al 2001) and reduced persistence 
(Heath PT et al 2003) have been observed previously following vaccination of 
premature infants with conjugate vaccines. These new data added further weight to the 
suggestion that prematurity was a risk factor for vaccine failure (Heath PT et al 2003).
The national case control study of social and environmental factors enrolled fewer 
subjects than initially hoped. Significant barriers to recruitment arose as a result of 
ethical constraints imposed, requiring multiple consent procedures at primary care trust, 
practitioner and patient stages. In spite of the associated loss of power, a number of 
variables were found to be significantly associated with altered risk of invasive Hib 
infections in the UK in an era of widespread vaccination coverage.
Within this study design, a history of prematurity was significantly linked with an 
increased likelihood of disease [OR 4.45 (1.3,15.6) p=0.02], in keeping with the 
evidence of reduced vaccine immunogenicity described above. Living in a sole parent 
household also conferred additional risk [OR 2.61 (1.1, 6.3) p=0.03]. The same finding
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had been noted from the US [OR 4.3 (1.2,14.8)] (Jafari HS et al 1999) and Switzerland 
[OR 3.52 (1.0,15.37] (Muhlemann K et al 1996) in communities with partial vaccine 
coverage. The way in which this effect is mediated in divergent populations may differ, 
and the mechanism was unable to be defined in this study. Incomplete immunisation 
was more common in children residing in single parent households in the US thereby 
clearly increasing disease risk (Jafari HS et al 1999), although no such relationship was 
seen in the UK. Antibiotics were more frequently prescribed over the first years of life 
for children subsequently presenting as Hib cases [OR (trend) 1.59(1.1,2.4)]. This 
finding may reflect the fact that children prone to infections may be expected to attend 
medical practitioners more often with illnesses requiring antibiotic therapy.
An unanticipated protective effect of nursery attendance in children aged between 2 and 
5 years was found, rising by 20% with each incremental increase in the number of 
children in care (OR (trend) 0.78 (0.64, 0.96) p=0.02]. This was in marked contrast to 
reports from the US in the 1980s of heightened risk of both primary and secondary Hib 
cases in such settings, most marked in children under 2 years of age. Different 
estimates were obtained between geographical areas in these studies, which were 
attributed to variation in the size of centres, and definitions of classroom contact 
(Broome CV et al 1987b). While no studies of community-based risk factors for Hib 
disease were conducted in the UK prior to vaccine introduction, it is unlikely that 
characteristics of day care on both sides of the Atlantic would be so different as to have 
opposite effects on outcome. Of note, a Swiss study involving predominantly 
unvaccinated children around the time of vaccine introduction showed a similar trend to 
reduction of risk of Hib infection in children over the age of 2 years attending nurseries 
or schools (Muhlemann K et al 1996). The authors of this study attributed their finding
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to increased opportunity for exposure to cross reactive antigens in this situation. 
Alternatively, it may be proposed that children able to mount an antibody response to 
Hib, either through maturation of natural immunity to polysaccharides or priming by 
conjugate vaccines, may benefit fi*om repeated boosting of specific antibody associated 
with episodes of Hib colonisation.
The further unexpected finding of a protective effect of having smokers in the 
household [OR (trend) 0.55 (0.33,0.91) p=0.02] may be postulated to act through a 
similar mechanism. Passive smoking has been linked with carriage of multiple strains 
of nt Hi (StSauver J et al 2000). If children of smokers are more heavily colonised with 
respiratory pathogens, this increased exposure may boost natural immunity. 
Alternatively, some unidentified confounding factor may be responsible for the 
observed association.
Vaccination was strongly protective against infection in the case-control study, the odds 
ratio of 0.04 corresponding with 96% direct efficacy. This figure should be interpreted 
with caution, as vaccine coverage in the control population recruited was 99%. Such a 
high level of immunisation uptake was well above the 91-93% observed in the UK over 
the past 1 0  years, indicating that our sample was unfortunately not truly representative 
of the population (Figure 2.1). On this basis, the estimate of efficacy cannot be directly 
compared with figures derived in other studies (Ramsay ME et al 2003).
119
3.3 Changes in population immunity in the UK 1990-2002, possible consequences for 
transmission and invasive disease
In considering possible aetiologic causes of the change in Hib epidemiology over time, it is 
worth reiterating the vaccines’s impact on transmission of the organism, with a subsequent 
reduction in boosting of natural immunity. Figures 3.3 a and 3.3b summarise the shifts in 
prevalence of specific antibody to Hib in the population in the past ten years, as measured 
in the HP A studies (Section 2.6.2).
Figure 3.3a: Seroprevalence of Hib antibody titres >1.0 pg/ml by age, 1990/1994
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Figure 3.3b: Seroprevalence of Hib antibody titres >1.0 pg/ml by age, 1994/2000
□ 2000 
□  1994
0 .7
c(Q
W
0.6
I
Co
0 .4
0 .3 -
t:oQ.s
0.2
0 . 1-
Q.
5 -7
8-11 12-15
3 0 -3 9
Age at Serum Collection
20
The reduction of antibody concentrations in toddlers among cohorts immunised in 
infancy (Figure 3.3b) has been seen to result in lower direct protective efficacy of 
vaccine (Section 3.1.1). Effects on herd immunity resulting fi*om this change remain 
incompletely understood. In addition, the potential for susceptibility to re-emerge in 
older age groups (Figure 3.3a) may contribute to a fiirther pool of potential transmitters 
of the organism at the opposite end of the age spectrum. The cost of population based 
carriage studies to monitor such changes on an ongoing basis is prohibitive, particularly 
when carriage prevalence is low. Further, even with persistently low levels of 
colonisation in the population, lower immunity at the point of exposure to the organism 
may lead to a proportional increase in cases arising fi-om a given number of carriage 
episodes. Mathematical models of the impact of immunisation on Hib transmission and 
immunity have been developed in order to explore these issues, and will be outlined in 
more detail in subsequent chapters.
SA Conclusion
Vaccine-related, host and environmental factors potentially contributing to ongoing Hib 
infections in the UK and their changing epidemiology over time have been explored in a 
series of studies conducted by the HP A, OVG and BPSU.
Direct efficacy of the accelerated infant immunisation schedule employed in the UK has 
been lower than anticipated fi-om phase II trials, at 61% in the first two years following 
vaccination, waning to 27% thereafter. This deficiency was masked for several years by 
the use of catch-up immunisation in the UK in 1992 to 1993, with an estimated short­
term protective effect of 97%. Superimposed on waning of the catch-up phenomenon
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was the use of a less immunogenic DTaP-Hib vaccine that was both temporally 
associated with a reduction in efficacy in the population, and correlated with an increase 
in the odds of vaccine failure in a matched case-cOntrol analysis. Each additional dose 
of DTaP-Hib given as part of the full infant primary schedule conferred a 2-fold 
increased risk of vaccine failure in two separate study designs. These changes in 
measured immunogenicity and efficacy corresponded closely with the population 
experience of paediatric invasive Hib disease.
Cohort and case-control studies were conducted in order to understand more of the 
mechanism of ongoing Hib disease and vaccine failure, and to potentially identify 
subpopulations that may benefit from additional measures to prevent Hib infection. The 
majority of children presenting with Hib in the vaccine era appeared healthy before their 
disease, with only 1 in 1 0  reporting a preceding clinical diagnosis associated with 
increased risk of bacterial infections in the cohort study. A significant association was 
found between frequent antibiotic use and Hib disease in the case-control study, suggesting 
that some degree of enhanced susceptibility to infection may have been present in a 
subgroup, in the absence of a definable clinical syndrome. In keeping with this hypothesis, 
immunoglobulin subclass deficiency was found in the convalescent serum of 25% of 
children presenting with Hib despite vaccination. This immunophenotype was of uncertain 
prognostic signficance, however, and was not associated with evidence of impaired 
priming by infant immunisation, as evidenced by the magnitude of the convalescent 
antibody response to invasive infection. Overall, Hib vaccine failures appeared to have 
been successfully primed for memory immune responses by infant immunisation, but were 
still not protected from disease.
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Measures of Hib vaccine immunogenicity following the infant primary course are reduced 
in children delivered prior to term. Evidence of deficient priming in infancy was further 
suggested by a marked reduction in convalescent Hib titres among vaecine failures with a 
history of prematurity, compared with those delivered at term. A previous analysis of the 
relationship between prematurity and vaccine failure in the OVG cohort study failed to 
show a significant contribution of this risk factor to disease. In the national case-control 
study, however, premature delivery was strongly associated with invasive Hib infection 
(OR 4.4), in keeping with the immunologic findings above.
Given imperfect protection by vaccination, other non-vaccine factors that may have 
contributed to disease risk in otherwise healthy children were explored. Living in a 
single parent household (OR 2.61) was linked with increased likelihood of invasive 
infection. In a surprising finding, a protective effect of exposure to other children 
outside the home in day care settings was observed, increasing with the number of 
children in care (OR (trend) 0.78). A further surprise was a protective effect of passive 
smoking (OR (trend) 0.55). Both of these latter two exposures have been associated 
with an increased likelihood of carriage of respiratory pathogens. Repeated colonisation 
with Hib in children who have been immunised may result in better persistence of 
vaccine-induced protection throughout childhood.
The medium to long-term impact of disruption of Hib transmission on maintenance of 
immunity in the population has been noted. The anticipated effect of these shifts in 
protection on carriage and disease will be explored in subsequent chapters, using 
epidemiological models of Hib infection and immunisation.
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Chapter 4: Model Structure
4.0 Introduction: Questions to be asked o f the model
An epidemiological model of Hib infection and immunisation was developed in order to better 
understand what key determinants might be involved in a resurgence of invasive Hib disease in 
the UK eight years after vaccine introduction, following a period of very low incidence. This 
ft-amework was designed to allow examination of several key assumptions to do with the 
protection afforded by natural and vaccine induced immunity including:
• Duration of protection
• Degree of protection against acquisition of Hib carriage
• Degree of protection against progression of established carriage to invasive disease 
Factors influencing transmission of the organism and subsequent maintenance of population 
immunity which could be explored included:
• Imposition of a vaccine known to block acquisition of Hib carriage
• The impact of assumptions regarding social mixing patterns between age groups on
vaccine effectiveness post implementation
Issues of particular relevance to the isolated rise in disease observed in the UK included 
consideration of aspects of vaccine implementation unique to Britain:
• How might the ‘catch-up’ immunisation programme, which accompanied the Hib 
vaccine’s introduction in the UK, have altered the observed effectiveness of the accelerated 
three dose primary infant schedule?
• How might the use of less immunogenic Hib combination vaccines, such as those used 
in the UK in 2000/2001, have contributed to the increase in Hib disease?
Based on an understanding of these interactions and their consequences for Hib disease over the 
past ten years, we wished to be able to ask:
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• What are the potential public health benefits of longer term interventions such as 
o a less accelerated primary schedule?
o addition of a routine booster dose?
o intermittent catch up campaigns?
4.1 Model structure
The model is a fully age structured deterministic susceptible-infected-resistant-susceptible 
(SIRS) model with modifications, expressed as a set of partial differential equations. State 
variables are defined in Table 4.0, and flows between compartments are illustrated in Figure 
4.0. These compartments may be broadly grouped into ‘susceptible’, ‘infected’ and ‘resistant’ 
states, as denoted by the shadings of green, yellow and blue, respectively. In order to address 
the questions defined in part 1 above, these categories have been fiirther subdivided into 
biologically defined subgroups described below in Table 4.0.
To avoid the need to consider maternal immunity, all subjects enter the model at the age of 6  
months, and progress through it until the age of 20.5 years, at which point they exit. Initial 
conditions reflect the population distribution of individuals who are susceptible to, infected 
with, or resistant to Hib infection in the pre vaccine era. At the time of introduction of 
immunisation, a fraction of each new birth cohort enters fiie vaccinated proportion, with the 
remainder continuing to be ‘bom’ into the unvaccinated class. The distinction between these 
two groups remains throughout life. ‘Catchup’ immunisation of individuals not vaccinated at 
birth is simulated by transfer of the relevant proportion of subjects in the target birth cohorts 
from the unvaccinated susceptible and resistant states to the vaccinated high antibody resistant 
compartment. Those children who are infected at the time of immunisation move to the 
corresponding vaccinated infected class.
125
All of the ‘infections’ in the model refer to episodes of oropharyngeal carriage. Some of these 
infections may progress to invasive disease. Due to the relative rarity of such an event, 
invasive episodes are not explicitly described within the model structure, but calculated with a 
quasi-steady state approximation, based on the number of infections of various types at any 
point in time.
4.1.1 PreVaccination Condition
Mutually exclusive compartments represent the different epidemiological status of individuals 
in the population in relation to the infection. Arrows describe flows between these 
compartments. Individuals are bom immunologically naïve (N), until they acquire their first 
Hib infection (F). The absence of any pre-existing immunity at the point of exposure to the 
organism means that this initial encounter is particularly prone to result in serious invasive 
disease. Following clearance of colonisation, individuals seroconvert and move to the high 
antibody (Ah) compartment. This state denotes a period of absolute resistance to reacquisition 
of infection. Over time, immunity wanes and individuals move into the low antibody (Al) 
category. Here the presence of low level measurable immunity provides incomplete protection 
against infection, which may be so poor as to be considered absent. With the waning of 
antibody from low to undetectable levels, individuals are once again hilly susceptible to 
acquisition (S). Infections acquired in the presence of low circulating antibody (II) are 
assumed to have a reduced likelihood of progressing to invasive disease. Those acquired in the 
absence of circulating antibody ( In )  have a slightly higher risk of becoming invasive, but there 
is still less chance of this occurring than with the first infection (F). With clearance of carriage 
from either the II or In state, immunity is stimulated to the protective (Ah) level and the cycle 
of waning immunity, reinfection and stimulation of immunity begins again.
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Table 4.0: Definitions of State Variables
State Variable Symbol Definition
a. Unvaccinated Proportion
Naïve N Unvaccinated individuals who have never been infected with Hib.
First infection F Unvaccinated individuals infected for the first time with Hib, who are 
highly vulnerable to progression to invasive disease.
High Antibody Ah Unvaccinated individuals who have cleared a recent Hib infection, with 
resultant development of specific immunity to a level sufficient to 
completely block reacquisition of carriage.
Low Antibody A l Unvaccinated individuals whose immunity following Hib infection is still 
detectable, but has waned to a low level. Reacquisition of the organism is 
possible in this state, although the likelihood may be reduced.
Susceptible S Unvaccinated individuals whose immunity following Hib infection has 
waned to a level undetectable on routine serum testing. Without 
measurable antibody, these individuals are fully susceptible to acquisition 
of carriage.
Low Antibody 
Infection
II Unvaccinated individuals who have become infected with Hib in the 
presence of low level serum antibodies. This level of immunity at the 
point of exposure is assumed to provide partial protection against invasive 
disease.
No Antibody 
Infection
In Unvaccinated individuals who have become infected with Hib in the 
absence of any measurable specific immunity. Previous exposure to the 
organism has left some residual immunity, but this is assumed to provide 
less protection against progression to invasive disease than the low levels 
of antibody present in the U compartment above.
b. Vaccinated Proportion
High Antibody 
Vaccinated
Ahv Vaccinated individuals who have achieved high post immunisation 
antibody titres sufficient to protect them from acquisition of Hib.
Low Antibody 
Vaccinated
Alv Vaccinated individuals whose antibody titres have waned following 
immunisation, or were insufficiently high following immunisation, to 
completely protect them against acquisition. They may be partially 
protected by the low level of specific immunity measurable.
Susceptible
Vaccinated
Sv Vaccinated individuals whose antibody titres have waned to undetectable 
levels following immunisation, or made no apparent response to 
immunisation. Without measurable antibody, these individuals are fully 
susceptible to acquisition of carriage.
Low Antibody
Infection
Vaccinated
I l v Vaccinated individuals who have become infected with Hib in the 
presence of low level serum antibodies. This level of immunity at the 
point of exposure is assumed to provide partial protection against invasive 
disease.
No Antibody
Infection
Vaccinated
I n v Vaccinated individuals who have become infected with Hib in the absence 
of any measurable specific immunity. Previous vaccination has left some 
residual immunity, but this is assumed to provide less protection against 
progression to invasive disease than the low levels of antibody present in 
the I l v  compartment above.
Boosted
Vaccinated
Bv Vaccinated individuals who have cleared infection with Hib, with resultant 
development of very high (‘boosted’) levels of immunity sufficient to 
block acquisition of carriage.
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Figure 4.0: Age Structured Model
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4.1.2 Vaccination
Immediately following primary vaccination, individuals enter the model with high ( A h v ) ,  low 
( A l v )  or undetectable (Sv) antibody levels. This bypassing of the immunologically naïve (N) 
state removes the risk of progression to invasive disease associated with the first ever infection 
(F) which is experienced by the unvaccinated class. The proportion in each immune category 
at the outset depends on the immunogenicity of vaccines in use at any given time. The degree 
of protection against acquisition in these three states is assumed to be identical to that 
experienced by unvaccinated individuals with high ( A r ) ,  low ( A l )  or undetectable (S) 
immunity. As before, infections may arise in the face of low or unmeasurable antibody, in this 
instance denoted as I l v  and I n v  respectively. The same risks of progression to invasive disease 
are assumed as from the II and In conditions. Following recovery jfrom infection, immunity is 
boosted to a higher level than would be seen in an unvaccinated population (By). From here, 
antibodies wane to the post immunisation level ( A r v ) ,  with this additional step making the 
duration of protection following an episode of natural exposure longer in individuals who have 
been vaccinated. With waning of immunity, the cycle of reacquisition and boosting of 
antibody levels can recur.
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The model is expressed in the following series of partial differential equations.
—  + —  = [l-(p(t) + q(t) + z(t))] X B -  k(a,t)N(a,t)
~  ~  = X(a,t)N(a,t) -  u’(a)F(a,t)
dt da
—  +  —  =  u ’(a )F (a ,t) +  u(lL (a,t) +  lN(a,t)) -  o)H(a)AH(a,t) 
dt da
— ~  "i   —  CDH(a)AH(a,t) — G)LAL(a,t) — (l-s)X (a,t)A L (a,t)
dt da
— + — = G)LAL(a,t) - X(a,t)S(a,t) 
dt da
— L  _i----- k  =  (l-e)X,(a,t)AL(a,t) - uÏL(a,t)
dt da
^  ^  = ya,t)S(a,t) - i)lN(a,t)
dt da
=  p ( t ) B  +  o ) B ( a )B v (a , t )  -  (O H v (a )A H v (a ,t)
dt da
dt da
q ( t ) B  +  (O H v (a )A H v (a ,t)  -  ( ® l v  +  (1- e ) k ( a , t ) ) A L v ( a , t )
= z(t)B + 0 )LvALv(a,t) - X,(a,t)Sv(a,t)
dt da
+ £)).(a,t)ALv(a,t) - UvlLv(a,t)
dt da
+  Ê t  = k ( a , t ) S v ( a , t )  - U v lN v ( a , t )
dt da
H   = uv(lLv(a,t) + lNv(a,t)) - C0B(a)Bv(a,t)
dt da
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Chapter 5: Model Parameters
5.0 Introduction
The model has a high degree of structure, requiring extensive analysis of the published 
literature in order to define a range of parameter values. The interactions defined in the 
model provide a strong organising fi-amework within which to examine this literature. 
Table 5.0 summarises the initial parameters estimated, and lists the chapter section in 
which each one is derived.
Table 5.0: Summary of Parameter Values
Model Parameter Mean Value Mean duration 
in class
Derived in 
Section
Demo^aphic parameters
Births per quarter, B 6  250
Population size, N 500 000
Proportions vaccinated, p, q, z 0 - 1  where p+q+z<l
Routiue infant 
immunisation
p=0.83, q=0.07, 
z=0 . 0 2
5.1
Poorly immunogenic 
vaccine
p=0.63, q=0.19, 
z=0 . 1 0
Biological parameters
Duration of carriage for first infection
u' 5 2.4 months 5.2
Duration of carriage for subsequent infections
n (unvaccinated) 5 2.4 months 5.2
uv (vaccinated) 5 2.4 months 5.2
Duration of immunity
Unvaccinated
cohi (0.5-1.99 years) 6.59 0.15 years 5.3.2, 5.5
®H2 (2-4.99 years) 0 . 6 8 1.46 years
coh3 (5-10.99 years) 0.47 2.13 years
(0 h4  (11-20.5 years) 0.49 2.05 years
©L (all ages) 0.09 1 1 . 0  years
Vaccinated
©Hvi (0.5-0.99 years) 0.81 1.23 years 5.3.3
©hv2 (1-1.49 years) 0.56 1.77 years
cohv3 (1.5-1.99 years) 0.48 2.08 years
©HV4  (2-20.5 years) 0.40 2.48 years
©Lv (all ages) 0.69 1.46 years
Duration of immunity followinj1 re-exposure to Hib in vaccinated indivic uals
© B i  (0.5-0.99 years) 0.43 2.30 years 5.3.4
© B 2  (1-1.49 years) 0.56 1,77 years
© B 3  (1.5-1.99 years) 0.69 1.46 years
© B 4  (2-20.5 years) 0.94 1.07 years
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Model Parameter Mean
Value
Mean duration 
in class
Derived in 
Section
Relative protection against acquisition from low antibody state
8 0 - 1 5.4
Force of infection, X
(0.5-1.99 years) 0.45 5.5
X2 (2-4.99 years) 0 . 2 2
X3 (5-10.99 years) 0.40
A4  (11-20.5 years) 0.55
Rate of progression to invasive disease, 5
Ô1 (0.5-0.99 years) 0.0127 5.6
0 2 (1 .0 - 1 . 9 9  years) 0.0042
Ô3 (2.0-2.99 years) 0.0037
0 4 (3 .0 -3 . 9 9  years) 0.0030
Ô5 (4.0-4.99 years) 0.0016
Ô6 (5.0-20.5 years) 0.00006
Protection against progression against invasive disease afforded by low levels 
of measurable antibody, 6
0 0 5.6
Protection against progression against invasive disease afforded by previous 
natural or vaccine exposure to Hib in the absence of measurable antibody, p
M 0 5.6
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5.1 Proportions Vaccinated (p, q, z)
5.1.1 Routine Infant Immunisation 
Literature Review
The proportions of individuals entering the model in the vaccinated (p+q+z) and 
unvaccinated [1-(p+q+z)] categories were derived from COVER data published 
quarterly by the HPA CDSC
(http://www.hpa.org.uk/cdr/archive04/immunisation04.htm). Figures for complete 
(three doses) Hib vaccine coverage by 12 months were used. These data are illustrated 
in Figure 2.1 to demonstrate the relative consistency of coverage over time, compared 
with receipt of the first dose of the combined measles, mumps and rubella vaccine by 
24 months of age which has fallen in recent years due to adverse publicity.
As well as denoting the proportion of the population who were immunised, the 
parameters p, q and z represent the quality of vaccine ‘take’ achieved at different times 
during the Hib immunisation campaign. This is of particular importance in considering 
the likely impact of introducing less immunogenic preparations, such as Infanrix-Hib -  
a Hib vaccine conjugated with tetanus toxoid, formulated in combination with acellular 
pertussis, diphtheria and tetanus (DTaP-Hib). This vaccine was in widespread use in 
the UK in 2000/2001. At that time, approximately one third of infants received three 
doses of Infanrix-Hib in their primary infant schedule, and another third received a 
mixture of this and the corresponding whole cell pertussis containing combination 
vaccine DTwP-Hib (MeVernon J et al 2003a). Evidence for the reduced efficacy of 
this vaccine, in association with its observed poor immunogenicity, has been outlined 
in Section 3.1.2 of Chapter 3.
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In the model, immunisation may be associated with induction of high, low or 
undetectable antibody titres which result in a different degree and duration of 
protection against acquisition of infection. Phase II clinical vaccine trials routinely 
report immunogenicity results according to the cutoffs of 1.0 and 0.15 pg/ml. These 
antibody titres were associated with long and short term protection against Hib disease, 
respectively, in the era before availability of conjugate vaccines (Kayhty H et al 1983). 
In the absence of any other satisfactorily defined serological correlate of protection, 
these values have been arbitrarily used to distinguish between the compartments A h v , 
A l v  and Sy. Vaccinees who fail to seroconvert following primary immunisation 
(<0.15 pg/ml ) may later demonstrate evidence of immunologic memory on boosting 
(Goldblatt D et al 1999) and so for the purposes of the model were initially considered 
to enter the vaccinated susceptible category rather than being completely naïve. This 
assumption was later explored in the sensitivity analysis, by varying the proportion of 
children who were primary vaccine failures and entered the fully naïve class (N).
Proportions of subjects achieving protective thresholds following immunisation with 
different vaccines administered according to the UK infant schedule are summarised in 
Table 5.1. Quite considerable variation is seen between studies. It should be noted that 
the combination vaccine in the Poolman study was a hexavalent preparation not 
available for routine use in the UK which also included hepatitis B and injectable polio 
vaccines.
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Table 5.1; Immunogenicity of different Hib vaccine schedules in infancy
Reference Vaccines and 
Schedule
Number 
of subjects
% >1 . 0  
pg/ml
% 0.15-1 
pg/ml
% <0.15 
pg/ml
Heath PT 2000 DTwP-Hib 
2,3,4 mo
105 8 8 % 1 1 % 1 %
Goldblatt 1998 DTwP-Hib 
2,3,4 mo
516 93% 5% 2 %
Bell F et al 
1998
DTaP-Hib 
2,3,4 mo
251 23% 48% 29%
Poolman J et al 
2 0 0 1
DTaP-Hib 
2,3,4 mo
172 75% 24.4% 0 .6 %
Goldblatt et al 
1999
DTaP-Hib 
2,3,4 mo
1 2 2 57% 38.1% 4.9%
Parameter Estimation
Taking an average of the seroconversion rates from the Heath and Goldblatt studies 
above, we may assume that following primary immunisation with DTwP-Hib, 90% of 
children achieve high antibody titres (>1.0 pg/ml), 8 % have low antibody (0.15-1.0 
pg/ml) and 2% undetectable antibody (<0.15 pg/ml). If population immunisation 
coverage is 92%, the following routine values for p, q and z are obtained:
p = 0.83; q = 0.07, z = 0 . 0 2
In 2000/2001 one third of children (30%) received three doses of poorly immunogenic 
Hib vaccine (DTaP-Hib), while the remainder (62%) were given at least one dose of 
DTwP-Hib. The worst case scenario in terms of seroconversion rates is assumed from 
Bell’s data to derive the following values for p, q and z over this two year period:
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Entry into model A h v  A l v  S y
3 doses DTaP-Hib 0.23 x 0.30 0.48 x 0.30 0.29 x 0.30
Any DTwP-Hib 0.90 x 0.62 0.08 x 0.62 0.02 x 0.62
Immunisation parameter p = 0.63 q = 0.19 z = 0.10
5.1.2 Catch-up Immunisation Campaign 
Literature Review
The catch-up immunisation campaign that accompanied Hib vaccine introduction over 
the first year of its use has been described in Section 2.1 of Chapter 2. Figure 2.0 
shows quarterly immunisation coverage by birth cohort in the North Thames region, 
which is the best data available on which to base estimates of national catch-up vaccine 
uptake (O’Brien H 1994). .
Table 5.2 below shows the excellent immunogenicity of a single dose of the CRM1 9 7  
conjugate Hib vaccine (HbOC) in children aged 12 months and older, with 98-99% 
achieving Hib antibody titres >1.0 pg/ml. This formulation was widely used for catch­
up immunisation in the UK (Section 2.3, Table 2.0). On the basis of these data, all 
susceptible and resistant children immunised in the catch-up were assumed to transfer 
directly into the A h v  compartment following immunisation in the model simulation.
Children who were infected at the time of immunisation were transferred to the 
corresponding low or no antibody immunised infected compartment (ie Il-^ Ilv,
I n  ^  I n v ) .  This was based on a study in toddlers which showed that conjugate
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vaccination did not clear established carriage over a subsequent six week period, in 
spite of evidence of seroconversion (Barbour ML et al 1995).
Table 5.2; Immunogenicity of different Hib vaccine schedules in toddlers
Reference Vaccines and 
Schedule
Number 
of subjects
% > 1 . 0  
pg/ml
Rothstein 1991 HbOC 12-15 mo 14 98%
Madore 1990b HbOC 15-23 mo 171 99%
Parameter Estimation
Table 5.3 shows the calculations used to parameterise the catch-up campaign over the 
first year following vaccine introduction at time t=5. Quarterly coverage data provided 
the cumulative proportion in the four relevant birth cohorts immunised by the end of 
each three month period. From this information, the fraction of the remaining 
unvaccinated population transferred to the immunised class was calculated at each time 
point.
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Table 5.3: Parameterisation of the catch-up immunisation campaign 1992-1993
Time Age Classes 
Involved
Cumulative
Coverage
Proportion of 
Remainder 
Transferred
Equations Describing 
Transfers Between 
Compartments
1989 Ehrth Cohort
5 12,13,14, 
15
0 . 1 0 0 .1 0 ^ 1 =0 . 1 0 Ahv“ 0. 10 X (N+F+Ah+Al+S) 
1nv=0. 10XIn; Ilv=0.lOxfr
5.25 13, 14, 15, 
16
0.25 0.154-0.90=0.16
7
Ahv~0. 167 X (N+F+Ah+Al+S) 
Inv=0. 167 X In; Ilv=0. 167 x II
5.5 14,15,16, 
17
0.30 0.054-0.75=0.06
7
Anv—0.067 x (N+F+Ah+Al+S) 
Inv=0.067 X In; Ilv=0.067 x II
5.75 15, 16, 17, 
18
0.34 0.044-0.70=0.05
7
Ahv“ 0.057 X (N+F+Ah+Al+S) 
Inv=0.057 X In; Ilv=0.057 x II
1990 Efirth Cohort
5 8, 9 ,10,11 0.25 0.254-1=0.25 Anv—0.25 X (N+F+Ah+Al+S) 
Inv=0.25 X In; Ilv=0.25 x II
5.25 9 ,10 ,11 ,12 0.40 0.154-0.75=0.20 Anv—0.20 X (N+F+Ah+Al+S) 
Inv=0.20x In; Ilv=0.20xIl
5.5 1 0 , 1 1 , 1 2 , 
13
0.60 0.204-0.60=0.33 Anv—0.33 X (N+F+Ah+Al+S) 
Inv=0.33 XIn; Ilv=0.33 x II
5.75 11, 12,13,  
14
0.77 0.174-0.40=0.42
5
Ahv~0.425 X (N+F+Ah+Al+S) 
Inv=0.425xIn; Ilv=0.425xIl
1991 Efirth Cohort
5 4 , 5 , 6 , 7 0 . 2 0 0.204-1=0.20 Any—0.20 X (N+F+Ah+Al+S) 
W = 0.20 xIn; lLy=0.20xlL
5.25 5, 6 ,7,  8 0.60 0.404-0.80=0.50 Any^O.50 X (N+F+Ah+Al+S) 
lNy=0.50 X In; fry=0.50 x II
5.5 6 , 7, 8,9 0.75 0.154-0.40=0.37
5
Any^O.375 x (N-HF+Ah+Al+S) 
W=0.375 X In; fry=0.375 xII
5.75 7, 8 , 9 ,10 0.87 0.124-0.25=0.48 Any—0.48 x (N+F+Ah+Al+S) 
1nv~0.48 X In; Uv^O.48 x II
1992 Efirth Cohort
5 1,2,3 0.50 0.504-1=0.50 Any—0.50 X (N+F+Ah+Al+S) 
W = 0.50 xIn; lLy=0.50xlL
5.25 2 , 3 , 4 0.75 0.254-0.50=0.50 Any—0.50 x (N+F+Ah+Al+S) 
lNy=0.50 X In; fry=0.50 x II
5.5 3,4 ,5 0.80 0.054-0.25=0.20 Aiiy=0.20 X (N+F+Ah+Al+S) 
1nv~0.20xIn; lLy~0.20xlL
5.75 4, 5 ,6 0.89 0.094-0.20=0.45 Any—0.45 x (N+F+Ah+Al+S) 
lNy=0.45 X In; fry=0.45 x II
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5.2 Duration o f Carriage (v\ v, vy)
Literature Review
Only a few longitudinal studies of Hib carriage in infancy and early childhood have 
been published. Turk observed infants entering a Jamaican orphanage, many of whom 
acquired Hib following approximately 6  weeks in the institution. The interval between 
swabbing visits was variable, and many infants were placed outside the nursery before 
clearance of carriage could be documented, making it difficult to give a precise 
estimate of the duration of colonisation, although ‘no child was observed to carry a 
type b strain for more than 3 months’ (Turk 1963). Table 5.4 is taken from his 1963 
publication.
Marina Barbour followed immunised and unimmunised UK infants in the early 1990s 
over the first year of life, swabbing at 6 , 9 and 12 months of age. Hib was isolated at 
least once fi"om 1.5% of vaccinees and 6.3% of controls over this period. Those who 
had been vaccinated tended to acquire infections later, at 9 months of age, compared 
with 6  months of age in the unvaccinated group. Of 91 swabs positive for Hib in the 
study, 20 were second or third isolates fi*om the same subject. It is not clear, however, 
how many of these repeat cultures were from the infants studied, and how many were 
from a slightly older group of children who took part in a further substudy, making 
estimation of carriage duration difficult. This latter group comprised 17 known Hib 
carriers of an age eligible to participate in the government’s catch-up vaccine 
campaign, half of whom were immunised with a single dose of conjugate vaccine.
They were then swabbed weekly for 6  weeks, at the end of which time 14 remained 
carriers. It would therefore seem reasonable to assume that very few babies carried on 
more than one occasion (Barbour ML et al 1995).
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Table 5.4: The Orphan Home Nursery, August 1960 to March 1961 (from Turk 
DC 1963)
Ref
No
Age
(mo) Sex
Date
admitted
Swab Date and Result
2 9 th
Aug
31®*
Aug
2 7 th
Sep
1 2 *“
Oct
27*“
Oct
28*“
Nov
26***
Jan
2 nd
Mar
1 7 F April b b + b b b +
2 1 2 F April b + (b) (b)
3 7 M April b b b b b+ + + +
4 8 F April b b + b b+ b
5 4 F May b b b b
6 9 M June - - + b (b)
7 2 F June + + b b b+ b b
8 5 M July b b b b b b + +
9 5 F July b b + + + b + +
1 0 9 M July + + b+ + + + b+ +
1 1 4 M 8  Sept - - - b b -
1 2 3 F 9 Sept - + - b+
13 ? 1 M 12 Sept - - 4- + + +
14 4 M 14 Sept - b ? b + +
15 8 F * ? b+ b+ + +
16 ? 8 M - - + b b+
17 3 M 21 Nov - + b+
18 1 2 M 30 Nov + +
19 5 F 24 Dec . . . . + +
Legend to symbols:
no H  Influenzae grown 
+ non-capsulate strains grown
b type b grown
b+ type b and non-capsulate strains grown
(b) type b grown but child was no longer in the nursery
? cultures overgrown by Proteus spp
not present on this date 
* in the home before period of observation began, but absent during August, early
September
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While these infant studies are a source of many valuable observations, they do not 
provide sufficient information upon which to base a precise estimate of the rate of 
clearance of colonisation. An average carriage duration of 2.4 months was noted in 
toddlers in a nursery in the United States observed over one year (Murphy TV et al 
1985). Such a figure is not inconsistent with the data from the studies in young babies, 
and so for the purposes of the model this value for the time spent in the infected class 
has been assumed to be age independent.
A previous estimate of carriage duration of 5 months incorporated in a mathematical 
model of Hib infection (Coen PG et al 1998) was derived from a family study of 
children recovering from Hib disease. This work was conducted in the era before 
routine use of Rifampicin prophylaxis to eradicate colonisation in disease contacts 
(Michaels RH et al 1977). It should be noted that only children with an existing carrier 
in the family to which they were returning were followed over a year in this original 
study, meaning that the estimate most likely incorporates episodes of reacquisition in 
children too young to mount an effective immune response. In support of this notion, 
the authors of the study noted that only 2 of 15 patients discharged to homes without 
carriers remained colonised after a period of ‘several weeks’. It is thus most likely that 
the average rate of clearance of carriage is more rapid than would be estimated from 
these data.
Parameter estimation
If the average time spent in the infected compartment is assumed to be 2.4 months, the 
annual rate of clearance is 12months 4 - 2 . 4  months = 5 episodes potentially cleared per 
year.
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5.5 Duration o f specific immunity (conia), col, C0Hv(a), colv)
5.3.1 Definition of the thresholds between high, low and no measurable antibody 
compartments
Literature Review
Individuals with high ( A h , A h v ) ,  low ( A l , A l v )  or undetectable (S, Sv) levels of serum 
antibody are assumed to experience different degrees of protection against acquisition 
of Hib carriage, and progression to invasive disease. In order to be able to parameterise 
the rate of movement between compartments, threshold antibody titres defining the 
divisions between these states must be estimated.
Prior to the use of conjugate vaccines, an attempt was made to correlate observed anti 
PRP antibody titres in polysaccharide immunised and passively protected individuals 
with development of invasive disease (Robbins JB et al 1996). In addition, 
seroepidemiologic studies were correlated with the observed age dependent incidence 
of Hib in whole populations (Kayhty H et al 1983a). The short and long term 
correlates of protection of 0.15 pg/ml and 1 . 0  pg/ml respectively were proposed.
Animal data obtained in an infant rat model have demonstrated reduced replication of 
Hib at the mucosa in the presence of a serum antibody concentration of 1.0 pg/ml (van 
Alphen L et al 1996). Much higher serum Hib antibody concentrations were required 
to block acquisition altogether in this model, ranging fi*om 7-20 pg/ml (van Alphen L 
et al 1996, Kauppi-Korkeila M et al 1996). Challenge trials of this nature have not 
been conducted in humans, forcing us to look to studies where immune status is known 
before spontaneous acquisition of carriage in the community is documented.
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Phase II vaccine trials combined with carriage studies are a source of this kind of 
information. One such study, conducted in the Dominican Republic, has estimated the 
level of serum antibody required to block colonisation in children to be 5.0 pg/ml.
This figure was based on correlation of antibody titres following conjugate 
immunisation with demonstration of carriage several months later (Fernandez J et al 
2000). Larger longitudinal carriage studies of groups of vaccinated individuals suggest 
that protection against acquisition may last for longer following primary immunisation 
than such a high threshold would imply. Vaccinated English infants studied in a family 
setting over the first year of life showed an 80% reduction in Hib colonisation 
compared with their unvaccinated counterparts (Barbour ML et al 1995). The expected 
Hib antibody GMC one month following primary immunisation at a 2,3 and 4 month 
accelerated schedule in British infants administered single antigen Hib vaccine is 4.60 
pg/ml (95% confidence intervals 3.51, 6.03) (Heath PT et al 2000a). At the same 
schedule, the response to Hib combined with diphtheria, tetanus and whole cell 
pertussis is similar at 6.23 pg/ml (5.53, 7.01) (Goldblatt D et al 1998c). If an antibody 
threshold of 5.0 pg/ml is believed to correlate with protection, this would have lasted 
for no more than a matter of weeks following immunisation as titres wane rapidly 
following the primary immune response. A similarly high degree of protection (81%) 
over the first year following vaccination was noted in toddlers attending nursery in the 
United States, in an analysis which matched immunised and unimmunised children on 
the basis of known exposure to a Hib carrier (Murphy TV et al 1993).
Parameter Estimation
In the absence of an adequately established correlate of protection, arbitrary cut-offs 
have been set in order to define the boundaries between state variables in the model. A
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titre of > 1 . 0  pg/ml has been assumed to protect against acquisition, and is thus defined 
as the lower limit of antibody required for individuals to remain in the high antibody 
unvaccinated ( A h )  and high antibody vaccinated ( A h v )  compartments. Those with a 
low but measurable antibody titre, between 0.15 and 1 . 0  pg/ml, remain in the low 
antibody unvaccinated ( A l )  and vaccinated ( A l v )  compartments. Once antibodies 
wane below detectable levels, individuals move into the susceptible categories S or Sv, 
depending on immunisation status. The justification for these choices is based in part 
on the observation of 80% protection against carriage acquisition in the year following 
immunisation, as described above. The choice is also partly dictated by convenience, 
as immunogenicity studies are routinely reported in relation to these pre-defined 
thresholds, making comparison with observed seroepidemiologic and vaccine 
immunogenicity data easier.
5.3.2 Duration of natural immunitv (a)H(aT cot)
coh G)lHigh
(Ah)
Low
Ab
(Al)
S u sc
Literature Review
These parameters describe the critical interactions between exposure to Hib and 
immunity. In an ideal epidemiological world, one would have access to large datasets 
describing longitudinal observation of carriage episodes in individuals. These studies 
would additionally outline the relationship between pre-existing immunity and the 
likelihood of carriage acquisition, and the resulting effects on immunity of established 
carriage in both immunised and unimmunised individuals. Unfortunately, with the
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exception of a few limited observations, these data do not exist. One must therefore 
consider what information can be gleaned from the available literature. Trends 
observed in small studies of carriage and immunity may be extended with data derived 
from immunisation trials and population level observations of the development of 
natural immunity with age in order to make sensible estimates of the duration of 
protection associated with a specific antibody response. These may later be subjected 
to sensitivity analyses within the spectrum of uncertainty inherent within the 
framework of such limited evidenee.
Family studies conducted in households with a child recently recovered from invasive 
Hib infection have confirmed that acquisition of carriage, at least above the age of 18- 
24 months, is temporally associated with rising antibody titres in hosts, which 
subsequently fall over several months (Michaels RH et al 1977). These antibodies do 
not necessarily clear carriage. Barbour extended these observations to documented 
episodes of carriage 3-4 years following infant immunisation. Carriage was associated 
with a higher antibody response in children previously immunised witii three doses of 
conjugate vaceine in infancy [Hib GMC 65.6 (95% Cl 27.1,102.8)] compared with 
those who had not been immunised [Hib GMC 3.51 (0.2, 31.2)]. The corresponding 
density of oropharyngeal colonisation, estimated using a semi-quantitative method of 
colony counting on an antiserum agar plate, was also lower in the vaccinated group 
(Barbour ML et al 1993).
Although these two studies give useful qualitative insights into the immunobiology of 
Hib infections, their design does not allow satisfactory estimation of the magnitude of 
the age dependent specific antibody response to Hib carriage. A long established 
surrogate for natural exposure, widely used by immunologists and vaccinologists alike, 
has been measurement of seroconversion following administration of the capsular
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polysaccharide vaccine PRP. Age dependent maturation of immune responsiveness to 
the isolated polysaccharide mirrors that observed following exposure to the whole 
organism, justifying its use as a proxy marker (Robbins JB et al 1996). Studies of the 
response to a dose of PRP vaccine administered at different ages give us an estimate of 
the likely magnitude of the age specific immune response to carriage. These studies 
also provide some limited data on the rate of decline of antibody following PRP 
immunisation.
One major limitation of the use of PRP as a model of natural exposure is the absence of 
additional protein antigens in the vaccine which are present on the surfaee of the 
organism. Individuals convalescing fi*om invasive Hib infection demonstrate an 
immune response to these antigens (Johnson PDR et al 1993). Their lack of correlation 
with bactericidal activity in serum, and lack of protective efficacy in animal models of 
infection (Srikumar R et al 1992), led to their abandonment as potential vaccine 
candidates. They may, however, have some accessory role in the immune response 
which is deficient in the PRP vaceine. There is a further problem with estimating 
waning rates by comparing antibody concentrations established following 
polysaccharide immunisation with those measured in the same individuals months or 
years later. It is highly likely that the young children involved in such studies will have 
had one or more episodes of exposure to Hib through carriage of the organism in the 
intervening period. Additional stimulation of the specific immune response by 
repeated colonisation may inflate the estimated duration of immunity following a 
single measured exposure. Key features of studies of polysaccharide immunisation are 
summarised below in order to draw general conclusions about the nature of 
development of the host response to polysaccharides, with these caveats in mind.
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Helena Kayhty’s group has published two papers on the age dependent immune 
response to polysaccharide vaccination, the first studying infants and children from 3 
months to 6  years of age (Makela PH et al 1977), the second assessing vaccine 
immunogenicity in adult women with a mean age of 32 years (Makela O et al 1987). 
Results from these two sources are pooled in Table 5.5 below and represented 
graphically in Figure 5.1.
Table 5.5: Hib antibody titres 1 month post vaccination with PRP polysaccharide 
vaccine expressed as GMCs with 95% confidence intervals
Age at 
vaccination
Age in 
years
Number
per
group
Hib GMC 
(pg/ml)
Lower
95%CI
Upper
95%CI
3-5 mo 0J3 1 1 0 . 1 0 . 1 0 . 1 1
6 - 1 1  mo 0.71 40 0.25 0.17 0.37
12-17 mo 1 . 2 1 30 0 . 6 6 0.42 1.05
18-23 mo 1.71 26 3.17 1.9 5.3
24-35 mo 2.46 6 8 6.96 5J6 &25
36-47 mo 146 52 9.04 6 jG 11.98
48-71 mo 4.17 119 11.59 10.05 13.35
Adult 32TW 25 225 13.8 36.8
Figure 5.1: Post polysaccharide immunisation Hib antibody GMC by age
30 -
20  -
10 -
30
Age (yrs) at Vaccination
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Figure 5.2 below details individual observations from another study conducted by this 
group of the rate of decline in antibody titres following primary and booster 
immunisation with the polysaccharide vaccine at different ages. While no specific 
numerical data is provided in the paper to correspond with these figures, it can be seen 
that the decay curves are parallel for all observations following a documented response 
to immunisation. If there is a minimum threshold for protection, it would thus seem 
logical that older children are protected for longer against re-acquisition, not because 
antibodies wane more slowly, but because they wane from a higher peak response.
Figure 5.2: Serum antibody decay curves following immunisation with Hib 
polysaccharide at different ages (from Kayhty H et al 1984)
antFHib
pg/ml
10
5.0
to
0.5
ai
first vaccination when 
3 to 17 months old
-r— I--- 1----- 1---- 1---- 1---- 1----1-
0 1  2 3 4 5 6 7
first vaccination when 
18 to35 months old
^  Î  ^ 3 4 5 6 7
first vaccination when 
36 to 47 months old
0 i 2 3 4 5 6 T
years from the first vaccination
Fig 5. Kinetics of serum antibody responses after vaccination with one, two, or three 
doses of Haemophilus influenzae type b capsular polysaccharide (Hib) vaccine in different 
age groups. First dose was given at time 0 , and children who were then younger than 18 
months received a second dose 3 months later. A further dose was given 3*/^  years after 
the first one. Serum antibody levels were followed for 7  years in children immunized 
according to this schedule (solid triangle), and levels are compared with those in unim­
munized children (solid circle) and those in children who received their first vaccine dose 
at indicated age (solid square).
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Parameter Estimation
Given the limitations of the measured data above, an ordinary differential equation 
model was developed in Excel in order to estimate the duration of protection in 
unimmunised individuals of different ages following an episode of Hib carriage. 
Transitions between the compartments were calculated using a modified Euler 
approximation. The model is described by the following series of ordinary differential 
equations:
—  = - l(a)N 
da
dF—  = l(a )N -n ’(a)F 
da
= n’(a)F + u [Il +  In] -  ©H(a)AH
da
— ~ -  ®H(a)AH -  coiAl -  (I-s)A,(a)AL 
da
—  =  c o I A l  - X,(a)S 
da
— -  -  (I-8)X,(a)AL - n i l  
da
—— — 1(a) S — oIn 
da
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Model outputs were compared with cross sectional population observations of the 
prevalence of Hib carriage and immunity using a log likelihood method, as follows:
Observed Positive
Deviance — 2 x [  (Observed Positive x In ( Model Positive x Denominator ) ) +
(Denominator — Observed Positive) 
((Denominator — Observed Positive) x In ((1-Model Positive) x Denominator) )  ]
Deviance between observed and expected estimates was summed across age classes for 
both carriage and seroepidemiology data, and minimised by simultaneously varying the 
estimates of duration of high level immunity (couCa)) , low level immunity (©l) and the 
force of infection (1 (a)) across all four age classes while keeping all other parameters 
fixed.
Two large population based studies of Hib carriage were conducted prior to the use of 
widespread vaccination in developed countries. The first was carried out in children 
attending Health Department clinics and paediatricians’ offices in the United States 
(Michaels RH et al 1976). While it is noted that the overall incidence of invasive Hib 
disease in the United States was almost twice that observed in the United Kingdom 
(Peltola H 2000), this study was unrivalled in its scope, sampling 1,110 healthy 
children ranging in age fi*om birth to 16 years. Michaels and Norden optimised 
specimen transport and plating techniques for the purposes of this study, and noted that 
‘approximately two-thirds of the carriers were colonized at an intensity too low to be 
detected by standard laboratory techniques’. The only similar UK based study was 
conducted in Wales in the late 1980s, but studied children only up to 72 months of age,
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and employed less sensitive microbiological techniques (Howard AJ et al 1988). The 
population sample included child welfare clinics and primary school reception classes. 
These studies were discussed in Section 1.5 of Chapter 1, and their findings illustrated 
in Figure 1.1a) and 1.1b). For the purpose of model parameterisation, the larger dataset 
was used, bearing in mind the limitations of its source in another population.
Previous authors (Coen PG et al 1998) have utilised pooled data fi-om many carriage 
studies spanning a range of countries in order to parameterise models of Hib infection. 
The difficulty in pooling such observations is firstly the range of microbiological 
methods used, which are recognised to have very different sensitivities as outlined 
above. In addition, the population fi*om which samples are taken is of the utmost 
importance. In institutionally based studies in day care nurseries and schools, known 
carriers are likely to be in close contact with other susceptibles, leading to clusters of 
infected children in the sample. Comparison of such carriage estimates over time may 
be most informative, but may overestimate the true prevalence of colonisation in the 
general public. Similarly, misinterpretation of family based data can lead to similar 
errors.
The seroepidemiology data used to parameterise the model were taken fi-om a study of 
changing UK population immunity to Hib over time conducted by the HPA (Trotter CL 
et al 2003b), discussed in detail earlier in Section 2.6.2. Data fiom 1990/1991 were 
collected before the introduction of Hib vaccination in the UK and are shown in Figure
5.3. 95% confidence intervals of estimates of the proportion of the population without 
protective antibody levels by age are represented by error bars. These are shown in 
relation to the two antibody thresholds used in the model of 1 . 0  pg/ml and 0.15 pg/ml.
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Figure 5.3: Age distribution of prevalence of Hib antibody titres, United 
Kingdom, 1990/1991 (from Trotter CL et al 2003b)
a) < 1 . 0  pg/ml b) <0.15 pg/ml
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Optimal model fit to the observed data is shown below in Figures 5.4 (carriage) and 5.5 
(seroepidemiology). Of particular interest is the higher than observed carriage rate 
required to explain population immunity under two years of age. Some or all of the 
exposures resulting in antibody formation at this age may be to cross reactive antigens 
and not Hib itself, which may in part explain the discrepancy.
Figure 5.4: Model fit to population carriage data (95% Cl refer to observed 
dataset)
0.25 0.25n n  Proportion Gamers
Proportion Infected (Model)
t  0.15 0.15
0.05 0.05
2 y r 5-8 yr 9-12 yr 13-16 yr1 yr 4 yr
Age C ategory
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Figure 5.5: Model fît to population seroprevalence data (95% CI refer to observed 
dataset)
(i) Hib antibody titres <1.0 pg/ml (ii) Hib antibody titres <0.15 pg/ml
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Distribution of individuals between compartments at equilibrium according to this 
fitted model is shown below in Figure 5.6.
Figure 5.6: Proportional age distribution of the population at equilibrium in the 
Excel model
a  0.6
m m thsr
Age (yrs)
■ AH(a)
□ ln(a)
■ IL(a)
□ F(a)
□ S(a)
B AL(a)
□ N(a)
153
The calculated parameter values for coH(a) derived from this model were as follows:
Table 5.6: Duration of naturally acquired specific immunity against Hib
Age Parameter
Estimated
Mean Value Mean Time to 
Waning
0.5-1.99 years O h i 6.59 0.15 years
2-4.99 years C0H2 0.68 1.46 years
5-10.99 years CÛH3 0.47 2.13 years
11-20.5 years ( » H 4 0.49 2.05 years
All ages COl 0.09 1 1 . 0  years
5.3.3 Duration of immunitv following conjugate vaccination (co^(a), corv)
S u sc
V acc’d
(Sv)
High Ab 
V acc’d 
(A h v )
Low Ab 
V acc’d 
(A lv )
Literature Review
Estimation of the magnitude of the response to conjugate vaccines in children of 
different ages is readily available in the published literature. These address 
immunisation using a range of different conjugate vaccine formulations and schedules. 
Data are also available detailing the waning of the specific antibody response following 
immunisation at different ages.
Studies of the immunogenicity of the conjugate vaccines used in the UK, administered 
according to the routine infant immunisation and catch-up schedules, are summarised 
in Table 5.7 below. Data are also included from one Finnish study which compared the
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antibody responses of adult women to Hib polysaccharide and an early diphtheria 
toxoid based Hib conjugate vaccine (PRP-D). Results in this last study are shown from 
14 days post immunisation. In the original paper, individual titres were reported for 5 
subjects at both 14 and 28 days, the latter values were equivalent or only slightly lower 
than those measured at the earlier timepoint.
Table 5.7: Age dependent immunogenicity of Hib conjugate vaccines
Study Vaccine and 
Schedule
Age at 
Immunisation
Time From 
Immunisation
Hib GMC 
pg/ml
Heath PT 2000 Separate PRP-T 2,3,4 months 1 month 4.60
Goldblatt 1998 DTwP-PRP-T 2,3,4 months 1 month 6.23
Rothstein 1991 HbOC 7-11 months 2  months 3.84
Rothstein 1991 HbOC 12-15 months 2  months 8.31
Madore 1990b HbOC 15-23 months 1 month 13.77
Makela 1987 PRP-D 32 years 14 days 44.54
A difficulty in estimating the anticipated response to immunisation from these data is 
the fact that antibody titres are reported 2 months following immunisation in 7-15 
month olds. In order to estimate what they might have been one month after the 
vaccine, we must calculate the anticipated rate of antibody decline following conjugate 
vaccination and work backwards. The following data are from Madore’s study of 
infants given three doses of conjugate vaccine, starting at 1-2 months, 3-4 months, and 
5-6 months, respectively. They were then followed until 24 months of age and serum 
measured at intervals as follows (Madore D et al 1990a):
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Table 5.8: Hib Antibody persistence following conjugate immunisation
Study
Group
No Average 
age at 
serum 
collection
Average time 
since 
primary 
course
Group 1 
Hib GMC 
(pg/ml)
Group 2 
Hib GMC 
(pg/ml)
Group 3 
Hib GMC 
(pg/ml)
1 163 6.5 mos 1 month 16.84
2 193 8.5 mos 1 month 26.23
3 49 10.5 mos 1 month 29.11
1 8 8 11.5 mos 6  months 7.41
2 188 13.5 mos 6  months 7.53
3 46 15.5 mos 6  months 13.37
1 65 24 mos 14.5 months 3.2
2 131 24 mos 16.5 months 3.28
3 37 24 mos 18.5 months 6.25
Figure 5.7: Antibody titres by time from immunisation, with regression line
o Group 1
a  Group 3
Group 2 
- Model Fit
20 -
E
3
Time (years) since vaccination
The equation describing the line of best fit for the regression model is:
In (Hib GMC) = In (post vaccination Hib GMC) -  1 . 3  x time (yrs) since 
vaccination
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Taking this rate of decline into account, antibody titres 1 month following 
immunization at 7-11 months, and 12-15 months, would be anticipated to have been 
4.28 and 9.26 pg/ml, respectively. Figure 5.8 graphs the observed data on antibody 
response to conjugate vaccines by age, with superimposed estimates of the peak 
concentration following exposure to be used in the model for the four age groups 
defined. In contrast to the slower development of responsiveness to polysaccharides, 
observed titres following administration of conjugate vaccine rise rapidly over the first 
two years of life. For this reason, divisions between age classes used to reflect 
maturation of the immune response differ from those previously used; 0.5-0.99 yrs (5.0 
pg/ml), 1-1.49 yrs (10.0 pg/ml), 1.5-1.99 yrs (15.0 pg/ml) and 2 years and over (25.0 
p,g/ml). Vertical bars define the age categories distinguished in the model.
Figure 5.8: Post conjugate immunisation Hib antibody GMC by age
- Hib GMC (mcg/ml) A Model Hib GMC (mcg/ml)
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Parameter estimation
Once again, in order to determine the duration of high antibody protection following 
immunization at different ages, information on the peak response achieved is combined 
with knowledge of the post conjugate immunization waning rate in order to derive the 
time taken to achieve the threshold titre of 1.0 pg/ml. The derived parameter values 
are shown in Table 5.9 and Figure 5.9.
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Table 5.9: Age dependent waning rates following Hib conjugate vaccination
Age Post Exposure 
Hib GMC 
pg/ml
Time to wane 
to 1 . 0  pg/ml
Parameter
estimated
Waning
rate
0.5-1 years 5.0 1.23 years ® H V 1 0.81
1-1.5 years 1 0 . 0 1.77 years W h V2 0.56
1.5-2 years 15.0 2.08 years C0h v 3 0.48
2 - 2 0  years 25.0 2.48 years C0h V 4 0.40
Figure 5.9: Age dependent waning following Hib conjugate immunisation
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Calculating the rate of decline from 1.0 to 0.15 fig/ml necessitates only one further 
calculation, resulting in an estimated time to waning of 1.46 years, with a parameter 
value for colv of 0.69.
158
5.3.4 Duration of immunitv following re-exposure to Hib in vaccinated individuals
cob
High Ab 
vacc’d 
(A h v )
Boosted
V acc’d
(Bv)
Literature Review
Response to a booster dose of conjugate vaceine has been assessed at 12 months of age 
following DTwP-PRP-T given according to the British accelerated schedule (Goldblatt 
D et al 1998d). In this study, the Hib GMC was 108.39 pg/ml (95% Cl 91.62, 128.23). 
In Canada, the boost response to PRP-T in children 4-5 years of age primed with the 
same vaccine at 2, 4, 6  and 18 months was assessed, and the GMC was found to be 102 
pg/ml (79.9, 129) (Scheifele DW et al 1999). Ten years following receipt of four doses 
of PRP-D between 3 and 18 months, a cohort of Finnish children showed persistent 
memory responses to a dose of PRP, achieving a GMC of 107.7 pg/ml (88.2, 131.4) 
compared with 28.6 (23.3, 35.0) in those not primed in infancy (Makela PH et al 2003).
Justification for using these estimates as a surrogate of natural exposure comes from 
Barbour’s observation of higher antibody titres in association with Hib carriage in pre­
school aged children vaccinated in infancy, compared with those who had not been 
vaccinated (Barbour ML et al 1993). Five children who had been vaccinated in infancy 
were identified as carriers -  their median Hib antibody concentration was 65.6 pg/ml 
(interquartile range: 27.1, 102.8). In contrast, the three carriers who had not been 
previously immunised had a median titre of 3.51 pg/ml (0.2, 31.2).
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Parameter Estimation
In order to calculate the time spent in the ‘boosted’ immunity category (By) several 
pieces of data must be combined. Let us assume that the peak boost response is 100 
pg/ml, and is independent of age. The rate of decline of antibody in conjugate vaccine 
immunised individuals has already been calculated above. In addition, peak post 
immunisation antibody titres have been assigned to each of the four age classes. Time 
in the boosted category is therefore age dependent, being the time taken to wane from 
100 pg/ml to 5, 10, 15 or 25 pg/ml, depending upon the age at boosting. Final 
parameter values based on these data are shown in Table 5.10 and represented in Figure 
5.10.
Table 5.10: Age dependent waning rates following boosting of Hib immunity 
through natural exposure -  time to wane into high antibody vaccinated ( A h v )  
category
Age Post Primary Hib 
GMC pg/ml at 
this age
Time to wane 
from 1 0 0 . 0  
pg/ml
Parameter
estimated
Waning
rate
0.5-1 years 5.0 2.30 years O bi 0.43
1-1.5 years 1 0 . 0 1.77 years O b2 0.56
1.5-2 years 15.0 1.46 years O b3 0.69
2 - 2 0  years 25.0 1.07 years O b4 0.94
Figure 5.10: Age dependent waning following re-exposure to Hib in vaccinated 
children
- Boost Group 1
- Boost Group 3
I
Median Age (years)
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5.4 Relative protection against acquisition from low antibody state, G
Studies relating Hib antibody titres to protection against acquisition of colonisation are 
described in Section 5.3 a) above. In the initial parameterisation of the model, it was 
assumed that no protection against carriage was provided by serum antibody 
concentrations <1.0 pg/ml. For this reason, protection against infection in the low 
antibody state (0) was set to 0. It was incorporated within the model in order to allow 
later sensitivity analysis to test this assumption.
5.5 Force o f infection, X(a)
The age dependent force of infection was calculated using the same ordinary 
differential equation model used to estimate duration of natural immunity, in section
5.3 a). Calculated estimates of these parameter values are shown in Table 5.11.
Table 5.11: Parameter estimates for the age dependent force of infection
Age Parameter
Estimated
Mean Value
0.5-1.99 years 0.45
2-4.99 years ^ 2 0 . 2 2
5-10.99 years ^3 0.40
11-20.5 years X.4 0.55
161
5.6 Calculation o f invasive disease incidence
Literature Review
While the model predicts that 60% of British children would have been exposed to Hib 
by the age of 5 years (Figure 5.6), only 30 per 100,000 children in this age group 
experienced invasive Hib infection every year before vaccine introduction (Anderson 
EC et al 1995). As such, invasive disease episodes made only a very small 
contribution to the total force of infection in the population. Further, due to the ready 
availability of effective therapy, the case fatality rate for Hib infections in Britain was 
less than 5% prior to vaccine introduction (Anderson EC et al 1995) and has remained 
stable (Heath PT et al 2000b) meaning that this infection has a negligible impact on 
total population size. For these reasons, invasive disease has been calculated as a 
quasi-steady state approximation of the number of colonised individuals in the 
population at any point in time.
The instantaneous incidence of Hib disease was determined by the balance between 
risk of progression to bacterial invasion, and rate of recovery from the illness. With an 
average antibiotic treatment course lasting five days, the duration of invasive disease 
was estimated at one week. The risk of developing disease during each episode of 
carriage is more complicated to ascertain. Figure 1.2 shows the exquisitely age 
dependent distribution of Hib disease incidence, with the vast majority of episodes 
occurring within the first 1 2  months of life when the prevalence of colonisation is 
relatively rare, declining rapidly thereafter.
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At a population level, these trends have been explained in terms of the prevalence of 
antibody to the Hib capsular polysaccharide PRP. Maternal antibody provides some 
passive protection against infections for the first few months of life. After this is lost, 
Hib incidence rises, with falling rates from the second year of life onwards correlating 
with the development of natural immunity through exposure to Hib or cross reactive 
organisms (Fothergill LD et al 1933) (Anderson P et al 1977a) (Kayhty H et al 1983a) 
(Figure 1.3 a), b), c)). A rhesus monkey model of invasive Hib infection has confirmed 
the increased susceptibility of very young animals to meningitis following established 
bacteraemia, due to reduced efficiency of reticuloendothelial clearance of organisms in 
the bloodstream (Smith AL 1987). Monkeys older than 2 months of age are able to 
contain bacteraemia so that equilibrium is maintained over several days. Those less 
than two months are vulnerable to rapid invasion of the cerebrospinal fluid, due to 
uncontrolled bacterial growth in the blood.
The age cohort model provided a framework within which to consider questions 
regarding this age dependent susceptibility to infection:
a. Can the age distribution of infections be solely explained by the higher 
prevalence of measurable Hib antibody, providing protection against bacterial invasion, 
in older age groups?
b. What is the protective efficacy of immunologic memory once antibody wanes? 
Should a history of past exposure alone prove insufficient to explain the age 
distribution of infection:
c. Are there factors other than the absence of antibody which place young infants 
at additional risk of serious bacterial infection, thus requiring an age dependent 
parameter to describe progression to invasive disease?
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Parameter Estimation
The quasi steady state approximations were defined according to the following series 
of equations, which describe the risk of invasive disease for each of the infected states 
described in the model. The average duration of infection (1/v) is one week, so the rate 
of recovery per year v = 52. Progression to invasive disease occurs at a rate ô, which is 
here denoted as age dependent, a feature to be explored in the sensitivity analysis. The 
efficacy of detectable antibody at preventing progression to bacterial invasion at the 
point of exposure to Hib is designated 9, and protection due to memory after antibody 
has waned is denoted p, where 0<  p <  9 < 1. No additional protection of antibody 
induced by vaccination as compared with natural exposure was assumed.
dt
= 0{d)F{ad)-cDp{a,t) DF(a,t) =
<7
— ^  = ( 1  -  0)0{a)Ip (a, t) -  oDj^ (a, t) DiL(a, t) = P
dt (T
— ^  = i i - p)ô{a)If^{ad)-oDj^{a,t) Dm(a,t) = 
dt a
dD
dt
-  ( 1  -  0)0{a)Ipy (a, t) -  DjLv(a, t)
i i - 6 ) y . ô { d ) x f y { a d )
dD
dt
ju)S{a)Ij^y{a,t)-oDj^^ DiNv(a,t)^
i l - j u ) S ( a ) I ^ y { a , t )
or
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The case per carrier ratio was calculated in Excel, based on weekly model outputs of 
infection prevalence, by age and type, prior to introduction of vaccination. This was 
compared against the observed pre vaccine case incidence in England and Wales by 
age from the combined HPA HRU/CDSC dataset. Deviance between these two sets of 
values was minimized using a log-likelihood method by simultaneously solving for 
optimal values of ô(a), 6  and p. Parameter values were initially calculated using the 
base case assumption that the protection afforded by low levels of antibody against 
acquisition (s) was equal to 0. A result of this critical assumption was that the model 
could not be solved for values of 0 and p which were greater than 0. Estimates for the 
age specific progression to invasive disease, ô(a), are shown in Table 5.12.
Table 5.12: Age dependent rates of progression to invasive disease, 8(a)
Age Parameter
Estimated
Average Rate of 
Progression to 
Invasive Disease
0.5-0.99 years Ô1 0.0127
1-1.99 years Ô 2 0.0042
2-2.99 years Ô 3 0.0037
3-3.99 years Ô 4 0.0030
4-4.99 years 6 5 0.0016
5-20.5 years Ô 6 0.00006
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5.7 Transmission coefficient, p
Initial conditions for the model were calculated using the age dependent forces of 
infection derived above. The force of infection was fiirther defined as follows, where 
C(a,a’)  determines the influence of infectious people of age class a ’m  contributing to 
new infections in age class a and P(a) denotes the age dependent susceptibility to 
acquisition of individuals in age class a.
X(a,t)= 0.5? '^  ^C(a,a’)P(a)[F(a',t)da’+lL(a\t)da’+lN(a’,t)da’+lLv(ci\t)da’+lNv(a\t)cia’J
This may be simplified to
X(a,i) = C(a,a ') p(a) [Y(a ’.pda ’]
where Y(a ’,t)da ’ = [F(a ’, t)da '+h(a ’,t)da '+1n (ci \ t)da '+Ilv(ci \  t)da ’+Inv(o. t)da ]
This effective contact parameter Cp is a two dimensional step function that can be 
represented by a matrix of constants, shown below. Values of P(a) were calculated 
according to the method of Anderson and May (Anderson RM et al 1985) using the 
equilibrium distribution of the number of infections by age, to comprise the elements of 
a ‘Who Acquires Infection From Whom’ (WAIFW) matrix under a number of different 
assumptions of the relative values of C(a,a ’). The WAIFW matrix was then used to 
calculate the force of infection X at all subsequent time steps based on the number of 
carriers by age at each preceding time step.
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A C b A c « A r ,
A C 2 2 A C 23A 2 Y2
A Q i A Q 3 A 3 Q 4 A 3 }^ 3
A . _ Q i A C 44A 4 . /4
The rate at which individuals of one age class transmit infections to others cannot be 
directly observed in populations. Components of social behaviour between potential 
hosts which contribute to this likelihood can, however, be used to infer a range of 
plausible contact matrices based on pre-vaccination data. These may be subjected to a 
sensitivity analysis. The contact matrix may thus be described:
C n C .Z C n C .4
Q , ^ 22 C23 C24
C 3 . C32 C33 C34
C 4 . C42 C43 C 44
For infants and young children, the likelihood of contact with an older sibling in the 
home environment can be inferred from national data collected on household size and 
birth intervals twww.statistics.sov.uk/statbase a, b) (Figure 5.11). These data show 
that just over half of all children in households have contact with an older sibling who 
is on average three years older. Approximately one in eight will be exposed to a 
further sibling, an average of six years older. Prior to the use of widespread 
vaccination, the presence of an older sibling in the household was a recognised risk 
factor for invasive Hib infection, suggesting that the older child acted as a source host 
(Ounsted C 1950,1951) (Cochi SL et al 1986).
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Figure 5.11: Household size and birth interval
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Patterns of mixing outside the home have been changing over the past ten years. The 
number of children under the age of eight cared for by nurseries and professional 
childminders in England, Wales and Northern Ireland has risen from 400,000 in 1992 
to 631,000 in 1999 -  the equivalent of an annual birth cohort for the region 
(WWW.statistics. gov.uk/statbase c). The social exuberance of toddlers, combined with 
their liberal sharing of nasal secretions, particularly facilitates transmission of 
nasopharyngeal commensals in day care (Murphy TV et al 1985). Increased relative 
risk of Hib disease in unvaccinated American day care attendees in the 1980s ranged 
from 12.3 (95% Cl 4.8, 31.1) for children less than 1 year of age to 3.8 (0.9, 15.7) in 2- 
3 year olds (Redmond SR et al 1984). Over the age of five, mixing with large numbers 
of peers within age classes occurs in a structured and more consistent way due to 
compulsory school education, although contact is not likely to be as close. The 
framework illustrated in Figure 5.12 was used for considerations of the likely 
proportionate contribution of mixing between different age groups to acquisition of 
infections:
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Figure 5.12: Mixing assumptions to be explored in the contact matrix
Age Group 0-2 yrs 2-5 yrs 5-11 yrs 11-20 yrs
0-2 yrs
Limited
unless
Nursery
Close
Sibling
Mixing
Limited
Sibling
Mixing
Negligible
Contact
2-5 yrs
Close
Sibling
Mixing
Nursery Play 
Group
Moderate
Sibling
Mixing
Negligible
Contact
5-11 yrs
Limited
Sibling
Mixing
Moderate
Sibling
Mixing
Primary
School
Distant
Sibling
Mixing
11-20 yrs NegligibleContact
Negligible
Contact
Distant
Sibling
Mixing
Secondary
School
University
Under an assumption of uniform mixing in the population, the contact matrix would 
look as follows:
1 1 1 r  
1 1 1 1  
1 1 1 1  
1 1 1 1
The most extreme assortative mixing assumption would be:
1 0 0 0
0 1 0 0
0 0 1 0
0 0 0 1
A range of matrices were explored in the sensitivity analysis, with a typical
configuration based on the assumptions in the table above being:
1 100 1 0
100 100 10 0
1 10 100 1
0 0 1 100
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5.8 Numerical Techniques
The method of characteristics was used to find numerical solutions to the partial 
differential equations (PDEs) described in Section 4.1. These were reduced to a series 
of ordinary differential equations (ODEs) along the characteristic lines t = a + 
constant, within eighty sequential three-month age cohorts. The equations were solved 
by fourth order Runge-Kutta integration using Model Maker Version 4 software 
(Cherwell Scientific, UK) with a step length of one week. The time step was chosen to 
reflect the speed with which transitions were occurring in the model. This provided 
suitable precision as no change in either the dynamics or the distribution of individuals 
in the population at equilibrium was noted with further reduction of the time interval. 
As the PDEs were a series of integro-differential equations, the force of infection for 
each age category was integrated and updated at each time step.
A schematic representation of the model over one year is shown in Figure 5.13, 
illustrating births into the model every three months. As aging occurred weekly, there 
were potentially thirteen birth cohorts in any given three month time period, but the 
figure illustrates the progression of just one such birth cohort. Outputs were recorded 
every three months, so that each cohort was viewed at only one age for comparison 
over time. Cohorts exited from the model and were lost to consideration after the age 
of 20.5 years.
The benefit of this method was the ability to use an established software package to 
perform the numerical integrations, without the need to write new code. The software 
was, however, quite cumbersome, and the package rather inflexible, making any 
changes to the model time consuming.
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5.9 Code Testing
Numerical accuracy of the age structured model was tested at a number of stages of 
development by different means.
Aging
In the first instance, the simulation of the unvaccinated population was tested by 
introducing a single naïve birth cohort at time 0, and charting its progress through the 
model compartments over time until age 20.5 years. All age groups were summed 
across compartments at each time point in order to ensure consistency of population 
size. Outputs were visually checked to ensure that the cohort moved on to the next age 
category at the appropriate time. Secondly, the model was run with a series of birth 
cohorts introduced three monthly with p, q and z set at 0, until the total population size 
achieved was 500,000 and all compartments were at equilibrium. The distribution of 
the population by age at a single time point at equilibrium was compared with that 
observed in the Excel spreadsheet model described earlier, which was used to 
parameterise the force of infection.
Calculation o f transmission coefficient, P
The number of infections by age group at equilibrium before introduction of 
vaccination was derived by running the model using the values calculated for the age 
specific force of infection, X(a). Numerical values for the effective transmission 
coefficients, C,yy^  were then calculated using the matrices described in section 7 above. 
Initial values of all compartments for models using p were imported from the 
equilibrium distribution observed in the preceding X model for that given parameter set. 
Each p model was allowed to run for a period of at least five years before
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immunisation was imposed. In this way, it was possible to check that the number of 
infected individuals remained constant over this period (ie X remained constant) and 
that no numerical error had been introduced in the analytic calculation of p.
Introduction o f vaccination
In order to ensure that no errors had been introduced in the model describing the 
vaccinated population, each new version of the model was checked in an Excel 
spreadsheet. Outputs from all 13 compartments were summed within each age 
category at each time point. These were visually checked to ensure that all were equal 
to the birth cohort size of 6,250. They were further summed across age categories for 
each time point in order to ensure that the total population size remained 500,000.
173
Chapter 6: Predicted Time Series Under Different Model Assumptions
6.0 Introduction
The model was designed to allow exploration of key theories about vaccine protection and 
subsequent effects on Hib transmission and immunity in the population. For this reason, we 
were more interested in investigating the structural sensitivity of the model than in conducting 
a formal sensitivity analysis using randomly sampled parameter values, as in risk analysis 
models (Vose D 1996).
Our aim was to recapitulate the observed time series for all four population measures for 
which UK data was available: prevalence of high and low serum antibody levels, carriage 
prevalence and invasive disease incidence. In exploring the behaviour of the system under 
vaccination, the most difficult thing to achieve was a late recurrence of disease in children 
under five years of age following an initial period of effective control, shown in the population 
data represented in Figure 6.0.
Figure 6.0: Invasive Hib disease reports by age group, England and Wales 1991-2002
50 1 —  0.5 -1 .99  yrs
—  2-4 .99  yrs 
5-10 .99  yrs
—  11-19 .99  yrs
4 5  -
4 0  -
35  -
Î3 3 0 -  
^  25*5
I120- 
15 -
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6.1 Effects of vaccine scheduling and immunogenicity
A number of aspects of Hib vaccine introduction and use in the UK have been unique in 
comparison with other developed countries. In order to understand the reasons why the UK 
has observed an increase in disease not experienced in those countries, the effects of the initial 
catch-up immunisation campaign and the recent switch to less immunogenic DTaP-Hib 
combination vaccines needed to be explored. The model was run using the parameter set 
summarised in Table 5.0 of Chapter 5 and immunisation was introduced at time t=5 years, 
corresponding to the calendar year 1993 when comparing outputs with observed data. An 
initial assumption was made of uniform mixing between all age classes (Section 5.7). 
Additional complexities were added during sequential simulations as follows:
a) Introduction of immunisation without a catch-up campaign
b) Introduction of immunisation with a catch-up campaign, staggered at quarterly intervals 
over the first year of vaccine introduction, using the coverage figures fi*om the South East 
Thames region shown in Table 5.3 of Chapter 5.
c) Introduction of immunisation with a catch-up campaign as in part b), and with the 
additional influence of use of a poorly immunogenic vaccine in years 12 and 13 
(corresponding to 2000/2001), administered to one third of the immunised population. Values 
calculated for p, q and z during these years are shown in section 5.1.1 of Chapter 5.
Figure 6.1 shows the total number of infections in each age class under each of these three 
conditions. It can be seen that catch-up immunisation produces a more precipitous fall in the 
number of infections immediately following vaccine introduction, but a large rebound occurs
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predominantly within the older age groups in only a few years. The use of a poorly 
immunogenic vaccine seven years later results in a second peak of infections which affects all 
age classes. Both of these factors, then, may be expected to have a profound effect on the 
epidemiology of Hib in the UK population, justifying the necessity of their inclusion in the 
model.
Figure 6.1: Effects of vaccine scheduling and immunogenicity on total number of 
infections in the population, by age class and time (Vaccine introduction: t=5 years)
a) Without catch-up immunisation
□ 11-20.5 yrs
0 5-10.99 yrs
□ 2-4.99 yrs
0.5-1.99 yrs
Time (years)
b) With catch-up immunisation
25000 -,
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c) With catch-up immunisation and use of poorly immunogenic vaccine in years 
t=12 and t=13 (corresponding to 2000/2001)
=  15000
□  11-20.5 yrs
□  5-10.99 yrs 
D 2-4.99 yrs 
■  0 .5-1.99 yrs
In attempting to understand how this bimodal peak in total infections may relate to observed 
trends in Hib disease in the UK, one must bear in mind changes in the proportion of children 
under five years of age with protective antibody levels between 1994 and 2000 (Section 2.6.2) 
(Trotter CL et al 2003b). Three years following the introduction of immunization, toddlers 
demonstrated very high levels of specific antibody against Hib as a result of the catch-up 
immunization campaign. We postulate that this immunity was sufficient to protect them 
against disease, even in the face of an increase in circulation of the organism among their 
older siblings five years after vaccine introduction. A second rise in infections coincided with 
a period when poorly immunogenic vaccines were being used, and was probably additionally 
fuelled by the increase in the size of the pool of susceptible infants. As the risk of bacterial 
invasion is exquisitely dependent on both age and antibody status at the point of exposure to 
the pathogen (Section 5.6 of Chapter 5), any reduction in immunity in the population under 5 
years may be expected to have a marked effect on the number of Hib disease cases for a given 
background level of carriage.
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6.2 Esîmation o f the interepidemic interval o f the SIRS system 
An alternative explanation would be that the dynamics of the model as configured are 
incorrect, and that the first peak of infections appears too early. A simple SIRS ordinary 
differential equation model was developed in order to explore this possibility further, by 
enabling analytic calculation of the anticipated interepidemic interval following perturbations 
of the system. It is described by the following series of equations where S, I and R refer to the 
susceptible, infected and resistant states respectively and total population size N=S+I+R.
— =(1-p)B-(X+h)S + (bR 
dt
— = lS -(u+ p)I
“  = nl -  (m+p)R 
dt
In this simple model, births (B) balance deaths (pN) resulting in a constant population size (N) 
of 500,000. Initial conditions are defined for an unvaccinated population where the proportion 
vaccinated, p=0. All individuals under this condition are bom into a susceptible class (S) firom 
which they acquire infections at a rate dependent on the force of infection, X. The average 
duration of infection is equivalent to the reciprocal of the recovery rate, 1/u. Following 
recovery, a period of resistance to reinfection (R) results, with immunity waning at a rate © to 
return individuals to the fully susceptible state. The duration of protective immunity was an 
average of 1/© across all four age classes m the age structured model, calculated in Section
5.3. This model described above was run to equilibrium and a value for the transmission 
coefficient, p, calculated where X = pi. The force of infection was integrated and updated at 
each time step. The initial parameter set used in the model is shown in Table 6.0.
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Table 6.0: Base Case Parameters in the SIRS Model
Model Parameter Mean Value Mean Duration in Class
Birth rate, B 10,000 per year
Death rate, p 0.02 per year 50 years
Force of infection, X 0.4
Rate of recovery from infection, u 5 2.4 months
Rate of waning of immunity, © 0.5 2 years
At equilibrium using the baseline parameter set, the proportion of the population that was 
infected was 4.3%, and the proportion resistant 41.5%. Both of these values were compatible 
with the UK data from 1990/1991 on which the age structured model was parameterized. The 
model was then run using a range of values for X and © in order to study the effects of 
changing these parameters on the equilibrium distribution of individuals in the population, and 
to allow calculation of p. The duration of carriage, u, was fixed at 2.4 months. The system 
was perturbed by moving 20% of the susceptible class to the resistant class at a single time 
point, and the behaviour of the system observed under each of these conditions. A series of 
perturbations from 10% to 40% were explored, with similar outcomes.
Numerical outputs of the models and perturbations are represented below. Figure 6.2 shows 
changes in the proportion of the population who are resistant, for a range of values of 1 and ©. 
The horizontal line indicates the observed value of approximately 40%. Figure 6.3 shows the 
corresponding prevalence of infections, in relation to a line denoting the observed 4%. The 
time to first rebound of infections, following the initial decline induced by a 20% perturbation, 
is shown under the same assumptions (Figure 6.4).
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Figure 6.2: Proportion of the population who are resistant
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Figure 6.3: Proportion of the population who are infected
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Figure 6.4: Time to first rebound of infections following 20% perturbation
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As can be seen from Figure 6.4, the critical parameter here determining the time to rebound of 
infections was the pre-perturbation force of infection. For a force of infection of 0.2 or 
greater, the interepidemic interval was five years or less. Even for the lowest force of 
infection studied (1=0.1) the longest time period to initial peak rebound of infections was 8 
years, given the fixed assumption of duration of carriage of 2.4 months. From Figures 6.2 and
6.3, it can be seen that a force of infection this low would be inconsistent with the observed 
distribution of resistant and infected individuals in the population at baseline. Analytic 
solutions were sought to describe the properties of this system further.
6.2.1 The damped harmonic oscillator
If we assume that the death rate, p, is 0 until a given age and infinite thereafter, the model can 
be simplified as follows to exclude consideration of births and deaths:
5 = - l S  + ©R (1)
/  = lS - n I  (2)
R = ul -  ©R (3)
This series of three equations was then reduced to two, based on the knowledge that total 
population size, N = S + 1 + R, therefore:
I = N - S - R  (4)
(4) into (3): R = uN -nS - uR -  ©R
R = K  -uS -  (n + ©) R (5) where K = uN
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Based on equations (1) and (5), the system could be described in the form of a second order 
linear ODE, derived as follows. From equation (1):
®R = 5 + IS
R = -  (S+XS) (6)
CO
(6) into (5): R = K -n S  -  * (t) + to) (S + XS) (7)
CO
Also from equation (1):
S = - R - -  S 
A
Differentiating this equation, we obtain:
S = - k -  - S  (8)
Z À
Rearranging this:
^  1
R = -  S + - S (9)
CO CO
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Thus RHS (7) = RHS (9):
-  S' + - 5 = K - u S - -  (u + (o)(S +XS)
CO (O CO
S + (1+v+ro) S + (lv+l©+©v)S — ®K = 0 (10)
This second order linear ODE takes the general form (Jordan DW et al 1999):
The discriminant of this equation, A = k^  — 4c, describes the oscillatory behaviour of the 
system. If A>0 (overdamped) or A=0 (critically damped), the magnitude of oscillations will 
decrease exponentially. If A<0, the system is described as a damped oscillator. For negative 
values of A, the oscillatory frequency can be estimated as follows:
(—A)^ ^^Oscillatory frequency = --------
Att
A was calculated, given estimates o f l  ranging from 0.1 to 0.5 and of © ranging from 0.05 to 
2.5. The duration of infection remained fixed at 2.4 months. All values for the discriminant 
within the parameter space explored for the model above were >0. As such, the system was 
characterised as overdamped, enabling us to predict that transient behaviour induced by 
perturbations would settle relatively quickly to a new stable equilibrium without an extended 
period of oscillations. While of use in describing the characteristics of the system, this method 
did not allow us to derive an analytic solution for the interepidemic period.
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6.2.2 Analytic solution for the interepidemic interval
Analytic results for the dynamics of epidemic and endemic oscillations in models of infection 
and immunity are discussed in Appendix C of Anderson and May’s textbook (Anderson RM et 
al 1990). In particular, the properties of models in which immunity is not life-long are 
considered. The resulting ‘steady input of fresh infectives.. .undercuts the propensity to 
oscillate’, as has been seen from the demonstration of overdamping in Section 6.2.1 above. 
Their approach is taken to our original equations for the SIRS system;
dS
dt
= (l-p)B -  (l-l-p)S + ©R (1)
dL
dt
= X,S -  (n+p)I (2)
dt
= nl -  (©+p)R (3)
Where R = N - S - I (4)
(4) into (1): dS
dt
= pN -  (l+p)S + ©(N-S-I) (5)
where: (6)
(6) into (5): ~  = (p+ © )N -  (l-t-p4- ©)S -
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If we consider the proportion susceptible, s:
^  = (p+ ®) -  (X+P+ ®)s- (7)
dt pN
Where: Ro = - (8)(v + p)
(8) into (7): — = p+ © -  Is -  ps -  ©s
Similarly,
dt Ro{v + p)
^  = p -(p + l)s  + © (1 - s - — -)  (9)
dt Ro(v + p)
— = lS -(n+ p)I (2)
dt
(6) into (2): — = piS -  (n+p)I
dt
-= I[P S -(u + n )]  (10)
dt
As I and % differ only by the proportionality constant, p:
—  =X[pS-(u+n>] 
dt
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If we consider the proportion infected, i, in terms of 1:
1 dx
N  dt N
dX PNs
T = ^ ( v + p ) [ ^  -1] (11)
dt {v + //)
(8) into (11): —  = X (v+p)[Ros - 1] (12)
dt
Within this system, the endemic equilibrium is:
s* = 1/Ro
(v + //)(i?0 - l) ( 6 ) + //) 
{CO +  V  +  p )
The general equation for the interepidemic interval is:
T = 2][(AD)^
Where A = 1/1*
Thus, A = ------- (2i±r±Z()------
{v + p){Ro -  l)(o) + p)
(13)
And D = 1/v (14)
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Values for T were calculated for the range of parameter values explored numerically above, 
with the following results:
Figure 6.5: Analytic solution for the interepidemic period, for different values of 1 and co
i :
Force of infection
These values can be seen to be very similar (although slightly larger) to those derived 
numerically, as represented in Figure 6.4. The strongest factor determining the interepidemic 
interval here is again the force of infection, with calculated results using different waning rates 
exactly overlapping in Figure 6.5.
Another stabilizing influence in this system is the relatively long duration of infection. 
Analytic results were obtained for the interepidemic period, given a range of values of X and u 
for a fixed value of m (arbitrarily fixed at 0.5).
Figure 6.6: Analytic solution for the interepidemic period, for different values of X and v
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Here the interepidemic interval can be seen to vary in response to both the force and duration 
o f infection. Again, the prevalence o f infected and resistant individuals was calculated for the 
range o f variables represented above, in order to determine which would produce results 
compatible with |UK population data.
Figure 6.7 Proportion of the population who are resistant
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Figure 6 . 8  Proportion of the population who are infected
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Here only the force o f infection determines the proportion resistant, with an estimate o f 0.4 
resulting in 40% seroprevalence o f protective antibody titres. The duration o f carriage for this 
force o f infection which would result in 4% prevalence o f  colonisation is between 2 and 3
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months. Under these assumptions, the interepidemic interval is calculated to be between 5 % 
and 6 14 years, which would have resulted in a peak rebound in all infections in 1998-1999. 
This result is not inconsistent with the model output shown in Figure 6.1 c) at the beginning of 
the chapter. As such, we believe that it is not unreasonable to deduce that the current rise in 
invasive Hib infections has resulted from a second wave of recurrence of circulation of the 
organism in the population, and that the first recurrence was ‘hidden’ due to the high antibody 
titres induced by the initial catch-up immunization campaign conducted in 1992/3.
6.3 Effect o f changing mixing assumptions
All of the models in Sections 6.1 and 6.2 assumed uniformity of mixing and subsequent Hib 
transmission in the population. Based on what we know about the social context of children’s 
daily lives, such a situation is unlikely to be true. The difficulty in parameterising contact 
patterns for the purposes of epidemiological models is the inability to quantify the true 
proportional significance of social interactions to infection risk and thus transmission 
coefficients between individuals of different ages, as discussed in Section 5.7. In 
consequence, it was necessary to explore the effect of imposing a range of contact matrices 
incorporating different assumptions about mixing between age groups in order to understand 
the sensitivity of model predictions to these differences.
Using the same baseline parameter set for the age structured model as in Section 6.1, a range 
of values for p were calculated, based on different contact mixing matrices. The consequences 
of vaccine introduction, with a catch-up campaign and use of poorly immunogenic vaccine, 
were then compared for these mixing assumptions to see which would result in levels of 
carriage and invasive disease consistent with the observed data. In Section 5.7, it was 
proposed that mixing would be strongly assortative, with most infections acquired from other
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children in the same age group, or the age group just above. Model outputs for the following 
matrices were as shown:
a) Purely assortative mixing
In this most extreme of mixing assumptions, children only acquired infections from others in 
the same age class.
~C„ C,2 C,3 "1 0 0 o~
Q, C22 Q] 0 1 0 0
q , ^ 3 2 C33 C34 0 0 1 0
_Q, C43 Q _ 0 0 0 1
Pi,=1.732 X lO”, P22=7.910 X 10’^  P33=6.005 x 10'", P44=4.644 x 10-5 \-5
Figure 6.9: Number of infections, by age class and time, under a purely assortative 
mixing assumption
a) Carriage b) Invasive Disease
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Such a situation would lead to complete eradication of Hib from children under 5 years of age, 
which has not been the UK experience. This result highlights the important role of mixing 
with older age classes in driving ongoing infection in the most vulnerable age groups.
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b) Social Mixing Assumption [1]
This matrix was strongly assortative, but assumed relatively large contributions of adjoining 
age elasses to the number of infections experienced by children of a particular age group. As 
discussed in Section 5.7, mixing within the youngest age group of infants was assumed to be 
less than that observed within groups of older children, as many more would be being cared 
for in the home environment, and thus not in contact with large numbers of children in their 
own age class.
■c„ c'^ 12 Q 3 1 5 1 0“
Q , 2^2 Q 3 Q 4 5 5 2 0
Q, 3^2 Q 3 C34 1 2 5 1
C4 , Q 2 Q 3 ^ 4 4  _ 0 0 1 5_
P11 1.943E-05 P21 2.735E-05 P31 7.503E-06 P41 0
P12 9.713E-05 P22 2.735E-05 P32 1.5G1E-05 P42 0
Pl3 1.943E-05 P23 1.094E-05 P33 3.751 E-05 P43 8.348E-06
Pl4 0 P24 0 p34 7.503E-06 P44 4.174E-05
Figure 6.10: Number of infections, by age class and time, under mixing assumption [I]
a) Carriage b) Invasive Disease
0 11-20.5 yrs
□  5-10.99 yrs
□  2-4.99 yrs 
■  0.5-1.99 yrs
Ç 15000
Z  10000
10
50
45
40
25
i
10
5
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Model Equivalent Year
191
This mixing matrix resulted in an insufficient reduction in the number of infections in the 
youngest individuals. In order to overcome this, a new assumption was made that mixing was 
more strongly assortative than previously supposed.
c) Social Mixing Assumption [2]
Q , C,2 q / '  1 10 1 0 .5 "
Q , ^ 2 2 ("23 Q 4 10 10 2.5 0.5
Q , ^ 3 2 C33 C34 1 2.5 10 1
Q , C42 C43 C44 0.5 0.5 1 10
p11 1.047E-05 P21 2.881 E-05 Psi 4.545E-06 P41
Pl2 0.0001047 P22 2.881 E-05 P32 1.136E-05 P42
Pl3 1.047E-05 P23 7.202E-06 P33 4.545E-05 P43 L
Pl4 5.233E-06 P24 1-440E-06 P34 4.545E-06 P44 I
Figure 6.11: Number of infections, by age class and time, under mixing assumption [2]
a) Carriage b) Invasive Disease
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Both mixing assumptions [1] and [2] resulted in a less than observed reduction in the number 
of infections in the younger age classes, particularly noticeable in those less than 2 years of 
age. As a result, an even more strongly assortative mixing structure was imposed.
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d) Social Mixing Assumption [3]
“Q. C.3 C,4' " 1 1 0 0 1 o . r
Qi ^ 2 2 2^3 Q 4 1 0 0 1 0 0 1 0 0 . 1
Qi Q 2 Q 3 C34 1 1 0 1 0 0 1
4^2 C43 4^4 _ 0 . 1 0 . 1 1 1 0 0
P11 1.559E-06 P21 3.632E-05 P31 5.646E-07 P41 4.616E-08
3i2 0.0001559 P22 3.632E-05 P32 5.646E-06 P42 4.616E-08
Pi3 1.559E-06 p23 3.632E-06 P33 5.646E-05 P43 4.616E-07
Pi4 1.559E-07 P24 3.632E-08 P34 5.646E-07 P44 4.616E-05
Figure 6.12; Number of infections, by age class and time, under mixing assumption [3]
a) Carriage b) Invasive Disease
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This model produced no late rebound in infections in 2-5 year olds arising from exposure to 
the age class above. On closer inspection, this was not surprising as the 2-5 year olds 
themselves exerted a relatively strong influence on acquisition of infections by the 5-11 year 
old group. Ecological studies of Hib infection implicated older school-aged siblings as an 
important risk factor for Hib disease in infants and toddlers, suggesting asymmetry of 
household transmission (Ounsted C 1950, 1951). In order to change the balance of power in 
the infectious relationship, the value of C32 was reduced from 10 to 1 in the following model. 
In addition, contact parameter values of 0.1, which were so negligible as to be insignificant in 
their effects, were changed to 0 for simplicity.
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e) Social Mixing Assumption [4]
C,! ^ 3 C.4 ' '  1 100 1 0 ■
q , 2^2 ^23 ^24 100 100 10 0
q , 3^2 ^33 C34 0 1 100 0
C42 C43 ^44 _ 0 0 0 100
p11 1.566E-06 321 3.639E-05 3si 0 3 4 1 0
P l 2 0.0001566 3 2 2 3.639E-05 3s2 5.980E-07 3 4 2 0
P l 3 1.566E-06 3 2 3 3.639E-06 3s3 5.980E-05 343 0
P l 4 0 324 0 3s4 0 3 4 4 4.644E-05
Figure 6.13: Number of infections, by age class and time, under mixing assumption [4]
a) Carriage b) Invasive Disease
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Social mixing assumptions [3] and [4] are associated with a more dramatic reduction in 
infections in the younger age classes after vaccine introduction, with a late rebound occurring 
from 1999 onwards. The latter model also results in an increase in invasive disease cases in 2- 
5 year olds from 2001. Under the baseline set of parameters, the number of cases which 
progress to invasive disease is, however, still too high.
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The fit of this last model to the observed seroepidemiology and carriage data is shown in 
Figure 6.14. The carriage data is from the HP A nursery carriage study described in Section 
2.5.1. The seroepidemiology data is from the same published study (Trotter CL et al 2003b) 
(Section 2.6.2) from which the pre-vaccination immunity data was derived.
Figure 6.14: Social Mixing Assumption [4] -  fit to observed data. In all of the figures 
below, columns represent observed population data, with error bars showing 95% 
confidence intervals of these estimates. Model outputs are represented by dots and lines.
a) English Nursery Carriage Dataset (1-4 year olds), by year and age
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b) English Seroepidemiologic Data -  High Level Immunity, by year and age 
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1990
^  1 T I 1 Observed
0.8- -^ M°del
1-1 .99  2 -2 .9 9  3 -3 .9 9  4 ^ .9 9  5 -7 .9 9  8 -1 1 .9 9  12- 
yrs yrs yrs yrs yrs yrs 15 .9 9
yrs
No measurable immunity
1994
j  1 1 j
-  0 .8 0 .8 -
-  0 .6 0 .6  -
-  0 .4 0 .4 -
- 0 .2 0 ,2  --
- 0 0 -
r — 10 bserved i
-Model
0.8 
0.6 
- 0.4  
- -  0.2 
0
1-1.99 2-2.99 3-3.99 4-4.99 5-7.99 8-11.99 12-
yrs yrs yrs yrs yrs yrs 15.99
yrs
1-1.99 2-2.99 3-3.99 4-4.99 5-7.99 8-11.99 12- 
yrs yrs yrs yrs yrs yrs 15.99
yrs
1997 2000
I O bserw d  
-Model
^  0.4 - É
J 1 1
-■ 0.8 0 .8
0 .6 0 .6
- 0 .4 0 .4
0 .2 0 .2
- 0 0
r z z i  Observed 
Model
1-1.99 2-2 .99  3-3 .99  4-4 .99  5-7 .99  8-11.99 12- 
yrs yrs yrs yrs yrs yrs 15.99
yrs
1-1.99 2 -2 .99  3 -3 .99  4 -4 .99  5 -7 .99  8 -11 .99  12- 
yrs yrs yrs yrs yrs yrs 15 .99
yrs
196
It can be seen that the model fits well to the observed carriage and high level immunity data. 
From 1997 onwards, however, the proportion estimated to have undetectable antibody levels is 
far in excess of that observed in the population. It was essential to correct this mismatch 
between model and data before moving on to test assumptions about vaccine protection 
against acquisition and progression to invasive disease firom a state where individuals had 
been exposed, but immunity had waned. For this reason, the parameter ©lv, determining the 
time period in which low measurable antibody levels were maintained, was subjected to 
sensitivity analysis.
6.4 Sensitivity analysis on duration o f low immunity in the vaccinated proportion (colv)
When estimating pre immunisation parameters, it was noted that the duration of low level 
immunity following exposure to Hib was longer than would be predicted fi*om the rate of 
waning of the acute phase antibody response, lasting 11 years (Section 5.3.2). The same 
would appear to be the case for vaccine induced immunity on the basis of Figure 6.15 c) 
above. This is likely to be due to ongoing antibody production by long lived plasma cells 
following waning of the primary immune response (Slifka MK et al 1998). A sensitivity 
analysis was conducted on the duration of low level antibody persistence.
a) Low level immunity lasts for 3 years ( © l v  = 0.33)
Figure 6.15: Undetectable immunity in England, 1997 & 2000, model fit if © l v  =  0.33 
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b) Low level immunity lasts for 4 years (wlv = 0.25)
Figure 6.16: Undetectable immunity in England, 1997 & 2000, model fit if colv = 0.25
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c) Low level immunity lasts for 5 years ( c o l v  = 0.2)
Figure 6.17: Undetectable immunity in England, 1997 & 2000, model fit if colv = 0.2
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This improved fit to the population data on undetectable antibody titres did not compromise 
the model fit to any other observed data. On this basis, it was possible to go on to further 
explore assumptions regarding vaccine protection against acquisition of infection and 
progression of established infections to invasive disease. Subsequent models incorporated the 
new parameter value: oolv = 0.2.
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6.5 Sensitivity analysis on assumed protection against acquisition from the low immune state
The level of serum anticapsular antibody required to prevent Hib aequisition in vaccinated 
children has not been conclusively established (Section 1.15). Given this uncertainty, a 
sensitivity analysis was conducted in order to estimate the relative protection afforded by Hib 
titres between 0.15 and 1.0 g/ml over a range of values from 0 (no protection) to 1 (complete 
protection). Two consequences of increasing e were:
(i) Increasing parameter values for the age dependent force of infection, X.
(ii) A relative increase in the proportion of all infections which were ‘first infections’. 
As a result, in situations where s was larger, log-likelihood estimation predicted 
improved protection against progression to invasive disease from the low immune 
and no measurable immunity (non-naïve) states, expressed in the parameters 0 and 
p respectively.
Model behaviour was explored over a range of these assumptions, to see which values would 
allow good initial control of infections, followed by the observed rebound in invasive disease 
incidence. As will be seen from Figures 6.18 to 6.20 below, increasing the value of s, and 
subsequently of 0 and p, resulted in improved control of disease following vaccine 
introduction, but removed the phenomenon of the late increase in invasive disease observed 
from 1999 onwards. The only models which were able to reproduce this population behaviour 
were those which assumed very little protection against either acquisition or invasive disease 
from the low immune state. The direct protective efficacy of immunologic memory, 
represented by individuals in the S and Sy compartments, was thus estimated to be in the order 
of 35%. This figure is remarkably similar to the calculated direct protective efficacy of infant 
immunisation two years or more after vaccine administration in the UK, derived using the 
screening method (Ramsay ME et a; 2003).
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a) Protection against acquisition from the low immune state, c = 0.25, 0 = 0.36, |x = 0.36
ki=0.47, 12=0.24, 13=0.47, 14=0.72
Figure 6.18: Invasive Disease Incidence Following Vaccine Introduction if  c = 0.25
— 0.5-1.99 
— 2-4.99 yrs 
5-10.99 yrs
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Model Equivalent Year
b) Protection against acquisition from the low immune state, e = 0.5, 0 = 0.68, |i = 0.68
li=0.48, 12=0.28, 13=0.57, 14=0.97
Figure 6.19: Invasive Disease Incidence Following Vaccine Introduction if  £ = 0.5
•— 2-4.99 yrs
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Model Equivalent Year
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c) Protection against acquisition from the low immune state, s = O.75,0 = O.81,q = O.81
Xi=0 .50, 12= 0 .33 , 13=0 .71, 14=1.37
Figure 6.20: Invasive Disease Incidence Following Vaccine Introduction if £ = 0.75
•0.5-1.99 yrs
5-10.99 yrs
Ï
IS8 I 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Model Equivalent Year
Based on the results of the analysis illustrated in Figures 6.19-6.21, it was concluded that the 
protective efficacy of both low level antibody and the memory state were very low, as these 
were the only conditions under which a rebound of infections in the youngest age classes 
could occur. After exploring a range of potential values for e in between those shown above, 
no better fit to the observed data was able to be achieved than was seen using the parameter 
value £ = 0.25. Figure 6.22 shows the year by year fit of the model to observed invasive 
disease incidence, by age at presentation, for this parameter value. Note the change in the 
scale of the y axis (Observed incidence rate per 10^ ) between 1992 and 1993.
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Figure 6.21; Observed and Model predicted Hib incidence by age and year, 1991-2002.
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6.6 Discussion of discrepancies between observed data and model predictions
This model very accurately recaptures the immediate impact of vaccine introduction. Two
major discrepancies between model and population behaviours remain, however.
6.6.1 Less effective control of disease by immunization in 1-2 year old children in the model 
between 1996 and 1999 than in the observed data 
A number of possible reasons may contribute to this difference:
a) Homogeneous transmission of Hib is assumed between age classes deemed to mix with 
each other according to the contact matrix. Prior to vaccine introduction, carriage prevalence 
in the population was in the order of 4-5%. Even in this state, much higher pockets of 
transmission were noted, particularly in places such as nurseries, where many children mixed 
together. Following near eradication of carriage in the youngest age classes resulting from 
vaccine introduction, it may be erroneous to assume that reseeding of the organism within 
communities occurs in a uniform manner. Clustering of small groups of children in homes, 
playgroups and nurseries may have resulted in a slower increase in infections over time, as 
some groups would have the infection introduced, but not others. This effect would be 
anticipated to be less in schools, where larger numbers of children of many ages mix.
This hypothesis is supported by the findhigs of carriage studies conducted in nurseries over a 
ten year period (Section 2.5.1). A rapid reduction in Hib carriage prevalence was observed 
between 1992 and 1994, with no carriers detected among hundreds of children sampled in 
1997 and 2000 (McVemon J et al 2003c). This did not mean that vaccinated children who had 
been exposed to Hib would not subsequently carry and transmit, however, as evidenced by an 
outbreak of invasive Hib infection among fully immunised children in a day care nursery in 
Northamptonshire (Section 2.5.2) (McVemon J et al 2003b). In this way, the inability of the
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model to incorporate the phenomenon of non-uniform transmission across Britain may have 
led to an overestimate of carriage prevalence and hence invasive disease incidence in the years 
shortly after vaccine introduction.
A further example of such a phenomenon is given by the observed change in the epidemiology 
of measles which resulted from widespread vaccine introduction in England. Before 
immunisation was available, the timing of epidemics was strongly correlated between large 
cities. A reduction in the size of epidemics resulting from vaccination led to a breakdown of 
this previously observed relationship, with outbreaks occurring in geographically distinct 
locations at very different times (Bolker BM et al 1996).
b) Prior to vaccine introduction, it is acknowledged that natural exposures resulting in the 
production of antibody with binding specificity to PRP may not all have been due to Hib, but 
also to cross-reactive organisms (Section 1.9). The pre-vaccination force of infection 
calculated for the youngest age group on the basis of observed immunity to Hib resulted in an 
estimated carriage prevalence of Hib rather higher than that observed in the population (Figure 
5.4). It is likely that a proportion of these immunising contacts may have been due to other 
infections. As such, the calculated value for the transmission coefficient, |3, in this age group 
may have been higher than warranted for Hib alone. As a result, the number of infections with 
Hib following vaccine introduction may have been selectively overestimated in this age 
category.
6.6.2 The recurrence of disease observed from 1999 onwards did not achieve the magnitude of 
the observed increase in England and Wales, although the distribution of ages at invasive 
disease was verv similar.
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The higher than predicted incidence of invasive disease in the UK from 2000 onwards may 
result from at least two further effects:
a) Vaccine efficacy may have truly diminished over time, resulting in more effective disease 
control in earlier years of the vaccination programme than that observed now. Evidence exists 
from the United States of declining immunogenicity of Hib conjugate vaccines over time.
Dan Granoff describes a sequential reduction in post immunization antibody titres achieved 
following administration of the same single antigen Hib conjugate vaccine, measured using 
the same assay in aingle laboratory over a number of years, as shown in Figure 6.22 below 
(Granoff DM 2001). This reduction in immunogenicity remains unexplained on 
immunological grounds, but may represent a decrease in vaccine potency over time. No 
similar data is available from the UK.
Figure 6.22: Declining anti PRP antibody responses to Haemophilus influenzae type b 
oligosaccharides conjugated to CRM 197 (HbOC) vaccine given as a separate injection to 
infants at 2,4 and 6 months of age, concomitantly with DTaP or DTwP
40-
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Each point represents the value from a separate vaccine trial in which antibody concentrations 
obtained 1 month after the third dose were measured by a radioantigen-binding assay.
(A) Geometric mean antibody concentrations
(B) Percentage of infants (95% Ci) with anti-PRP antibody concentrations >1.0 pg/ml.
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b) 2002 saw an increase in adult Hib disease cases to levels similar to or greater than those 
observed prior to vaccine introduction, as described in Section 2.4.3 (McVemon J et al 
2004d). Transmission of Hib from adults to children is well described (Glode MP et al 1984). 
A lack of population based carriage and seroepidemiology data prevented inclusion of adults 
over 20 years of age in the model, but it appears likely that this may have resulted in omission 
of an important source pool of infections. Had adults been included in the model, it is likely 
that a greater increase in the force of infection would have been seen in the last few years than 
was noted in their absence.
In a similar scenario, m countries with established pertussis immunisation schedules, 
awareness of ongoing transmission of the disease among adolescents and adults raises 
question of the need for booster immunisation in these age groups (Fine PEM 1997). This 
issue has prompted study of a range of potential interventions to either boost immunity in the 
older cohort in order to provide direct protection for a large number, or to vaccinate parents as 
a ‘cocoon’ strategy aimed predominantly at indirect protection of infants (Van Rie A et al 
2004).
c) Approximately 20% of infants who received three doses of DTaP-Hib vaccine made no 
apparent antibody response by the end of the primary course. It has been previously assumed 
in the model that these children were all primed by vaccination, but it is possible that they may 
represent true primary vaccine failures. As such, this proportion of the 2000/2001 birth 
cohorts in the model may alternatively be considered to be fully naïve at entry (N), rather than 
contributing to the population of vaccinated modified susceptibles with no measurable 
antibody (Sv). The effect of changing this assumption is shown in the simulation below.
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Figure 6.23: Effect of assuming that all vaccine ‘non-responders’ following three doses of 
DTaP-Hib are primary vaccine failures 
a) Base case assumption
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If all non-responders to primary immunisation are deemed to be primary vaccine failures, no 
significant increase in invasive disease incidence is observed in 2 0 0 0 - 2 0 0 2  compared with the 
base case (Figure 6.24). Given the low protective efficacy of prior exposure in the absence of 
measurable antibody in the model, this is perhaps not surprising. It was thus neither necessary 
nor feasible to invoke a high rate of primary vaccine failure to explain a late increase in 
invasive Hib infections in the UK.
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6.7 Conclusions
The model as configured is highly parameterized, but has the benefit of being based on a large 
number of data points, using data of different types. Carriage, seroprevalence and invasive 
disease data have all been used to enable characterization of the relationships between Hib 
exposure, immtmity and disease experience in the pre-vaccine condition. At baseline, 8  age 
specific estimates of carriage prevalence and 16 data points describing age specific immunity 
were used to define the age dependent forces of infection and waning rates. Age related 
progression to invasive disease was initially calculated against 7 age-specific measures of 
incidence.
Validation of model behaviour following introduction of immunization against ten years of 
observed population experience has allowed exploration of important theoretical assumptions 
regarding the mechanism and duration of vaccine protection. A further 16 serological data 
points were available for each of three years over this time (ie 48 measures of post­
immunisation immunity). Carriage in children attending nursery in four age groups was 
available for comparison for four separate years (16 data points). Seventy measures of Hib 
disease incidence were available between 1993 and 2002 (7 age groups per year over 10 
years), in order to assess the adequacy of parameter estimates of 5, e, 0  and p.
Key theoretical conclusions of the model included a very low direct efficacy of immunologic 
memory following the primary course alone against disease, in keeping with estimates derived 
from the UK population using the screening method (Ramsay ME et al 2003). Minimal 
protection against acquisition of Hib was also observed in individuals with low-level 
measurable immunity. The age dependence of progression to invasive disease was in excess 
of the risk conferred by the observed absence of anti-polysaccharide antibodies, and could not
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be solely explained by an increased risk of bacterial invasion associated with the first ever 
exposure.
Given these findings, the use of poorly immunogenic vaccines in 2000/2001 placed infants 
and young children at substantial risk of invasive Hib infections. According to the time scale 
predicted by the model, the increase in the size of the susceptible pool at this time was 
superimposed upon the second phase of a rebound in infections in older children associated 
with transients induced by catch-up immunisation in 1992/1993. While enormously 
successful at producing rapid disease control, catch-up campaigns such as this can be 
anticipated to induce marked fluctuations in transmission in the longer term. It was reassuring 
to note that the intrinsic properties of the system were likely to result in strong damping of 
these fluctuations, producing a new stable equilibrium within a relatively short time.
The model highlights the need for a greater understanding of the impact of immunisation on 
circulation of organisms in the adult population. Adults were not included in the model, due 
to an absence of baseline data upon which to parameterise the force of infection. A return of 
Hib disease incidence in this age group to pre-vaccine levels in recent years (Section 2.4.3) 
has potentially provided another source population likely to transmit to infants, fiirther fuelling 
the rise in observed cases.
On the basis of the above analyses, the following final parameter values were used for the 
assessment of possible public health interventions on the ongoing epidemiology of Hib 
infections in Chapter 7.
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Table 6.1; Final parameter set for use in the public health model
Model Parameter Mean Value Mean duration 
in class
Demographic parameters
Births per quarter, B 6  250
Population size, N 5 0 0  0 0 0
Proportions vaccinated, p, q, z 0 - 1  where p+q+z<l
Routine infant immunisation p=0.83, q=0.07, z=0.02
Poorly immunogenic vaccine p=0.63, q=0.19, z=0.10
Biological parameters
Duration of carriage for first infection
o' 5 2.4 months
Duration of carriage for subsequent infections
n (unvaccinated) 5 2.4 months
uv (vaccinated) 5 2.4 months
Duration of immunity
Unvaccinated
®Hi (0.5-1.99 years) 6.36 0.16 years
®h2 (2-4.99 years) 0.67 1.50 years
cdh3 (5-10.99 years) 0.46 2.18 years
(Oh4 (11-20.5 years) 0.51 1.96 years
©L (all ages) 0 . 1 2 8.06 years
Vaccinated
©Hvi (0.5-0.99 years) 0.80 1.25 years
®HV2  (1-1.49 years) 0.56 1.79 years
®HV3 (1.5-1.99 years) 0.48 2.08 years
©hv4 (2-20.5 years) 0.43 2.33 years
©LV (all ages) 0 . 2 0 5 . 0  years
Duration of immunity following re-exposure to Hib in vaccinated individuals
©Bi (0.5-0.99 years) 0.43 2.33 years
© B 2  (1-1.49 years) 0.57 1.75 years
©b3 (1.5-1.99 years) 0.69 1.45 years
©b4 (2-20.5 years) 0.95 1.05 years
Relative protection against acquisition from low antibody state
8 0.25
Force of infection, X
X\ (0.5-1.99 years) 0.47
%2 (2-4.99 years) 0.24
X] (5-10.99 years) 0.47
X4  (11-20.5 years) 0.72
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Model Parameter Mean Value Mean duration 
in class
Rate of progression to invasive disease, 5
6 i (0.5-0.99 years) 0.0118
0 2 (1 .0 -1 . 9 9  years) 0.0044
Ô3 (2.0-2.99 years) 0.0044
0 4 (3 .0 -3 . 9 9  years) 0.0039
Ô5 (4.0-4.99 years) 0.0021
Ô6 (5.0-20.5 years) 0.00009
Protection against progression against invasive disease afforded by low levels of 
measurable antibody, 0
0 0.36
Protection against progression against invasive disease afforded by previous natural or 
vaccine exposure to Hib in the absence of measurable antibody, p
0.36
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Chapter 7: Public Health Implications of the Model
7.0 Introduction
The implications of a range of possible changes to the UK vaccine schedule were 
explored using the model developed in Chapter 5. In attempting to simulate the effects 
of these changes, the considerable variation in immunogenicity observed between 
vaccine trials made it difficult to fix upon definitive values for the parameters 
describing the duration of protection following boosting (©bi-4).
Results of immunisation trials using accelerated (2, 3, 4 months) and standard (2, 4, 6 
months) schedules combining PRP-T with either DTwP or DTaP were compared. Only 
those incorporating a booster phase were included. Post primary and post boost (with 
conjugate or PRP) titres from a range of studies are shown in Figure 7.0 and Table 7.0.
Figure 7.0: Prime/boost titres achieved in Phase II trials using different vaccines 
and schedules (country of study shown). PRP denotes polysaccharide booster.
1000
100
8*
uzo
X
-*-246  DTwP (Can) 
234DTWP (UK) 
-* -246  DTaP (Swe)
—  246 DTaP (US)
—  246 DTaP (US)
—  246 DTaP (Isr) 
-* -234  DTaP (UK)
—  234 DTaP (UK)
—  234 DTaP (Ger)
—  246 DTaP-PRP (Isr)
—  234 DTaP-PRP (UK)
prime boost
212
I§
IÎ
«
%
I
I
I
I
0  
!1■s
I
01
H
▼H
A
i |I Io j. tt  un
* n
° | j
A
siIi&
%oP4 Ü
I
t
I
i
ON4
ÏNcn
00
CO
CO
r-
00
a  
o
Û
(w *Q 
' o  CO
• s sCO r—I
<Ni
o \
8
e ,
ON
CO
0Ôo
CN
CO
O n
NO r-4
OO o
NO
NO c«T
NO
CO NO
O CO
NO CN
NO
g
O n Ut—t (U
00 >>
w cno Oo O
x>
O  B o «
g  a
”  to «  OB
NO 10 ^  0
m 'g
<N U <N O
i
ON
O n
g
5
COITi
O
liSÎ
t5  g
i |
o 00 
/ s
CJ c3
i
I
g
c/3
11::g
<u
Q ^
o a
g
oo
00
VO
(N
g
00
oo
fN
oo
« 0
CO
•ISJ
cd
o|ll| i
Ph <N
o
<
%
3;
<N
CO
» n
c6g
(N
CO
<
NO
OO
(N
<N
l îJ!
CÜ ^
«  8  
as fe
Ii
<NQ
COg
O n
NO
e
00
NO
CO
g
g
M
r ~
NO
' T
o
oo
I
II
CO g
c i o
00
O n
O n
cQ
Ü
k
" o
PQ
i
I
C4
00
oo
g
CNoo
oo
NO
00
O nê
CO
( N
NO
<N
8
rOI
CO
c i ô
i
oo
O n
( N
O
NO
NO
r - -
NO
NO
c s
00
CN
W3
it
m g
<N O
So
8 8  
P h (N
O
:z ;
ON
CO
o
NO
CN
c6
00
NO
NO
<
oo
NO
NO
OO
CN
CN
O83
pH
C3 ^  
W
■ é è
II
o
NO
00
o
CO
N /^
NO
00
g
i
00
NO
oo
ON
I
NO
CN
o8II
CN*' P h
CO
CN
In examining these data, several consistent findings may be observed in spite of 
considerable inter-study variation:
(i) Acceleration of the schedule does not have an adverse effect on either post 
primary or post-boost immunogenicity when DTwP is combined with PRP-T.
(ii) While accelerated schedules using DTaP have been associated with lower 
post-primary immunisation titres than standard courses in one vaccine manufacturer’s 
summary (Vidor E et al 2001), similar ranges of immunogenicity results are seen when 
multiple trials are compared (Table 7.0). Interestingly, higher post boost titres are 
consistently observed following priming with the 2 ,3 ,4  month infant regimen (Figure 
7.0).
(iii) Boosting with conjugate vaccine usually results in antibody concentrations 
5-10 fold higher than are observed following polysaccharide boosting. Again, however, 
results vary widely following the fourth dose of conjugate. A log difference may be 
observed between the highest and lowest titres in the studies above, ranging from 12.75 
pg/ml (Carlsson RM et al 1998) to 108.39 pg/ml (Goldblatt D et al 1998). The lowest 
values observed are in the order expected of those seen with primary immunisation in 
the second year of life, hardly corresponding to a ‘boost’ response at all.
7.1 Approach to examination o f public health issues
On the basis of the data reviewed in section 7.0, the following approach was taken to the 
exploration of public health implications of the model. All simulations incorporated the 
catch-up immunisation campaign employed in the UK in 1992/1993 and the use of less 
immunogenic vaccines in 2000/2001, as described in Section 6.1.
(i) No justification could be seen for comparing a 2,4, 6 month priming 
schedule with the currently used 2, 3,4 month regimen.
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(ii) The model in Chapter 5 assumed a post-boost titre for all vaccine recipients 
of 100 iig/ml, based on the response to carriage observed in three pre-school aged 
children in a single published study (Barbour ML et al 1993). It was thus tacitly 
assumed that exposure to an intact organism was more immunogenic than plain 
polysaccharide. This assumption may have been an overestimate, even when 
considering antibody titres achieved following boosting with conjugate vaccines. For 
this reason, a series of models were run and the resulting effects on disease incidence 
over time compared if the peak post boost response was 15, 50 or 100 pg/ml. Parameter 
values for ©b by age group were calculated using the same methods shown in Section 
5.3.4. Results are shown in Table 7.1.
(iii) The anticipated effect of a routine booster with 80% uptake in the 
previously immunised population, used from the time of implementation in 1992, was 
assessed for each of the post boost assumptions. The booster was scheduled at age 12 
months, 15 months, 18 months or 4 years.
(iv) The effect of a one-off catch-up immunisation campaign, as employed in the 
UK in 2003, was explored given each of the three post boost assumptions, for coverage 
estimates of 20,40, 60 and 80%.
(v) The effect of a one-off catch-up immunisation campaign as employed in the 
UK in 2003, accompanied by introduction of a routine booster with 80% uptake in the 
previously immunised population, was explored given each of the three post boost 
assumptions, for catch-up coverage estimates of 20% and 60%. The booster was 
scheduled at either age 12 or 18 months, based on the timings found to be optimal in 
part (iii).
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7.2 Model outputs assuming different magnitudes of boosting following natural
exposure in immunised children
7.2.1 Boost response to natural exposure =100 ug/ml
50
— 0.5-1.99 yrs 
— 2-4.99 yrs 
5-10.99 yrs 
—  11-19.99 yrs
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0
Year of Presenta tion
7.2.2 Boost response to natural exposure = 50 |j-g/ml
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ë  30
Year of Presentation
7.2.3 Boost response to natural exposure = 15 ^s/ml
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—  2-4.99 yrs 
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7.3 Model outputs assuming 80% uptake o f a routine booster dose from 1993 onwards, 
at various ages and for different magnitudes o f boost response
7.3.1 Boost response to vaccine or natural exposure =100 ug/ml
(i) Boost at 12 months
i
I
Year of Presentation
(ii) Boost at 15 months
—  0.5-1.99 yrs
—  2-4.99 yrs 
4-10.99 yrs?I
I 20
^  ^
Year of Presentation
(iii) Boost at 18 months
—  2-4.99 yrs
I
cf.
Year of Presentation
(iv) Boost at 4 years
I
25
I 20
I
Year of Presentation
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7.3.2 Boost response to vaccine or natural exposure = 50 ug/ml
(i) Boost at 12 months
50
—  0.5-1.99 yrs
—  2-4.99 yrs 
5-10.99 yrs
— 11-19.99 yrs
&
I
35
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I  20
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(ii) Boost at 15 months
X 20
^ ^ ^ ^ ^ ^ ^ 1
Year of Presentation
(iii) Boost at 18 months
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(iv) Boost at 4 years
-  10
Year of Presentation
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7.3.3 Boost response to vaccine or natural exposure = 15 ug/ml
(i) Boost at 12 months
50
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■to 40 
g. 35
30
25
X 20
15
i 10
Year of Presentation
(ii) Boost at 15 months
—  0.5-1.99 yrs
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(iii) Boost at 18 months
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(iv) Boost at 4 years
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7.4 Model outputs assuming various levels o f uptake o f the 2003 catch-up immunisation
campaign, for different magnitudes o f boost response
7.4.1 Boost response to vaccine or natural exposure =100 fig/ml
(i) 20% uptake of catch-up dose
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—  0.5-1.99 yrs
I  20
Year of Presentation
(iii) 60% uptake of catch-up dose
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7.4.2 Boost response to vaccine or natural exposure - 50 ug/ml
(i) 20% uptake o f catch-up dose
—  0.5-1.99 yrs 
- 2 - 4 . 9 9  yrs 
5-10.99 yrs
I
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(ii) 40% uptake of catch-up dose
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7.4.3 Boost response to vaccine or natural exposure = 1 5  ug/ml
(i) 20% uptake o f  catch-up dose
&
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7.5 Model outputs assuming various levels o f uptake o f the 2003 catch-up immunisation
campaign, accompanied by introduction o f a routine fourth dose o f vaccine
7.5.1 Boost response to vaccine or natural exposure = 100 ug/ml
(i) 20% uptake of catch-up dose, with introduction of routine 12 month boost
■to 40
I
1I 30
f  20
I
Year of Presentation
(ii) 20% uptake of catch-up dose, with introduction of routine 18 month boost
I
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# 2 0
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(iii) 60% uptake of catch-up dose, with introduction of routine 12 month boost
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(iv) 60% uptake of catch-up dose, with introduction of routine 18 month boost
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Year of Presentation
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7.5.2 Boost response to vaccine or natural exposure = 50 ug/ml
(i) 20% uptake of catch-up dose, with introduction of routine 12 month boost
40
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Year of Presentation
(ii) 20% uptake of catch-up dose, with introduction of routine 18 month boost
% 20  -
Year of Presentation
(iii) 60% uptake of catch-up dose, with introduction of routine 12 month boost
ë  30
X 20
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(iv) 60% uptake of catch-up dose, with introduction of routine 18 month boost
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Year of Presentation
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7.5.3 Boost response to vaccine or natural exposure -  15 ug/ml
(i) 20% uptake of catch-up dose, with introduction of routine 12 month boost
— 0.5-1.99 yrs
—  2-4.99 yrs 
5-10.99 yrs
—  11-19.99 yrs
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(ii) 20% uptake of catch-up dose, with introduction of routine 18 month boost
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Table 7.2: Model-predicted Hib incidence rate per 100,000 in 2010 in children
under 5 years of age given a range of interventions
Intervention Boost response 
100 pg/ml
Boost response 
50 pg/ml
Boost response 
15 pg/ml
No catchup or boost 2.52 2.52 2.88
Booster dose o f vaccine given from 1993 onwards
Boost 12 months 0.61 0.81 1.34
Boost 15 months 0.62 0.83 1.32
Boost 18 months 0.65 0.87 1.42
Boost 4 years 0.79 1.09 1.51
Catchup campaign initiated mid~2003, various levels o f coverage
20% catchup only 2.35 2.54 2.89
40% catchup only 2.42 2.57 2.90
60% catchup only 2.51 2.60 2.92
80% catchup only 2.63 2.65 2.94
Catchup campaign initiated mid-2003, accompanied by introduction o f fourth dose
20% catchup/boost 12 months 0.59 0.69 0.97
20% catchup/boost 18 months 0.63 0.85 1.41
60% catchup/boost 12 months 0.58 0.68 0.97
60% catchup/boost 18 months 0.67 0.86 1.41
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Table 7.3: Model-predicted Hib incidence rate per 100,000 in 2020 (equilibrium) in
children under 5 years of age given a range of interventions
Intervention Boost response 
100 pg/ml
Boost response 
50 pg/ml
Boost response 
15 pg/ml
No catchup or boost 2.30 2.52 2.88
Booster dose o f vaccine given from 1993 onwards
Boost 12 months 0.61 0.81 1.34
Boost 15 months 0.63 0.83 1.32
Boost 18 months 0.66 0.87 1.42
Boost 4 years 0.79 1.09 1.51
Catchup campaign initiated mid-2003, various levels o f coverage
20% catchup only 2.30 2.52 2.88
40% catchup only 2.30 2.52 2.88
60% catchup only 2.31 2.52 2.88
80% catchup only 2.31 2.52 2.88
Catchup campaign initiated mid-2003, accompanied by introduction o f fourth dose
20% catchup/boost 12 months 0.57 0.68 0.98
20% catchup/boost 18 months 0.65 0.87 1.42
60% catchup/boost 12 months 0.57 0.68 0.97
60% catchup/boost 18 months 0.66 0.87 1.42
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Figure 7.1a: Invasive Hib disease incidence in children aged 0.5-1.99 years
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Figure 7.1b: Invasive Hib disease incidence in children aged 2-4.99 years
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7.6 Summary o f results o f the model simulations
While it is recognised that the simulations above cannot provide true population 
estimates of future Hib incidence in the UK, they do allow us to draw broad conclusions 
about the likely relative impact of alternative interventions. Overall messages derived 
from this exercise, summarised in Tables 7.2 and 7.3 and Figure 7.1 were as follows:
(i) The catch-up immunisation campaign that accompanied Hib vaccine introduction 
was associated with a greater decrease in invasive disease incidence in the first few 
years of the campaign than could be expected using the routine infant schedule alone. 
Incidence rates of Hib disease were rising to an equilibrium point before the use of 
poorly immunogenic vaccines in 2000/2001.
(ii) In the absence of any specific intervention, the increase in disease associated with 
use of poorly immunogenic vaccines may have resolved by 2005-2006. The 
equilibrium incidence was closely related to the duration of protection associated with 
natural boosting.
(iii) The use of a catch-up immunisation campaign alone as a means of disease control 
produced a short-term reduction in disease incidence. This was a transient effect, 
however, with an associated rebound in cases within 7 years. The magnitude of this 
rebound increased with coverage achieved during the campaign. Following resolution 
of this transient behaviour, the equilibrium incidence of disease was identical to that 
observed without any intervention, thus conferring no long-term benefit.
(iv) In order to achieve maximum impact, routine booster immunisation was best 
administered between 12 and 18 months of age. Boosting at 4 years of age was too late 
to include the period of peak susceptibility to disease.
(v) The greatest impact of a routine booster superimposed on the 2003 catch-up 
campaign was observed when the fourth dose was given at 12 rather than 18 months. 
This combination was associated with a greater reduction in disease than if routine 
immunisation had been administered all along, without the catch-up. The magnitude of 
this effect was closely linked to the duration of protection associated with boosting.
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7.7 Conclusions
The model outputs strongly suggest that, in order to obtain maximum benefit from the 
2003 catch-up campaign, a routine fourth dose of Hib vaccine should be scheduled as 
close to 12 months of age as possible. The equilibrium incidence of disease in the 
absence of such a dose is estimated to be between 3 and 5 times higher than if the 
booster is given. The cost-effectiveness of such an intervention is likely to be a 
significant factor in determining whether or not it is introduced.
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Chapter 8 -  Ecological aspects of BBb virulence
8.0 Introduction
Prior to the use of widespread Hib vaccination, high rates of colonisation were noted in 
household contacts of Hib cases. Further, children with older siblings were at greater 
risk of invasive Hib disease. These observations led Ounsted to hypothesise that 
repeated passage of the organism through multiple carriers resulted in evolution of 
strains with heightened virulence potential (Ounsted C 1950). Subsequent reports of 
institutions and day care centres with a very high density of carriers, but no cases of 
invasive disease, made this hypothesis less credible, although the effect could be 
restricted to family settings (Turk DC 1963) (Murphy TV et al 1985).
In considering reasons for the recent increase in Hib disease incidence in the UK, some 
discussion of the possibility that immunisation has selected for more virulent Hib strains 
in the population is required. An evolutionary framework for consideration of such 
concepts is introduced. The specific question addressed in this chapter is whether 
changes in medical treatment of invasive Hib infections over the last century may have 
impacted on the life history of the organism, and thereby altered the evolutionarily 
stable level of virulence of circulating strains.
8.1 ‘Trade-off models and evolutionarily stable levels o f virulence
A number of theories have been proposed to explain the evolution of pathogen virulence 
in human hosts (Williams GC et al 1991) (Ebert D 1999). These may be most 
meaningfully examined in the context of specific infectious diseases, based on an 
understanding of the pathogenesis and the relevance of virulence to transmission in each
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case. For organisms that have recently crossed species boundaries, virulence properties 
in the new host may be an unfortunate ‘coincidence’, not due to any characteristics that 
would be selected for in the original host reservoir. Unique manifestations may relate 
as much to the interaction of the new host’s immune system with the organism as 
properties of the pathogen (Weiss RA 2002). For many diseases such as Hib however, 
humans are the unique host, and in this instance an alternative explanation for the 
expression of virulence must be sought.
Direct benefit models propose that the nature of the symptoms produced by the 
pathogen actually facilitates its transmission to the next host. Oft-quoted examples are 
diarrhoea induced by enteric viruses, favouring faecal-oral spread, and coughing as a 
feature of lower respiratory tract infection promoting aerosol spread. Invasive bacterial 
disease is frequently cited as a counter to such theory, as ‘invasion’ by definition 
involves the spread of an organism into a relatively inaccessible site such as the 
bloodstream or CSF from where transmission is unlikely to occur (Frank SA 1996) 
(Lipsitch M et al 1997a).
A ‘trade-off between the potential costs and benefits of virulence has been 
hypothesised. Characteristics of a pathogen or its disease manifestations that favour 
transmission may also incur cost, by placing the primary host at risk of morbidity and 
mortality. If the host dies, the duration of the infectious period is shortened, and there is 
no net benefit to the pathogen. This can be seen by considering the basic reproductive 
rate (Ro), the number of secondary cases produced by the introduction of one infectious 
individual into a fully susceptible population. The infected host remains so until he or 
she clears the pathogen (p) or dies, due to natural causes (p) or invasive disease (a). In
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a population where all are bom susceptible at birth rate (B) and die at rate (p), the Ro of 
an organism with transmissibility (p) will be:
Ro= H{p + a-^fS)
For Ro to remain constant or increase, the cost of a shorter infectious period (because of 
faster death (a) or quicker clearance (p)) must be at least offset by higher infectiousness 
(P). Such models predict the evolution of an intermediate stable level of vimlence 
(Frank SA 1996) (Anderson RM et al 1991). The classic biological example given to 
demonstrate this theory is that of the selection for avirulent strains of myxoma vims in 
European rabbits in Australia after it was deliberately introduced as a biological control 
strategy. Strains that induced high fatality rates diminished in prevalence in the 
population, and less vimlent strains began to predominate within a matter of a few years 
(Levin S et al 1981, Fenner F 1983).
The survival of an organism in the population is not only based on its ability to be 
transmitted, however. Considerations of the trade-offs involved in fitness have been 
further subdivided into within-host and between-host components (Frank SA 1996). A 
complex range of adaptive strategies may benefit within-host survival, including 
tropism for specific tissues that may expand the ecological niche available (Bull JJ 
1994). Within host competition depends on the relatedness of strains, and should 
increase in the setting of superinfection with unrelated organisms as each pathogen 
stmggles to compete for the available niche. For closely related organisms, kin 
selection (Frank SA 1996) or collective action (Brown SP et al 2002) theories predict
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that evolution to reduced virulence may occur. This may particularly be the case in 
infections where the pathogen depends not only on ready made host products for its 
survival, but also on substances produced by the interaction of pathogen with host, as in 
some viral infections (Brown SP et al 2002).
Models studying competition between unrelated strains, predict the ‘tragedy of the 
commons’ phenomenon, where ‘rapacious pathogens gain a disproportionate share of 
host resources by mpid exploitation’ (Frank SA 1996). Models of superinfection have 
been developed to explore the likely effect of competition on the virulence and diversity 
of bacterial strains encountered in human populations. Where strains can 
simultaneously co-infect the host, the relationship between transmission and virulence 
within individual strains has a marked influence on the conclusions drawn by such 
models. If all strains are equally transmissible, a wide range of isolates persists in the 
population, with the more virulent strains being less prevalent. Where the two are 
linked in a ‘trade-off relationship, a smaller number of strains tend to persist, of higher 
intrinsic virulence (May RM et al 1995). If a dominance hierarchy is assumed, where 
more virulent organisms replace less virulent ones, again fewer hosts are infected with 
strains of higher virulence, but the number of strains present in the population increases 
as the average virulence rises (May RM et al 1994).
The most severe end of this spectrum is the ‘short sighted’ evolution theory where a 
single ‘selfish’ clone may pursue short-term advantage to its ultimate cost. Such a 
theory has been proposed to explain progression to invasive disease by normally 
avirulent encapsulated organisms such as Hib (Levin BR et al 1994). Here, within-host 
competition results in dominance of a single virulent clone of bacteria that are capable
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of invading into the bloodstream or CSF, but are not necessarily more likely to be 
dispersed to subsequent hosts. Based on this, Frank cautions that ‘one should not 
mistake rare, extreme cases of virulence for the distribution of virulent effects in the 
population, in spite of the attention that naturally focuses on these extreme cases’ (Frank 
SA 1996).
The importance of host immunity in shaping virulence must also be considered. The 
ability to evade host immune pressure is clearly going to confer survival advantage on 
individual parasite strains (Bull JJ 1994). Bacteria have evolved many mechanisms by 
which they may evade host defences, including molecules which improve attachment to 
host surfaces, enzymes which destroy proteins involved in the immune response and 
capsules which mask immunogenic surface antigens (Gotschlich EC 1983). Some have 
suggested that the effect of host immunity on growth rates may actually be responsible 
for the maintenance of virulence (Antia R et al 1994). Enhanced clearance resulting 
from immune mechanisms reduces the duration of the infectious period leading to 
selection for more transmissible pathogens that, according to the argument, harbour 
increased potential to cause morbidity and mortality.
Evidence for the impact of host immunity on pathogen selection is seen in the divergent 
population structures of different serogroups of Neisseria meningitidis (Gupta S et al 
2001). The immune response to group A meningococcus is dominated by antibodies to 
the capsular polysaccharide, which is strongly immunogenic and highly conserved.
Type A strains therefore compete purely on the basis of fitness within the host, as all are 
equally susceptible to immune attack. In contrast, the serogroup B capsular 
polysaccharide is a weak immunogen. As a result, host antibodies are predominantly
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directed against a range of OMPs (including PorA) on the surface of the pathogen.
Much less antigenic diversity is exhibited in the PorA proteins of serogroup A than B.
It has been hypothesised that the diversity of group B strains is predictable because of 
the range of epitopes under selection pressure, resulting in the production of a series of 
‘small island’ populations of the organism with non-overlapping antigenic variants 
(Gupta S et al 2001).
Widespread immunisation as a disease control strategy may thus be expected to have an 
effect on pathogen selection. Where the vaccine acts to reduce the potential reservoir of 
susceptible hosts, relatedness between strains should increase, favouring reduced 
virulence. Imperfect vaccines control pathogen growth rates while not eliminating them 
from the population, potentially selecting for increased virulence (Gandon S et al 2000, 
2001). Proof of such theories would be provided by clinical evidence of worsening 
disease severity in the unvaccinated proportion of the population (Gandon S et al 2001). 
For pathogens with complex population structure and multiple serotypes, effects may be 
more unpredictable and will depend critically on vaccine design (Lipsitch M 1997b).
8.2 Population structure o f Hib, changes in clonal distribution over time
The highly clonal population structure of Hib has been discussed at length in Section
1.2 of Chapter 1. Globally, 9 clones are responsible for the vast majority of invasive 
disease due to this pathogen (Musser JM et al 1990). Within a given geographic region, 
only one or two clones tend to predominate. Quite marked variation occurs in the 
dominant clones between populations however, even those that are closely related 
geographically and historically such as Canada and the US, or different states of the US. 
One explanation of this may be that Hib has a relatively slow dispersal velocity (Musser
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JM et al 1990). Another may be the immnnodominance of the serotype b capsule, 
resulting in limited genetic variation as is observed in group A meningococcus (Gupta S 
et al 2001). Supportive of this notion is the marked genetic diversity of nt Hi (Section 
1.2) (Cody AJ et al 2003) which, like group B meningococcus, lacks an 
immunodominant epitope.
Changes in predominant clones within populations have been described over time. In 
the United States, the frequency of the clone ET-l/OMP IH increased dramatically 
between 1939-1954 and 1977-1980 (Barenkamp SJ et al 1983) (Musser JM et al 1985).
Following vaccine introduction in Finland, a marked decrease was observed in the 
frequency of isolation of 3 of 4 common phenotypic subtypes of Hib, with a slower 
decrease in the 1-II-9 strain. It is of interest to note that this strain was predominant in 
the most densely populated region of Finland before vaccine introduction and 
maintained this geographical distribution. As such, opportunities for transmission may 
have been greater than for other strains, highlighting the ongoing importance of 
environmental factors to pathogen survival (van Alphen L et al 1992). A recent study of 
Hib strains in Alaska demonstrated variation in dominant biotypes between the early 
1980s and the late 1990s, corresponding with the introduction of a national Hib 
immunisation programme. This change in the functionally characterised behaviour of 
isolates was not associated with a distinguishable shift in the genetic makeup of strains 
as defined by surface expressed CMP subtype (Lucher LA et al 2002).
Variation in the gene region encoding the type b capsule has been characterised. Using 
strains taken from cases of invasive disease in vaccine trials in the US and Finland, the
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distribution of genotypes causing disease in vaccinees (72) was compared with those 
observed in unvaccinated controls (143). No difference in the distribution of ribotype 
patterns was observed, nor was there any difference in the proportions of individuals 
infected with isolates which were genotypically type b, but lacking capsular expression 
(b- strains) (Falla TJ et al 1995).
8.3 Relationship between genotype and phenotype
In attempting to interpret the above observations, it must be remembered that no 
consistent association has been drawn between clones or subclones of Hib and 
pathogenicity, making the significance of either any change or no change equally 
uncertain. Most clones are equally represented in collections drawn firom carriers and 
individuals experiencing invasive disease in large population based studies. Rare 
exceptions are the association of ET21.8, otherwise described as OMP subtype Ic, with 
meningitis in Finland (Musser JM et al 1990) (Takala AK et al 1987) and the low 
representation of OMP subtype 13L amongst invasive isolates compared with its 
carriage prevalence (Hampton CM et al 1983). Based on the observation of outbreaks 
of Hib in children in day care centres, Barenkamp et al suggested that the OMP IH 
subtype might be more pathogenic than other strains. Carriage studies performed in 
three nurseries where more than one case of invasive disease had been reported revealed 
widespread transmission of the disease causing strain from the index case for all 
subtypes, but a greater association of OMP IH with secondary cases of serious infection 
(Barenkamp SJ et al 1981).
It therefore remains unclear what markers should be studied in an attempt to relate 
genotype with phenotype under selection pressure. Current techniques may detect
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changes in clonal dominance, but may otherwise be blunt tools to describe changes of 
functional relevance to pathogenicity. ‘Contingency loci’ within the Hi genome have 
been associated with phase variable expression of characteristics that may heighten 
virulence by conferring increased adaptability to a range of host environments (Section
1.4 of Chapter 1) (Bayliss CD et al 2001). What would be of interest are genes that 
control the speed with which such new variants may be produced. Deletions in the dam 
gene of N  meningitidis have been associated with an increased capsule phase variation 
rate in one laboratory, corresponding with a higher observed frequency in isolates taken 
from individuals with invasive disease than asymptomatic carriers. Such a finding has 
not been confirmed in subsequent studies, however (Bayliss CD et al 2001).
Examination of the impact of immunisation on the clinical course of Hib disease in the 
UK does not suggest that there has been any overall increase in the severity of disease 
presentations due to the organism over the past ten years. As outlined in detail in 
Section 2.4.1, the only epidemiological shift over the period has been an increase in the 
number of presentations with bacteraemia, which may well reflect changing clinical 
practice in the management of the febrile child. No increase in case fatality has been 
observed, with no differential between vaccinated and unvaccinated cases. Information 
on sequelae of Hib infections is lacking, and may be an area for further study. In short, 
while it is important to continue examining disease trends for evidence of changing Hib 
virulence, no evidence of such an effect of immunisation has been observed to date.
8.4 Potential impact o f antimicrobial therapy on life history o f Hib
Changes in both the population structure (Musser JM et al 1985) and incidence of 
invasive Hib infections were reported from the US over the second half of the 20^ ^
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century. Centres in the US and Canada noted a marked increase in the number of 
presentations with bacterial meningitis in children due to Hib, compared with other 
pathogens, between 1950 and 1970 (Koch R et al 1961, Gossage JD 1964, Haggerty RJ 
et al 1964, Michaels RH 1971, Finland M et al 1997). This time course corresponded 
with the use of life-saving antimicrobial therapy. Could antibiotic use and enhanced 
survival have conferred fitness benefit on disease associated ETl/OMP-lH clones, 
which also became more prevalent over this time period (Musser JM et al 1985)?
Evolutionary trade-off models, as discussed in Section 8.1, make much of the impact of 
death as a consequence of virulence on a pathogen’s life cycle. Prior to the advent of 
antibiotics, the case fatality rate associated with bacterial meningitis caused by Hib was 
in the order of 80-100%, making the assumption of a trade-off justified. From the 
1940s onwards, however, combination therapy with sulphonamides and penicillins, 
often coupled with chloramphenicol or streptomycin, reduced this death rate to below 
10%. If a trade-off between transmissibility and virulence did exist for Hib, what might 
have been the consequence of removing this ‘cost’ of virulence fi-om the equation?
Children convalescing fi’om Hib disease following antimicrobial therapy revealed 
ongoing carriage of the organism for up to a year. Thus, the duration over which the 
organism might be transmitted was no longer shortened by progression to invasive 
disease. A higher than expected carriage rate of Hib was further seen in their immediate 
family members (Michaels RH et al 1977, Li KI et al 1986) and day care contacts 
(Ward JI et al 1978, Murphy TV et al 1983a). This elevated carriage prevalence was 
also observed in secondary contacts, namely the parents and siblings of asymptomatic 
Hib carriers who had associated with an index case of invasive disease in a day care
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nursery setting. Of interest, colonisation rates in these secondary contacts were higher 
when the primary contact carried a Hib strain identical to the index case as opposed to 
an unrelated strain, but this difference did not achieve significance (Table 8.0) (Li KI et 
al 1986).
Table 8.0: Carriage of Hib in Secondary Household Contacts of an Index Case in 
Day-Care
Characteristics of Household 
Primary Contact
Colonisation Rates
Number of 
households
Total positive 
swabs
Parents Siblings
Household of colonised day-care 
classmate (all)
21 10/48 (21%) 5/36 (14%) 5/12
(42%)
Primary contact carries OMP subtype 
identical with index patient
14 8/32 (25%) 4/23 (17%) 4/9 (44%)
Primary contact carries OMP subtype 
different from index patient
7 2/16 (13%) 1/13 (8%) 1/3 (33%)
Associated with this evidence of exposure was an estimated risk of secondary disease in 
household members under 5 years of age as high as 4%, 500 times higher than the 
population risk (Ward JI et al 1979). The likelihood of a secondary case occurring in a 
day nursery contact was harder to estimate, but ranged from 0-4% in four large 
prospective studies in the United States (Fleming DW et al 1985, Makintubee S et al 
1987, Osterholm MT et al 1987, Murphy TV et al 1987).
Such observations may be consistent with the hypothesis that strains of Hib that cause 
invasive disease are more efficiently transmitted than other strains. No logical direct 
benefit of the disease state itself can be proposed, and indeed individuals 
asymptomatically carrying invasive disease causing strains transmit just as efficiently. 
The way in which these two attributes are linked is unclear, but may be through growth
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rates or other characteristics that are coded for by genes in linkage disequilibrium. As 
described above, there is no clear evidence for distinct Hib clones being involved in the 
pathogenesis of invasive disease, but current molecular methods are blunt tools, and the 
genetic basis of virulence imperfectly understood.
Subsequent recognition of the risk of secondary cases, as well as the risk of recurrent 
infection in the index case due to ongoing colonisation, led to the recommendation of 
rifampicin therapy to eradicate carriage in Hib cases and contacts (Cartwright KAV et al 
1991). Such therapy had a 98% short-term efficacy at eliminating the carrier state 
(Glode MP et al 1985), and documented benefit in the prevention of fiirther cases in 
both the home and nursery settings for children under 4 years of age (Band JD et al 
1984). The introduction of such an intervention on a large scale might be expected to 
once again increase selection pressure on the organism by removing disease-causing 
strains, reversing the fitness benefit resulting firom enhanced host survival.
A simple strain competition model was developed in order to simulate the divergent 
effects of:
(i) Antimicrobial therapy to treat invasive disease alone
(ii) Antimicrobial therapy to halt transmission of disease causing strains
8.5 Strain competition model to simulate impact o f antimicrobial therapy on fitness 
Suppose two Hib strains, or clones, coexist in the population. Strain 1 is less infectious 
than strain 2, but also less likely to invade and cause disease. Based on the absence of 
demonstration of Hib co-infection in carriage studies (Section 1.2), it is assumed that 
individuals are only infected with one strain at any given time. Following infection 
with one strain, some measure of natural immunity ensues, which confers equal cross
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protection against both strains. This assumption is based on the observation that the 
immunodominant antigen in Hib is the capsular polysaccharide, which is highly 
conserved (Section 1.9). The corresponding host immune response to this antigen is 
also highly conserved, with a limited number of germline encoded heavy and light chain 
regions dominating the antibody response across a number of distinct populations 
(Section 1.11) (Lucas AH et al 1999). Prior to the advent of antibiotic therapy, invasive 
disease due to either strain resulted in an 80% case fatality rate. The model describing 
the behaviour of the two strains is shown in Figure 8.0.
Susceptibles are bom into a fully susceptible state, S at birth rate B, and die at rate \i. 
Strain 1 is initially circulating in the population, and strain 2 is introduced at time t=250. 
Hosts become infected with either strain at a rate dependent on the intrinsic 
transmissibility of each (pi and pa) and the number of individuals in the population 
infected with either strain. These may be asymptomatic carriers (L and H) or be 
experiencing invasive disease (Di and Da). No increased infectiousness is conferred by 
bacterial invasion. Individuals recover from the carrier state at rate pi and pa 
respectively to a relatively resistant state, R. From this state, there is a 50% reduced 
risk of infection with either strain. The alternative to recovery is progression to invasive 
disease (at rate ôi or ôa). Diseased individuals have an increased risk of death (ai and 
aa) in addition to the background mortality rate, p. Those who survive recover at rates 
pDi and Pd2 to the carrier state, and from there to the resistant class. With use of 
Rifampicin therapy, the situation changes and diseased cases recover directly to the 
resistant class, at rates poi’ and po2 ’ (denoted by dashed line in the model). The partial 
protection provided against infection by previous exposure is only temporary, as it 
wanes at rate ©.
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The series of ordinary differential equations describing this model is as follows:
dS/dt = B — [Pi(Ii+ Di) + ^2 (1 2+ D2) + |a]S + oR 
dli/dt = Pi(Ii+ Di)S + 0.5Pi(Ii+ Di)R — (pi + 5i + q,)Ii 
dl2/dt =  P2O2+ D2)S +  0 .5 P2( l2+  D2)R -  (p2 + 8 2  +  |l)l2 
dDi/dt = Ô1I1 -  (pdi + ai + p)Di 
d 0 2 /d t  =  Ô2I2 -  (P d2 + 0 /2  +  p )D 2
dR/dt = Pill + PdiDi + P2I2 + PD2D 2 — [0.5Pi(Ii+ D i) + 0.5P2(l2+ D2) + co + p]R
Figure 8.0: Strain competition model
B
B+ai
P d i
p D i’
PD2 ’
pD2
P+%2
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A total population size of 500,000 was assumed. The annual rate of births balanced 
deaths, keeping total population size stable.
B =  10,000 p = 0.02
Asymptomatic infection persisted for 2 months, with invasive disease lasting 1 month.
P i =  P2 =  6  P d i  =  P d2 =  P d i ’= P d2’=  12
Partial protection against infections from the resistant state waned to give an average 
duration of protection of 2  years.
CO = 0.5
Strain 1 was less virulent than Strain 2: 1.5% of infections due to the former strain 
progressed to invasive disease, and 3% of the latter. Calculated values for Ô were as 
follows:
ôi/(ôi + pi + p) = 0.015 6 2 / ( 6 2  + p2  + p) = 0.03
61 =  0.09 62 =  0.19
The case fatality rate, given progression to invasive disease, was assumed to be the 
same for both strains, falling from 80% to 1 0 % with availability of antibiotics.
Pre-Antibiotics: Antibiotic era:
a /(a  +  p D + p) = 0.8 a /(a  + p D + p )  = 0.1
oti = tt2 = 48.08 ai = tt2 = 1.34
The total force of infection, X, under initial conditions was assumed to be 0.3. Under 
this assumption the average age at first infection would be approximately 3 years. 
Equilibrium values for each of the state variables using the above parameter set were 
calculated using matrix algebra in Excel. The value of the transmission coefficient pi 
could then be derived, given that % = pi(Ii+ Di). p2 was set to be slightly higher than pi, 
thus correlating transmissibility with virulence.
Pi = 1.58x10'^ P2 = 1.59x10'^
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The basic reproductive rate (Ro) for each pathogen was calculated using next generation 
matrices (Diekmann O et al 1990). Within this model, there are two types of infectious 
individuals, carriers and diseased, potentially producing the same two kinds of 
secondary infections. Consequently, Ro is as follows for each strain:
Roi ~ +
a ( A  +  +  a )  K P x +  +  P ) { P d \ +  «1 +  a )
Ro2 = +
p { p i + A+ p i p i + A+ p){Pd2+ 2^
Prior to introduction of antibiotics, Roi = 1.293769 and Rq2 = 1.2875. The dominance of 
Strain 1 can be seen when it is introduced into a population at time t=50 initially 
infected with Strain 2 in Figure 8.1.
Figure 8.1: Balance of Strains from the competition model, Strain 1 introduced at 
time t=50
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With introduction of successful antibiotic therapy, reducing the case fatality rate from 
80% to 10%, the dominance of strains is reversed: Roi = 1.300986 and R02 = 1.301841, 
The subsequent effect on the prevalence of each strain (colonisation and invasive 
disease episodes) in the population is seen in the simulation below, where the 
intervention is introduced at time t = 1000. As Strain 2 is far more likely to cause 
invasive disease than Strain 1, the overall number of disease cases as a proportion of 
these infections at equilibrium is increased. At time t = 1000, there are 19 invasive 
disease cases due to Strain 1 and one due to Strain 2. By time t = 2000, there is no 
disease attributable to Strain 1, but 285 cases of Strain 2. The relationship of the two 
strains over time is illustrated in Figure 8.2.
Figure 8.2: Balance o f strains from the competition model, with introduction of 
antibiotic therapy at time t=1000 (all infections for each strain)
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Thus, it can be seen that the more transmissible strain, with its associated higher risk of 
causing invasive disease, is benefited when the ‘cost’ of virulence is removed. Far from 
being removed from circulation by the death of the host, the organism is able to 
continue to reproduce in the population. The use of chemoprophylaxis to eradicate
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disease causing organisms places a new ‘cost’ on more invasive strains, resulting in a 
reversal of this effect (Figure 8.3).
Figure 8.3: Effect o f Introducing Rifampicin to Eradicate Carriage in
Individuals Recovering from  Invasive Disease (at time t=1500)
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8.6 Conclusion
Widespread immunisation against Hib has the theoretical potential to exert evolutionary 
pressure on the organism, resulting in altered intrinsic virulence. Clinical indicators of 
such change might include differences in the spectrum or severity of disease 
presentations, particularly in un vaccinated children. In addition, evidence of increased 
invasive potential in older age groups in the face of measurable natural immunity may 
imply emergence of immune ‘escape’ mutants. No such impact on Hib epidemiology 
has been observed in Britain (Section 2.4.1). The only consistent association with the
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increased disease rates observed in the UK has been a reduction in the prevalence of 
detectable serum antibody titres at both ends of the age spectrum (Section 3.3).
Genetic studies of Hib have been unable to define markers consistently associated with 
phenotype. The same strains appear equally likely to cause both asymptomatic 
colonisation and serious infection. No shift in the population structure of the organism 
has been observed following the introduction of Hib vaccination in several countries 
studied. Interpretation of the consequences of this finding for phenotype is difficult, 
given the limitations of current molecular tools.
Evolutionary ‘trade-off models provide a framework within which to explore the 
consequences of intervention on the life history of pathogens. Such models assume that 
the benefit of virulence, arbitrarily defined as heightened transmissibility, is balanced by 
its cost, which is death of the host. The introduction of antibiotics to treat Hib 
infections largely removed death from the equation, and could thus be predicted to have 
a major impact on the evolutionarily stable level of virulence.
An increase in the observed incidence of Hib meningitis in the US was reported in the 
second half of the 20^ century, coinciding with availability of antimicrobial therapy. 
Over the same period a new clone became predominant in the population. A simple 
strain competition model was used to show the way in which a reduction in case fatality 
may switch the dominance of two circulating strains. Use of Rifampicin to block 
ongoing transmission of disease causing isolates reversed this trend, by again 
introducing a ‘cost’ of invasion to the pathogen.
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Chapter 9 -  Summation
9.0 Summary o f findings
Conjugate vaccines have been remarkably effective at reducing transmission of Hib in 
countries where they have been introduced for widespread use (Section 1.15). In addition, 
they are able to directly protect even very young infants against invasive disease. (Section 
1.15) The exquisite susceptibility of children under the age of 2 years to serious Hib 
infections has been attributed to immune hyporesponsiveness to the Hib capsular 
polysaccharide, PRP (Section 1.9). The efficacy of conjugate vaccines in this age group 
correlates with their ability to induce levels of anticapsular antibody deemed to correlate 
with clinical protection.
What are the key components of vaccine induced protection against Hib? Based on this 
understanding, how many doses of Hib vaccine are required to protect children over the 
first five years of life? Early success of the UK’s Hib immunisation programme, which 
relies purely on an accelerated primary infant schedule without a booster dose, led some to 
assert with confidence that immunologic memory would provide clinical protection even 
after anticapsular antibodies had waned, making a routine fourth dose of vaccine 
unnecessary (Booy R et al 1997) (Heath PT et al 2000a). Recent experience in the UK 
suggests that such may not be the case (Section 2.4.1).
Lower serum antibody titres to the Hib capsular polysaccharide PRP in the population have 
been associated with greater disease risk in the following studies:
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• Antibody titres wane rapidly following primary infant immunisation -  a 
corresponding decline in vaccine efficacy was observed when the first two years 
following vaccination were compared with subsequent years (Section 3.1.1).
• In contrast, high levels of immunity were achieved and maintained over the first 5 
years of life following catch-up immunisation, as employed in the UK in 1992/3 
(Section 2.6.2). Corresponding estimates of efficacy were far higher than those 
calculated following the infant primary course (Section 3.1.1).
• Introduction of a poorly immunogenic DTaP-Hib combination vaccine in 
2000/2001 was temporally associated with higher rates of invasive disease and 
vaccine failure (Section 2.4.2), a reduced duration of protection following 
immunisation (Section 2.4.2) and declining vaccine efficacy (Section 3.1.1). 
Inferior protection at an individual level was confirmed by a case-control study 
comparing vaccines received by children presenting with invasive Hib infection 
with those administered to healthy controls (Section 3.1.2). Children who had 
received two or three doses of the primary immunisation series as DTaP-Hib were 
significantly more likely to present with breakthrough infection than those who had 
been given three doses of another Hib vaccine.
• In keeping with the notion that lower antibody responses are associated with 
inferior protection, a significantly increased risk of Hib disease has been noted in 
infants bom before 37 weeks’ gestation (Section 3.2.3). Such children demonstrate 
reduced post-primary and post-booster antibody concentrations (Section 3.2.2).
An additional impact of widespread Hib immunisation has been a reduction in circulation 
of the organism in the community (Section 2.5.1). While providing excellent indirect 
protection against disease by reducing opportunities for acquisition, such an effect may be
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anticipated to have adverse consequences for maintenance of immunity in the medium to 
long term for an infection such as Hib, where resistance is not life long.
• A decline in the prevalence of protective Hib antibody titres was observed in older
unimmunised cohorts within only a few years of introduction of Hib vaccine 
(Section 2.4.3). A subsequent rise in invasive disease incidence has been observed 
in these age groups, particularly among adults in their 30s and 60s, who are likely 
to be in close household contact with infants and young children.
• In a similar fashion, less effective maintenance of post immunisation immunity 
may be expected to occur in children immunised in more recent years than early in 
the national Hib campaign, when ongoing carriage could still be documented in 
nursery settings (Section 2.5.1).
• A national study of social and environmental factors associated with ongoing Hib 
infection identified nursery attendance and household exposure to cigarette smoke 
as variables reducing the risk of invasive Hib disease in vaccinated children 
(Section 3.2.3). This was in direct contrast to observations before vaccine 
availability, as both of these exposures have been linked with increased Hib 
carriage in the past (Section 1.6). Nursery attendance in particular was a significant 
risk factor for invasive disease in unimmunised children (Section 1.8). A possible 
explanation for these surprising findings may be that a consistent level of 
background exposure to the organism assists in the maintenance of vaccine induced 
immunity.
British children are dependent on immunologic memory for protection once antibodies 
have waned to low or undetectable levels. However, many children who experience 
invasive Hib disease demonstrate evidence of previous priming for memory responses
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(Section 3.2.2) that has been insufficient to prevent bacterial invasion. If one considers the 
estimate of vaccine efficacy obtained two years following primary infant immunisation to 
be a proxy measure of the protection afforded by memory, this may be as low as 27% 
(Section 3.1.1). Seroepidemiologic studies have revealed an increase in the proportion of 
individuals without measurable antibody in many age groups in the UK over the past 10 
years (Section 2.6.2). Greater susceptibility to bacterial invasion at the point of exposure 
to Hib may conceivably result in a higher incidence of Hib disease for a given background 
carriage prevalence.
Mathematical models of Hib infection and immunisation were developed in order to allow 
study of the effects of interruption of transmission on levels of protective immunity in the 
population. Further, they provided a framework within which to investigate key 
assumptions regarding the mechanism of vaccine protection. Conjugate vaccines were 
assumed to have two main effects based on an understanding of their immunologic 
properties as TD antigens:
(i) Generation of antibody levels deemed protective following immunisation in 
infancy
(ii) Induction of immunologic memory, manifest as ‘booster’ antibody responses 
following re-exposure to the pathogen or subsequent vaccination
Vaccine induced immunity was otherwise assumed to act in a similar way to natural 
immunity. Features of interventions unique to the UK, such as an initial catch-up 
immunisation campaign and the use of less immunogenic vaccines over a two-year period, 
were able to be incorporated.
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The high coverage achieved for the catch-up immunisation campaign had a rapid and 
substantive impact on reducing all infections, but also resulted in large transient effects. 
The second of these rebounds in circulation coincided with the use of poorly immunogenic 
vaccines in the model and was amplified in consequence (Section 6.1). The relatively 
short time scale seen for these transient effects resulted fi*om the intrinsic properties of the 
system (Section 6.2). Strong damping was observed, due to both the relatively long 
duration of infection and the reversion of resistant individuals to the susceptible state 
(Section 6.2.2).
Model outputs describing the proportion of the population resistant to Hib acquisition, and 
those without detectable immunity, showed good correlation with the observed 
seroprevalence data over a ten year period (Figure 6.14b)) (Figure 6.17). The effect on 
carriage prevalence in children of nursery age was also within the 95% confidence limits of 
population measures (Figure 6.14a)). Strongly assortative mixing patterns, with a 
significant contribution of an older sibling to infection risk in young infants, achieved the 
observed relative balance of invasive disease in children of different age groups (Section
Having achieved a reasonable fit to measures of infection and immunity, the relative 
protection afforded against acquisition (Section 5.4) (Section 6.5) and progression to 
invasive disease (Section 5.6) (Section 6.5) could also be calculated against the UK 
incidence data. In order to recapitulate both excellent initial control of disease and a late 
resurgence in infections, the parameters describing efficacy at both of these stages could 
only be in the order of 25-35% (Section 6.5). This estimate of the direct protection
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afforded by memoiy was very similar to that calculated at a population level using the 
screening method (Section 3.1.1).
It is interesting that a resurgence in Hib infections in vaccinated children in Alaska 
occurred within 5 years of the introduction of a conjugate vaccine programme. Associated 
features at the time included very high rates of carriage in older children, and the use of 
HbOC in infants (Section 1.16). This vaccine produces much lower post-primary 
immunisation antibody titres than the formerly used PRP-OMP. In a setting where the 
median age at presentation with Hib infection was substantially younger than that in the 
UK, this opening of a susceptible six-month window was sufficient to result in a 
substantial increase in infections, perhaps fuelled by transient behaviour. The importance 
of maintaining high anticapsular antibody titres in order to protect infants from infection is 
reinforced by this additional population experience.
The possibility that the intrinsic virulence of Hib may be increasing under selective 
pressure induced by immunisation was considered. There are no clinical indicators from 
the epidemiology of ongoing Hib infections to suggest any worsening of disease 
presentations or increase in case fatality in either vaccinated or unvaccinated individuals to 
suggest that this is the case (Section 2.4.1) (Section 8.3). The absence of any clear genetic 
markers of virulence for Hib makes monitoring of such a possibility at the molecular level 
difficult (Section 8.3). No shifts in clonal population structure have been observed 
following vaccine introduction in communities where this question has been addressed 
(Section 8.2).
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9.1 Immunologie implications o f the UK Hib experience
If increasing dependence on immunologic memory is to be blamed for the UK’s increase in 
invasive Hib disease, we must further pursue the additional question: why was the 
protective efficacy of memory so much lower than anticipated?
9.1.1 Should memorv be expected to protect at all?
Rapidly rising antibody titres have been observed in both vaccinated (McVemon J et al 
2003b) and unvaccinated (Anderson P et al 2000) children presenting with invasive Hib 
infections. Such responses were consistent with previous priming, and yet these children 
were not protected. Why was memory insufficient to prevent disease in these cases?
Memory is only one component of the immune repertoire in the face of bacterial invasion 
(Lucas AH et al 2001). As our understanding of immunology improves, the associations 
between genotype and immune responsiveness to a range of diseases become more 
complex (Kwiatkowski D 2000). The critical role of individual susceptibility in 
determining the likelihood of bacterial invasion is strongly implied by the fact that, prior to 
vaccine availability, 5% of children under 5 years were colonised with Hib at any given 
time, yet only 30 per 100,000 would go on to experience invasive disease. Why were 
some children vulnerable and not others? Factors other than memory are likely to play an 
important role (Lucas AH et al 2001).
Some believe that protective immunity and memory are distinctly separate entities. It has 
been postulated that memory exists primarily to allow mothers to pass on antibodies to 
their unborn infants (Zinkemagel RM 2000) and should not be relied upon for protection.
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Such a view is at one extreme end of the spectrum, but perhaps provides an appropriate 
note of caution.
9.1.2 Do memorv responses continue to provide the same qualitative protection, regardless 
of time since last exposure to antigen?
A debate rages in immunology over whether or not maintenance of pools of memory cells 
requires ongoing exposure to the initiating antigen. Many assert that the process is antigen 
independent (Maruyama M et al 2000), with separate populations of memory lymphocytes 
and long-lived plasma cells persisting for many years without the need for additional 
stimulation (Slifka MK et al 1995). Alternatively, polyclonal activation of the long-lived 
memory cell pool has been invoked as an explanation for the continual production of new 
populations of antibody forming cells (Bemasconi NL et al 2002). While measurable 
antibody responses have been noted in adoptive transfer experiments of memory 
lymphocytes in mice, their functional capacity may suffer in the absence of both antigen 
and T cells (Zinkemagel RM 2002).
The alternative view proposes that ongoing specific stimulation of memory pools of cells is 
needed (Zinkemagel RM 2002). In the case of immunisation, ongoing antigenic exposure 
may be endogenous, due to persistence of vaccine in immune complexes on dendritic cells 
(Zinkemagel RM 2000). In the UK, three doses of Hib conjugate vaccine are 
administered, at 2, 3 and 4 months of age. For lifelong immunity, 3 doses of tetanus toxoid 
are insufficient, with 5 doses required to ensure persistence of protection (Gray D 2001). 
Are infants in the UK receiving an insufficient quantity of antigen, in the absence of a 
fourth dose?
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Such a question becomes more important when one considers that opportunities for 
exogenous Hib exposure have been markedly reduced by widespread immunisation 
(Adegbola RA et al 1998, Barbour ML et al 1995, Fernandez J et al 2000, Takala AK et al 
1991). Cross-reactive capsular antigens on organisms such as E coli KlOO were believed 
to be important in priming for Hib responses in infancy. They do not, however, 
consistently bind to antibodies produced in response to PRP vaccine, or following invasive 
Hib infection (Insel RA et al 1982). As such, these organisms would seem unlikely to 
boost immunity to Hib that has been primarily induced by vaccination. Antibody titres in 
adults were seen to wane within only a few years of vaccine introduction, in keeping with 
the anticipated decrease in Hib exposure (Section 2.4.3). How long should we expect 
functional memory responses to persist in such a situation?
The mathematical models of Hib infection developed (Chapters 4, 5, 6, 7) assumed that 
boost responses would continue to have the same qualitative and quantitative attributes, 
regardless of the time since immunisation or last natural exposure. Were this assumption 
to prove incorrect, one may predict a substantial reduction in long-term population 
protection against Hib resulting from immunisation.
9.1.3 Are there reasons whv memorv induced bv vaccination mav be inferior to that 
generated bv natural exposure to the intact organism?
In the natural protective response to encapsulated bacteria, T cells that recognise bacterial 
proteins presumably help the B cells that recognise the capsular polysaccharide (Lucas AH 
et al 1999). Conjugate vaccines employ carrier proteins such as diphtheria and tetanus 
toxoids to elicit T cell help, rather than peptides specific to Hib bacteria. T cells involved
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in the initial response to such conjugates are specific for the carrier protein (Perez-Melgosa 
M et al 2001).
Following Hib conjugate priming, boost responses are observed with administration of 
plain PRP. Tenfold higher titres can be elicited by re-immunisation with conjugate 
vaccine, however (Goldblatt D et al 1999). This discrepancy would imply that while 
primed B cells are capable of responding to re-exposure to the polysaceharide antigen, the 
assistance of specific T cell help improves the magnitude of antibody production with a 
subsequent stimulus. While not necessarily required for natural immunity, T cells may 
provide a valuable adjunct in the protection of large populations (McVemon J et al 2004c).
A reduction in the circulating Hib pool has removed opportunities both for boosting B cell 
polysaccharide specific immunity, and also T cell immunity to exposed surface proteins. T 
cells may be important both in the maintenance and effector phases of the specific immune 
response to Hib. Thus, a reduction in transmission, so beneficial to herd immunity, may 
be a double-edged sword with negative as well as positive consequences for protection 
(McVemon J et al 2004c).
9.2 Wider implications o f the UK Hib experience
The most obvious additional case to which this analysis is relevant is the meningococcal 
serogroup C (Men C) conjugate vaccine, also administered in the UK at 2,3 and 4 months 
of age without a booster dose. This vaccine, introduced routinely as a primary infant course 
in late 1999, is required to provide protection well into the second decade of life when 
there is a peak in morbidity and mortality due to serogroup C meningococcus (Balmer Pet 
al 2002). The implication of the present hypothesis is that if vaccine failures occur (i.e.
2 6 0
infection in vaccinated children), we ean expect to find them late after vaccination, when 
antibody levels have waned and the lack of helper T cells begins to be felt (McVemon J et 
al 2004c).
There are also significant implications for the debate surrounding possible introduction of 
the more recently licensed pneumococcal conjugate vaccines. Proponents in favour of 
wide scale implementation in the UK quote vaccine efficacy of 97.4% (McIntosh EDG et 
al 2002), a figure derived from experience of a four dose course administered at 2 ,4 ,6  and 
12-15 months (Black S et al 2000). Whether or not a three dose accelerated primary 
schedule would deliver a similar level of protection must substantially influence 
considerations of the cost-effectiveness of such a proposal.
In contrast to Hib, susceptibility to invasive disease caused by the pneumococcus is evident 
both during the first five years of life, and in adults aged 65 and over (Sleeman K et al 
2001). Introduction of routine infant pneumococcal conjugate vaccination in the United 
States (US) has been associated with a significant reduction in invasive pneumococcal 
disease in all age groups over 20 years (Whitney CG et al 2003). Only time will tell 
whether a resurgence of infections will be observed in the medium term, similar to the 
UK’s experience with Hib. Should such an increase occur, the greater underlying 
susceptibility of the elderly to this pathogen might be associated with a more marked 
elevation in the number of adult cases.
2 6 1
9.3 Where to from here? Regaining control o f invasive Hib infections in the UK 
The addition of a fourth dose of Hib vaccine as was given to children aged between 6 
months and 4 years in the national ‘catch-up’ campaign outlined in the Chief Medical 
Officer’s letter of the 14^ of Februaiy 2003 (http://www.doh.gov.uk/cmo/index.htm) is 
expected to provide protective levels of antibody to a cohort of children throughout the risk 
period for Hib disease. Whether a booster dose will be routinely required once less 
immunogenic vaccines have been withdrawn from the infant immunisation course requires 
further study.
Investigation of the models of Hib infection and immunisation developed suggested that 
the recent increase in invasive Hib disease should resolve with the withdrawal of DTaP- 
Hib vaccine, returning to a stable equilibrium within a matter of years (Section 7.4). 
Exploration of the possible impact of a range of interventions indicated that this 
equilibrium point would not be shifted by a one off cateh-up immunisation campaign, such 
as that employed in the UK in the second half o f2003 (Section 7.5). In addition, the 
transients associated with such a campaign would be likely to result in a further brief 
increase in infections in seven years’ time.
Implementation of a routine fourth dose of vaecine would be predicted to result in a lower 
equilibrium incidence of Hib disease in children less than 5 years of age (Section 7.3, 
Section 7.5). Maximum benefit would be obtained if this vaccine was administered as 
close to 12 months of age as possible, due to the exquisite age dependency of susceptibility 
to bacterial invasion (Section 7.5). Had such a dose been incorporated in the routine 
schedule from the outset, it is unlikely that the use of DTaP-Hib vaccines would have
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resulted in an increase in serious Hib infections, regardless of ongoing transmission in the 
wider community (Section 7.3).
Data from the second half of 2003 have confirmed a reduction in the number of Hib reports 
from the UK, compared with the same period in the preceding year. Coverage figures 
from the catch-up campaign are still being collated. The HPA is conducting further studies 
to investigate the anticipated duration of protection of a routine additional dose of Hib 
vaccine administered at different ages. The effect of any such intervention, should it be 
instituted, will continue to be monitored using the population surveillance mechanisms 
aheady in place, which have allowed early detection and a timely response to the current 
problem.
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